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Although several dozen different compounds are able to transiently alter chloroquine 
resistance via chemosensitisation, the phenomenon has never evolved beyond laboratory 
practice as a result of in vivo difficulties. Chemosensitising compounds either need to be 
administered at doses which are toxic to the host in order to reverse resistance, or the drug is 
so highly bound to serum proteins that there is an insufficient circulating quantity available to 
restore sensitivity. 
Nine chemosensitisers were evaluated in vitro against several resistant isolates of the malaria 
parasite in order to develop a cocktail treatment of three compounds which could reverse 
resistance additively or synergistically when used at low doses with chloroquine. This would 
bypass any toxicity issues which might arise from the use of a high dose of a single agent. 
Six of the chemosensitisers were selected for combination into six different cocktails which 
were tested in vitro. Each cocktail contained one antidepressant, one antihistamine and one 
antipsychotic. Low doses of each drug were able to alter resistance to a small extent singly 
and in combination; this was shown by determining the effect of drugs and cocktails on both 
chloroquine transport using radiolabelled chloroquine, and chloroquine efficacy using the 
lactate dehydrogenase assay for parasite viability. The reversal activity was shown to be 
additive in the cocktail treatments and not synergistic, and was highly dose-dependent. There 
was no direct correlation between the change in chloroquine transport and the extent of 
resistance reversal. 
The chemosensitisers’ effect on chloroquine transport was evaluated in a mouse model of 
malaria and shown to be similar to that seen against cultured human parasites; following this, 
the cocktails were tested for efficacy in mice infected with chloroquine-resistant malaria. Five 
of the six cocktails were able to significantly alter parasite survival in the mice in conjunction 
with a low dose of chloroquine.  
Drug levels in the mice were quantified via mass spectrometry and liquid chromatography in 
order to correlate the efficacy data. One of the compounds in the failed treatment was shown 
to circulate at low levels in the animals and this is possibly why that treatment, although 















When eating bamboo shoots, remember those who planted them.  
– Chinese proverb 
 
 















This is what you’ll get if you mess with us. 
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Chapter 1 – Introduction 
1.1. Perspective 
Current estimates for malaria identify the at-risk population as being about half of the number 
of people in the world (World Health Organisation, 2010b) as shown in Figure 1.1 below. 
There were an estimated 243 million infections in 2008 and about one million deaths from the 
disease; in approximately 90% of cases, these were children in sub-Saharan regions of Africa. 
The disease in humans is caused by four separate species of a parasite from the genus 
Plasmodium; in order of prevalence they are P. falciparum, P vivax, P. ovale and P malariae. 
 
 
Figure 1.1: Malaria-endemic regions of the globe. Taken from World Health Oranisation, 2010. 
 
In addition to the morbidity and mortality directly attributable to malaria, it has been 
estimated that the economic burden of the disease accounts for up to 50% of both in-patient 
and out-patient cases in developing countries and up to 40% of their public health budgets 
(World Health Organisation, 2002). The World Health Organisation and the World Bank 
estimate the cost of the disease in Africa to be in excess of US$ 12 billion annually – a figure 
representing up to 1.3% of the gross domestic product of the continent. Methods for 
controlling the disease have included the following: targeting the host mosquitoes with 












physical deterrents such as insecticide-coated bed-nets and mosquito repellents; and 
eliminating parasites from infected individuals by drug measures. Efforts to produce a vaccine 
against the parasite have thus far been of limited value. Whilst each of these interventions has 
partially, and often only temporarily successful, to date there has been a failure to eradicate 
the disease completely. 
1.2. The malaria parasite 
Plasmodium is a protozoan parasite from the phylum Apicomplexa, which is transmitted 
between numerous vertebrate hosts by the female mosquito only. 
 
 
Figure 1.2: The life cycle of the human malaria parasite. The erythrocyte stages of the life cycle, 
which this thesis focuses on, are highlighted in blue. Image used with permission from the Centers for 
Disease Control. 
 
There are more than 200 species of Plasmodium currently described, and these between them 













goats, water buffalo), several genera of bird (penguins, ducks, chickens, canaries, buzzards 
and others), monkeys and apes, and a variety of reptiles (more than 3200 species of lizard and 
snake) in addition to humans (Prescott et al., 1993; Campbell, 1993). 
1.2.1 The parasite life cycle 
The parasite undergoes a complex life cycle comprising both sexual and asexual replication 
phases in different hosts. 
In terms of species infective to humans, asexual stages occur in the human host’s blood and 
within the liver; sexual stages are found in the invertebrate host, the Anopheles mosquito. 
Other genera of mosquito can transmit the parasite; however, only Anopheles can infect 
humans. The complete cycle of Plasmodium falciparum is depicted in Figure 1.2. 
1.2.2 Parasites and haemoglobin metabolism 
This study deals only with the blood stages of the parasite (contained in the blue square in 
Figure 1.2), both in the in vivo and in vitro models of the disease.  
1.2.2.1 Haemoglobin breakdown 
During these stages, the parasite ingests massive amounts of haemoglobin (HB) from the host 
red blood cell, as much as 80% of the erythrocytes’ HB content (Egan et al., 2002), which it 
breaks down to liberate peptides for use in its own growth processes. HB is ingested by 
endocytosis via the cytostome on the parasite plasma membrane (Hoppe et al., 2004).  
Vesicles containing HB are transported via the cytoskeleton to a specialised organelle called 
the food or digestive vacuole (DV). The DV is the parasite equivalent of a lysosome 
commonly found in mammalian cells and is acidic in nature with its pH maintained by V-type 
ATPases on its membrane. The DV forms via the fusion of multiple vesicles containing 
endocytosed material; in Plasmodium, it both digests HB and stores the undigested haem 
moiety which remains after the protein component has been metabolised.  
1.2.2.2 Detoxification of haem 
This haem moiety is ferriprotoporphyrin IX (FPIX; Figure 1.3) and it is known to be toxic 
since it can associate with and destabilise membranes (Ginsburg et al., 1998). In the DV, the 
molecules of FPIX dimerise; these dimers associate via hydrogen-bonding and thus are 













Since the demonstration that β-haematin, a synthetic molecule chemically identical to HZ and 
made from the HB derivative haematin, can form spontaneously under in vitro conditions 
with no enzymes involved in the process (Egan et al., 1994; Dorn et al., 1995; Hoang et al., 
2010), it is presumed that HZ can form the same way, although the existence of a specific 
enzyme dubbed haem polymerase was postulated initially (Slater and Cerami, 1992). Several 
antimalarials, most notably the quinoline drug family, are known to exert their effects on the 
parasite by interacting with the metabolism of HB and the subsequent production of HZ 
(Foote and Cowman, 1994). While considerable progress to elucidate the process by which 
these compounds work has been made in the last two decades, the exact mechanism of action 
remains unresolved and various theories are discussed in 1.4 below. 
 
 
Figure 1.3: The structures of FPIX (left) and haemozoin (Pagola et al., 2000). FPIX dimers form via 
co-ordination between the distal COO
-
 and the Fe
3+ 
center of adjacent molecules, highlighted in red 
and blue in both images; dimers associate via hydrogen bonding from the carboxyl group in green, 
shown by dashed red and blue lines at right. 
 
1.3. Antimalarial chemotherapy 
Several diverse classes of antimalarial are currently in use in various regions of the globe.  
The three major antimalarial classes are discussed below and include: 
• compounds affecting the DNA production pathway, notably atovaquone, proguanil 
and sulfadoxine/pyrimethamine  
• compounds which create oxidative stress, specifically the endoperoxide artemisinin 






















• quinoline compounds altering different aspects of haemoglobin digestion  
o 4-aminoquinolines such as chloroquine (CQ) and amodiaquine (AQ) as well 
as 8-aminoquinolines like primaquine. This study focuses exclusively on CQ 
use. 
o Aryl-amino quinolines, also called quinolinemethanols, such as quinine (QN) 
and mefloquine (MQ) 
o related phenanthrene methanol derivatives including halofantrine and 
pyronaridine 
Some of the aforementioned drugs are used solely for treatment of the disease while others are 
more commonly prescribed for prophylaxis; however, several are utilised for both of these 
indications.  
Ever-increasing levels of resistance to several drugs from each of the different classes has 
largely undermined their effectiveness as treatment in the last fifty years, however, and some 
drugs are now useless for all intents and purposes in certain malaria-endemic regions. 
Although this is more pronounced with the quinoline and antifolate drugs, reports of 
resistance to the more-recently introduced artemisinin derivatives are becoming considerably 
common. 
1.3.1. The nucleic acid production inhibitors 
Drugs from this class of antimalarial target the enzymes involved in the folate production 
pathway of the parasite (folate antagonists) or alternatively the enzymes of the mitochondrial 
electron-transport chain (naphthoquinones), which are the processes whereby purines and 
pyrimidines are synthesised by the parasite. Disruption of these pathways thus interferes with 
DNA production and parasite replication. 
The most widely-used antifolate preparation is a combination of two separate drugs – 
pyrimethamine, and the sulphonamide compound sulfadoxine; the combination is generally 
referred to as SP. Pyramethamine targets the enzyme dihydrofolate reductase (as does another 
registered antimalarial, proguanil), while sulfadoxine disrupts the function of dihydropteroate 
synthase. When used together, the combination cripples parasite DNA production at two 
crucial stages. SP is effective at targeting schizonts in both the exo-erythrocytic/hepatic and 
erythrocytic stages of the parasite life cycle. However, mutations in both target enzymes make 












southern China, and the Amazon Basin; resistance in malaria-endemic regions of Africa vary 
and are reported to be as high as 45% (Wongsrichanalai et al., 2002). Another anti-folate 
compound, Proguanil, remains useful and is usually co-administered with another antimalarial 
agent– either CQ or atovaquone. 
Atovaquone is a naphthoquinone compound which decouples electron transport in the 
mitochondrion and collapses the membrane potential of the organelle. This prevents 
regeneration of ubiquinone, which is a coenzyme for dihydroorotate dehydrogenase, an 
essential enzyme in the pyrimidine pathway. 
1.3.2. The Artemisinin derivatives 
The Artemisinin family of drugs are endoperoxide compounds (Cumming et al., 1997).  
Artemisinin, called qinghaosu, is a sesquiterpene lactone. It has been used for hundreds of 
years in China but has only recently become known and used in other parts of the world. It 
was initially extracted from the leaves of the Artemisia annua plant. However, its 
bioavailability is poor and subsequently semi-synthetic derivatives (artemether, arteether and 
artesunate) were developed. 
 
 
Figure 1.4: The structure of dihydroartemisinin with the endoperoxide bridge highlighted in red. 
 
Although all these compounds break down to the active metabolite dihydroartemisinin (DHA; 
Figure 1.4), their mechanism of action remains unclear. Current research suggests that an 
interaction with a calcium-linked ATPase called PfATP6 is responsible (Fidock et al., 2008). 





















endoperoxide bridge of DHA, ultimately leading to the release of oxygen free radicals that 
damage the parasite (Cumming et al., 1997), cannot be ruled out.  
At present, artemisinin derivatives are being used combined with other classes of antimalarial 
in an attempt to increase the efficacy of existing treatment regimens. The combination 
treatment also limits the parasites’ exposure to sub-optimal circulating concentration of a 
single compound, which is conducive to the development of resistance to these drugs. 
1.3.3. The Quinolines 
This family of compounds has been the mainstay of antimalarial therapy in recent history. The 
parent compound, quinine, is a quinolinemethanol and was first isolated from the bark of the 
cinchona tree in the Amazon basin, having been used by native tribesmen there for centuries 
as a cure for fevers (Bagla, 1997). However, the synthetic derivative chloroquine (CQ; Figure 
1.5), a 4-aminoquinoline, has been the preferred drug since its development and introduction 
in the 1940s. A course of CQ treatment is comparatively cheap (Wilkins et al., 2002; 
Goodman et al., 2001c); additionally, for many years CQ showed a high level of efficacy 
coupled with a fairly minor side-effect profile and it can be administered orally. More 
recently, mefloquine (MQ) has been developed and marketed – this compound is chemically 
more closely related to quinine than to chloroquine. 
Resistance to CQ was first reported in the early 1960s and has spread rapidly since then 
through almost all malaria-endemic regions of the world, rendering CQ virtually ineffective as 
an antimalarial agent. Resistance to QN and MQ is far less prevalent; however, the increased 
cost and unpleasant side-effect profile of MQ, and the fact that QN can cause significant 
cardiac problems and requires an intravenous infusion via a drip in a hospital/clinic 
environment, largely undermine their feasibility in the field.  
Newer quinoline derivatives such as pyronaridine, halofantrine, lumefantrine and 
amodiaquine, as well as combination treatments, are similarly too expensive for widespread 
use in developing countries – in Sudan in 2005, treatments containing two or more 
antimalarials eg artesunate-SP or artemether-lumefantrine cost up to $9.60 for a full course 
(Malik et al., 2006), appreciably more than that estimated for CQ a few years earlier. As a 













The mechanism of action of the quinoline drugs has been the source of much debate and is 
still not fully understood; the mechanism of resistance also remains unresolved although 
substantial progress has been made in the last few years. Since this study focuses exclusively 
on CQ, the various hypotheses regarding these mechanisms are discussed in detail below. 
1.4. Mechanism of action of chloroquine 
CQ acts solely on the erythrocytic stages of the parasite life cycle, specifically during the 
trophozoite phases of growth when the parasite is consuming haemoglobin from the host red 
blood cell (Goldberg, 1993). Its exact mechanism of action has been the subject of much 
debate over the years; several relevant theories are discussed. 
 
 
Figure 1.5: The chemical structure of chloroquine 
 
1.4.1. CQ alters pH in the DV 
The parasite cytosol has an estimated pH of approximately 7.4 while the DV is an acidic 
compartment with a pH estimated to be around 4.5-5.2 (Dzekunov et al., 2000; Ursos et al., 
2000; Lehane et al., 2008). CQ is a divalent weak base with pKa values of 8.1 and 10.2 at the 
protonation sites (the nitrogens shown in blue in Figure 1.5). It thus remains unprotonated at 


















Weak bases are known to accumulate in acidic environments (Daniel and Wójcikowski, 1997; 
Yayon et al., 1984a) and, as a result, CQ is able to diffuse down both the concentration and 
the pH gradients into the DV simply by crossing the DV membrane from the parasite cytosol.  
Once inside the DV at lower pH, however, CQ becomes diprotonated and is then unable to 
cross the membrane in the opposite direction since it is now a charged species. Because the 
charged and uncharged species are different, the concentration gradient continually drives 
uncharged CQ into the DV from the cytosol, leading to a rapid accumulation of CQ into the 
parasite.  
This increase in uptake should continue until the buffering capacity of the DV is exceeded. At 
this point, the pH in the DV will rise and various enzymes and key processes will be 
adversely affected. Addition of CQ to parasites has been shown to increase pH in the DV 
(Krogstad et al., 1985; Yayon et al., 1985). 
1.4.2. Interactions inside the DV 
It was estimated that CQ can reach millimolar concentrations within the DV when the 
external concentration is only at low micromolar levels. Mathematically, however, this rules 
out the pH and concentration gradients as the sole driving forces of the process. 
1.4.2.1 Enzymatic interactions 
It has been postulated that the detoxification of FPIX via production of HZ was regulated by 
an enzyme, haem polymerase. It was demonstrated that the enzyme is inhibited by CQ in a 
dose-dependent manner (Slater and Cerami, 1992); however the discovery that synthetic β-
haematin, chemically identical to HZ, can be produced in vitro in a protein-free environment 
renders this theory improbable at present (Dorn et al., 1995; Egan et al., 1994). 
1.4.2.2 Chemical interactions with FPIX 
Bray and colleagues (Bray et al., 1998; Bray et al., 1999) demonstrated that CQ accumulation 
correlates well with levels of free haem in the parasites and that its uptake appears to be 
dependent on the presence of haem. Furthermore, CQ binds to haematin from both CQR and 
CQS isolates in equal measure and like many other quinolines can interact directly with FPIX. 
Once CQ has associated with either the monomers or dimers of FPIX, crystallisation into HZ 
is inhibited and the free haem builds up to toxic levels in the DV, leading to membrane 












Using structure-activity relationship studies, Egan and colleagues have shown that CQ binds 
directly to haem in a predictable manner (Egan et al., 2000). It has been shown that the two 
CQ protonation sites – the terminal nitrogen on the basic side chain and the ring nitrogen 
(nitrogens in blue in Figure 1.3) – are important atoms in the accumulation process while the 
planar ring structures (in the orange block in the figure) provide direct interaction via π-
stacking with the haem to form a complex . The chlorine atom interferes directly with 
formation of β-haematin. 
In the presence of lipids, β-haematin can form spontaneously in vitro under conditions similar 
to that of the DV (pH 4.8; 37°C) as has been shown (Egan et al., 2006); this method is far 
more rapid and efficient than in the absence of lipids described previously. In the presence of 
lipids β-haematin formation occurs in less than a minute, compared to about an hour in their 
absence, and uses the microsomes as seeding sites from which the FPIX dimers associate into 
long chains of HZ.  
This suggests that the lipid microsomes present in the DV are vital in the FPIX detoxification 
process. Since it is known that FPIX and the CQ-FPIX complex can bind to membranes and 
lipid bilayers, interaction between CQ-FPIX complexes and microsomes may disrupt 
formation of HZ in addition to destabilising the DV membrane.  
1.4.3. Interactions with FPIX in the cytosol 
Although CQ is able to prevent polymerisation of FPIX into HZ, this may not be the only 
method employed by the parasite to detoxify free haem in the DV.  
It was suggested that approximately one-third of the remaining free haem was polymerised 
into inert HZ crystals; the rest was exported to the parasite cytosol where it was then 
eliminated.  
Elimination occurred in the cytosol by one of two proposed mechanisms: 
• via linkage to glutathione (Ginsburg et al., 1998) in a process well-known to protect 
thiol groups of proteins from binding by reactive species (Campbell, 1991a) and thus 
preventing cell death. Glutathione would bind to the haem to prevent interaction with 
and damage to proteins and membrane structures in the cytosol 












In the case of the former, glutathione is able to degrade free haem. It was then shown that CQ 
and AQ can both prevent degradation of either membrane-bound haem, or free haem in 
solution, in the presence of glutathione.  
In terms of the latter proposal it was demonstrated that, under simulated DV conditions in 
vitro, free haem is degraded quite rapidly by peroxide and that addition of CQ inhibits this 
decomposition. Neither theory suggested what might happen to the remaining iron atoms left 
after FPIX breakdown. Both of these theories were later disproved by the determination that 
approximately 60% of the iron in a parasitised erythrocyte is contained within the parasite 
itself, with 90% of that iron within the DV (Egan et al., 2002) and not in the cytosol. 89% of 
the iron was bound into HZ.  
This discovery strongly suggests that CQ action is primarily linked to production of HZ in the 
DV, and that the other two proposed pathways play at most a very small role in the process of 
FPIX detoxification. 
 
1.4.4. Interactions with HB in vesicles 
More recently, it has been shown that the presence of CQ causes a build-up of undigested HB 
in the parasite, found in endosomes being transported to the DV (Famin and Ginsburg, 2002; 
Hoppe et al., 2004) as well as a build-up of endosomes already in the DV (Yayon et al., 
1984b).  
It has therefore been suggested that CQ prevents the endosomes from fusing with the DV, 
thereby inhibiting metabolic breakdown of HB. It has also been suggested that CQ is able to 
interfere with the aspartic proteases and a cysteine protease (the plasmepsins and falcipain 
respectively) responsible for the initial cleaving of HB; this leads to the increase in undigested 
HB in the parasite (Moura et al., 2009; Kolakovich et al., 1997).  
In either case, this would effectively stop digestion of HB at the uptake stage and 
subsequently starve the parasite of the peptides released during this process. Since host HB 
breakdown is the primary source of nutrients essential for the parasite’s own metabolic and 












1.5. Mechanisms of chloroquine resistance 
Resistance to CQ was first observed in the early 1960s; since then, the phenomenon has 
pervaded and spread globally to the point where CQ was no longer regarded as an effective 
antimalarial from the mid 1980s onwards (reviewed in Foote and Cowman, 1994).  
Although other aforementioned antimalarials retain efficacy to a lesser or greater degree, none 
of them are as safe nor as cost-effective as CQ was (Goodman et al., 2001b). Understanding 
CQ resistance is vital for malaria-endemic countries from 2 perspectives: to prevent resistance 
to other antimalarials, and to overcome CQ resistance with the possibility of reintroducing CQ 
for mainstream use.  
Drug resistance can arise in several different ways.  
• Change in the drug target 
o drug targets can alter through mutations as was observed with resistance to SP  
o drug targets can be over-expressed leading to reduced effectiveness of the drug 
since there are more targets available to carry out the required function that the 
drug is intended to disrupt.  
 
• Alternatively, the drug itself may be altered to the point where it no longer interacts 
with its target, as is seen in penicillin-resistant bacteria where the β-lactamase enzyme 
cleaves the antibiotic into an inactive form  
 
• There may be a change in the environment (e.g. pH or osmotic pressure) in which the 
drug acts, leading to a disruption in drug activity 
 
• Lastly, the drug may not ever reach its intended target – either a reduction in drug 
uptake or an increase in drug efflux would play a role in this case  
Several of these mechanisms have been suggested to play a role in CQ resistance since the 
appearance of the CQR phenotype; current research indicates that it is probably a combination 












1.5.1 Change in the pH of the DV 
Studies examining kinetic modeling (Ginsburg and Stein, 1991) and use of pH-altering 
chemicals (Bray et al., 1992b) indicated that perhaps the ATPases on the DV membrane 
responsible for maintaining pH in the DV might have altered function through mutations in 
CQR isolates, leading to a decrease in proton transport and thus an increase in the pH of the 
DV. This in turn would cause a decrease in accumulation of any weak base, including CQ. 
However, experimental evidence obtained via single-cell analysis indicated otherwise 
(Dzekunov et al., 2000) when the observed pH was shown to be lower in the DV of a CQR 
parasite (pH 5.21 in P. falciparum Dd2) than in a CQS parasite (5.64 in P. falciparum HB3). 
The experiment was conducted with Acridine Orange, a weakly-basic fluorescent compound, 
and involved calculating its concentration and then deducing the pH of the DV from that 
value. Researchers suggested the lower pH reduced the amount of soluble free haem (Ursos et 
al., 2000), and since CQ uptake is highly dependent on the level of haem it would explain the 
decrease in accumulation in CQR isolates.  
The experimental analysis was questioned, as was the technique used since it concerned an 
observation of one parasite only (Kirk and Saliba, 2001; Bray et al., 2002). Moreover, several 
phenomena remain unexplained by this theory – firstly, a change in pH should affect all of the 
weakly-basic quinolines and not only CQ; secondly, there are several existing analogues of 
CQ able to circumvent CQ resistance (De et al., 1996; Ridley et al., 1996) which seems 
unrelated to pH-linked accumulation and suggests that the changes occurring are highly 
specific to CQ.  
Altered pH in the DV is believed to play a role, however, and is discussed further in 1.5.2.4 
below. 
1.5.2. Differences in CQ accumulation via transporters 
It was demonstrated that CQR strains take up less CQ than CQS strains (Fitch, 1969) and this 
is generally accepted as one of the definitive determinants of CQ resistance. The difference in 
uptake varies; CQS isolates are known to accumulate three to ten times more radiolabelled 
CQ than CQR isolates (Taylor et al., 2000; van Schalkwyk et al., 2001; Bray et al., 1992a; 
Krogstad et al., 1987), depending on the strains utilised. However, comparing the published 












and the level of CQ accumulation in the parasite within either CQR or CQS isolates i.e. the 
CQS strain with the lowest IC50 does not necessarily accumulate the highest amount of CQ. 
Previously, CQR parasites were shown to efflux CQ up to forty times more rapidly than CQS 
parasites (Krogstad et al., 1987). This process is highly energy-dependent and its efficacy is 
reduced in the absence of glucose. More recently, however, research from several groups has 
shown that rates in some CQR and CQS isolates are similar, suggesting that reduced uptake 
rather than increased efflux is responsible for the differences observed in CQ accumulation. 
1.5.2.1 The P-glycoprotein homologue 
Several different proteins have been implicated in this alteration of CQ transport in the 
parasite. It was shown that a homologue of the P-glycoprotein (PGP) – the multi-substrate 
transporter responsible for resistance to anticancer drugs in certain mammalian cancer cell 
lines by pumping the compounds out of the cell (Ma et al., 1987; Goldstein et al., 1992; Ling, 
1987) – exists in the malaria parasite as Pgh1, encoded by the genes pfmdr1 and pfmdr2 
located on Chromosome 5. Pgh1 interacts similarly to PGP in the presence of certain PGP 
substrates such as verapamil (Martin et al., 1987); additionally Pgh1 is over-expressed in 
some CQR strains of P. falciparum (Cowman et al., 1991) and thus was suspected to be 
responsible for the CQR phenotype. Both PGP and Pgh1 are members of the ATP-binding 
cassette (ABC) superfamily of transporters (Goldstein et al., 1992), collectively known to be 
responsible for trafficking a massive variety of substrates in many different cell types across 
the biological spectrum. 
Further work has since revealed that there is no difference in Pgh1 sequences between CQR 
and CQS isolates (Barnes et al., 1992), and that drug pressure with CQ can cause 
deamplification of pfmdr1 and loss of expression of Pgh1 in the parasite which in turn leads to 
an increase in sensitivity to MQ (Lim et al., 1996). Pgh1 does however appear to modulate 
sensitivity to several antimalarials (Reed et al., 2000; Sidhu et al., 2005) as well as 
transporting several quinoline drugs in addition to the anti-cancer agent vinblastine (Sanchez 
et al., 2008). Polymorphisms in the gene do alter substrate specificity, and mutations in it may 
decrease accumulation of CQ in a reversible manner; however Pgh1 alone does not confer CQ 
resistance. 
1.5.2.2 Other ABC superfamily proteins 
Altering resistance to CQ with a diverse variety of functionally-related antidepressant agents 












compounds (Coutaux et al., 1994), which is to prevent transport of neurotransmitters across 
the membrane of neurons in the synaptic cleft via other members of the ABC superfamily. 
However, altering resistance seems to be related more to chemical structure than clinical 
function. This is discussed in detail in section 1.6.2.2 below 
1.5.2.3 CG2 
A genetic cross between CQS and CQR lines demonstrated that it was not one of the pfmdr 
genes which was responsible for the resistance phenotype. Further genetic crosses mapped 
resistance to a locus on chromosome 7 believed to contain several hundred genes (Wellems et 
al., 1991), and further research yielded a candidate gene called cg2 which contained several 
different polymorphisms in some forty strains of CQR and CQS parasites (Su et al., 1997).  
These differences were highly varied in CQS isolates, but quite specific in the CQR strains. 
Additionally, the polymorphisms were geographically distinct in the CQR strains, suggesting 
two different origins of resistance – one from Indochina as early as the 1950s seen primarily 
in Asian and African (now called Old World or Dd2 type) isolates, and another from South 
America (New World or 7G8 type) which arose more recently. The importance of the 
difference in 7G8 vs Dd2 type resistance is discussed in 1.6.2.3. below.  
The protein product CG2 was shown to localise on the parasitophorous membrane, the 
interface at which HB ingestion from the host cell occurs, and was found in the presence of 
HZ, suggesting it might be involved in the activity and efficacy of CQ.  
1.5.2.3 The sodium-hydrogen antiport 
It was proposed that a mutated Na+/H+ exchanger (NHE) might be responsible for 
observations of altered accumulation – in CQS strains, the protein could function as a CQ/H+ 
exchanger and import CQ into the parasite (Sanchez et al., 1997; Wunsch et al., 1998). 
Conversely, CQR strains with a mutant exchanger simply did not import CQ. The evidence 
for this theory came from the observation that in the presence of amiloride, a potent inhibitor 
of this exchanger, CQ uptake was reduced.  
However it was later shown that amiloride, like CQ, binds to haematin and thus competes 
with CQ for binding sites (Bray et al., 1999). 
1.5.2.4 PfCRT 
When CQR parasites were transfected with cg2 from CQS parasites, there was no change in 












genome, this suggested that another gene from the locus containing cg2 and in close 
proximity to it was responsible for the CQR phenotype. Further research (Carlton et al., 2001) 
uncovered a likely candidate in the highly polymorphic pfcrt, a putative transporter belonging 
to the drug-metabolite transporter family (Martin and Kirk, 2004), containing ten 
transmembrane regions but lacking an ATP-binding domain (Figure 1.6 and 1.7) and thus not 
classed as an ABC protein.  
Mutations in pfcrt were highly conserved across CQR isolates (Carlton et al. 2001a; Fidock et 
al. 2000b) with eight predominant mutations occurring and two of those, K76→T and 
A220→S, present in the protein product PfCRT of all 24 CQR isolates examined of both Old 
and New World origin.  
However, one CQS isolate had six of the mutations except the one at position 76; when this 
was introduced via a cross as K76→I, CQ resistance was observed in the progeny. This 
suggests that position 76 is critical in determining resistance. The observed K76 mutations all 
involve the replacement of lysine (K), a positively charged amino acid, to a neutral one. The 
substitutions have included the neutral amino acids threonine (T), isoleucine (I) and 
asparagine (N).  
 
 
Figure 1.6: The sequence of PfCRT. The trans-membrane domains are indicated in grey and the 
eight point mutations identified in CQR isolates are highlighted. Data taken from Fidock et al, 2000b. 
 
Disrupting pfcrt lead to a decrease in parasite survival, suggesting that the protein product 
PfCRT (the P. falciparum chloroquine resistance transporter) serves an important function in 
Plasmodium falciparum (Waller et al., 2003). Altering PfCRT expression had no effect on 
parasite sensitivity to other quinolines, but altering the gene pfcrt lead to changes in pH in the 












CQ transport experiments in which both mutant and wild-type PfCRT were expressed in 
oocytes from Xenopus laevis showed that mutant PfCRT was able to transport CQ while wild-
type was not (Martin et al., 2009), directly implicating altered PfCRT alleles in the CQ 
resistance mechanism. 
The K76T mutation in PfCRT has recently been shown to be associated with a leak of protons 
from the DV in CQR strains (Lehane and Kirk, 2008; Lehane et al., 2008). The transport of 
protons into the DV to maintain the low pH occurs via the V-type ATPases present on the DV 
membrane. When ATPase activity is suppressed, the DV alkalinizes faster in transfected 
parasites containing the CQR phenotype of PfCRT than in CQS parasites.  
This indicates that PfCRT has some function in transporting protons from the DV, perhaps to 
moderate pH. With ATPase activity inhibited, the DV in CQR-type transfectants alkalinized 
significantly more rapidly in the presence of CQ; conversely, the rate of alkalinization 
decreased in the CQS-type parasites. When coupled with the findings that CQR parasites 
accumulate less CQ than their CQS counterparts, the data suggests that the pH-modulating 
effect of wild-type PfCRT is inhibited by CQ while mutant PfCRT co-transports CQ and 
protons, presumably in the form of diprotonated CQ, from the DV back into the cytosol. 
 
 
Figure 1.7: The structure and orientation of PfCRT with all observed mutations indicated. Image 
adapted from Carlton et al, 2001. 
 
K76T has also been shown to decrease the effectiveness of quinidine and quinine (Cooper et 
al., 2002). Another mutation, K76I, has been associated with quinidine resistance coupled 
















the following section. Conversely, while K76N has shown no change in quinidine sensitivity 
it has conferred resistance to both quinine and CQ. The importance of position 76 cannot be 
understated in the quinoline resistance mechanisms. 
1.6 Resistance reversal 
Since the early 1980s, it has been possible to circumvent drug resistance in vitro in a process 
known as chemosensitisation, or resistance reversal.  
1.6.1 The mammalian MDR phenotype 
The phenomenon was observed originally in multi-drug resistant (MDR) tumour cell lines 
(Tsuruo et al., 1981; Rogan et al., 1984) using the calcium channel blocking agent verapamil 
(VPL), which was a known substrate of the P-glycoprotein responsible for the MDR 
phenotype. VPL was able to prevent the P-glycoprotein from transporting anticancer 
compounds from the tumour cells, the mechanism of multi-drug resistance, and thus allowed 
the compounds to reach the toxic levels required to disrupt vital functions and thus kill the 
tumour cells. 
1.6.2 Chloroquine resistance reversal 
Similarly, since Pgh1 was known to exist in Plasmodium, VPL was shown to reverse 
resistance to CQ in vitro (Martin et al., 1987), suggesting that the MDR and CQR phenotypes 
were similar. This was followed by attempts at altering the CQ IC50 with a large range of 
chemosensitisers from diverse d ug classes, as reviewed recently (van Schalkwyk and Egan, 
2006). Notable successes were achieved in vitro with a variety of antidepressants such as 
desipramine (Bitonti et al., 1988) and fluoxetine (Gerena et al., 1992), other calcium channel 
blockers like nifedipine and analogues of VPL (Kalra et al., 1993; Ye and Van Dyke, 1988), 
antihistamines (Peters et al., 1990; Singh and Puri, 2000), and a series of natural compounds 
isolated from plants (Rafatro et al., 2000) among others. Some structures are shown in Figure 
1.8 below.  
Reversal is commonly measured as the Response Modification Index, or RMI, and is the ratio 
of the shifted CQ IC50 in the presence of the chemosensitiser to the original CQ IC50. Lower 
RMI values indicate a larger shift in the modified IC50 and thus an increased level of 
chemosensitisation. Resistance reversal is usually characterized by a shift in the IC50 of CQ in 
the presence of a chemosensitiser to a lower level in a CQR isolate, often a level comparable 












1.6.2.1 Mechanism of reversal 
The mechanism of resistance reversal is not yet fully understood. Thus far, the RMI 
determined in CQS isolates with all known chemosensitisers has not been significantly 
different to 1, indicating no shift in the IC50. The agents are usually co-administered with CQ 
at a concentration at which the chemosensitiser is sub-lethal to the parasite. These data show 
that the compounds only potentiate the action of CQ, and that the reversal observed is not 
merely an additive toxic effect. 
Several times, the shift in the CQ IC50 was correlated with an increase in uptake of CQ in the 
presence of the chemosensitisers (Taylor et al., 2000; van Schalkwyk et al., 2001). This was 
demonstrated by quantifying the accumulation of CQ tagged with tritium, which indirectly 
suggests a mechanism of action involving a change in CQ transport. VPL has been shown to 
increase the uptake of CQ as well as inhibiting the aforementioned increase in pH in the DV 
via proton leakage seen in the presence of CQ in CQR isolates, suggesting a direct interaction 
during reversal with PfCRT (Lehane et al., 2008).  
1.6.2.2 Chemosensitiser structure vs function 
In terms of their clinical use chemosensitisers are functionally quite diverse as described 
above. Drugs from many different therapeutic classes are able to reverse resistance to varying 
degrees both in MDR cells and in the parasite. Analysis showed that compounds share a 
number of common structural features believed to play a role in their mechanism of action 
(Gerena et al., 1992). A typical chemosensitiser would: 
• Be lipid-soluble 
• Have two or more planar, preferably aromatic, ring structures 
• Carry a cationic charge 
• Have one or more tertiary or secondary basic nitrogen atoms 
 
These features would allow the compound to cross membranes and accumulate down the pH 
gradient to the DV. This observation was strengthened when it was shown that PGP substrates 
such as Cyclosporin A and progesterone, which lack one or more of these features but are able 
to chemosensitise MDR cells, were unable to reverse CQ resistance in the parasite (van 
Schalkwyk et al., 2001). Additionally, although many molecules containing a tricyclic core 












Singh and Puri, 2000), those lacking either a side chain or a basic nitrogen, such as 
carbamazepine which has neither, cannot do so (Coutaux et al., 1994). 
The side chain has seemed important in CQ resistance for some time. CQ analogues able to 
circumvent resistance mentioned in 1.5.1 above were only able to do so if the side chain was 
less than 4 or greater than 8 carbon atoms long; CQR parasites showed varying levels of 




Figure 1.8: The chemical structures of verapamil (top), desipramine (bottom left) and fluoxetine 
(bottom right) respectively. Key features are highlighted – basic nitrogen groups in red and aromatic 
structures in blue. 
 
The nature of the nitrogen atom/s is also quite critical. On the whole, secondary/tertiary amino 
groups have been shown to increase CQ accumulation whereas amides do not. In addition to 
this, the location of the nitrogen atom relative to the planar/aromatic rings seems to be 
relevant; if the nitrogen is too far away – further than 4 atoms down the chain – 
chemosensitisation is limited.  























Resistance reversal is also adversely affected if the nitrogen is closer than 2 atoms to the ring 
structures (Alibert et al., 2002; Bhattacharjee et al., 2001; Bhattacharjee et al., 2004). All of 
these data implicate a fairly specialised mechanism of resistance reversal, suggesting 
interaction with a specific protein target. 
This knowledge has lead to the design and synthesis of several compounds able to reverse 
resistance in vitro (Wu et al., 2005; Yeh et al., 2006; Osa et al., 2003; Bhattacharjee et al., 
2004).  
1.6.2.3 PfCRT and resistance reversal in Old World and New World phenotypes 
Many CQR isolates of P. falciparum have responded in vitro to chemosensitisation; however, 
it has been shown that certain isolates from South America do not (Menezes et al., 2003; 
Martin et al., 1987). This appears to be related to the haplotype of PfCRT found in each 
isolate (Mehlotra et al., 2001). While position 76 of PfCRT appears to be responsible for 
resistance to CQ, the sequence of amino acids in positions 72-75 seems to determine whether 
or not the resistant isolate responds to chemosensitisers in vitro.  
So-called Old World or Dd2-type resistance as seen in Asia and parts of Africa is 
characterized by the sequence CVIET in positions 72-76; New World or 7G8-type resistance 
typically found in South American isolates has SVMNT in these positions. CQS isolates in 
both regions are characterized by CVMNK. This suggests that the mutations in PfCRT 
evolved through different pathways in different geographical regions, although CQR isolates 
from the Philippines and Papua New Guinea with the 7G8 haplotype have been discovered.  
It has been demonstrated that Dd2-type resistance is completely reversible in vitro by VPL 
whereas 7G8-type resistance responds to a far lesser degree (Menezes et al., 2003). Whether 
or not this would affect in vivo experimental use or clinical use of chemosensitisers remains 
unknown at present – pfcrt has simply not been studied to any great extent in animal models 
of malaria, and resistance reversal is not yet well-developed enough to have moved from the 
laboratory into patients.  
Although pfcrt homologues have been found in CQS isolates of both the primate malaria 
species Plasmodium knowlesi as well as the murine parasite Plasmodium berghei and the 
slime mould Dictyostelium discoideum (Nomura et al., 2001), very little research has been 
carried out on different strains of these species beyond simply identifying the gene and 












that this region appears to be conserved in Plasmodium, and the rodent and primate species 
evaluated largely mimic the CVMNK amino-acid sequence seen in CQS isolates of P. 
falciparum and P. vivax. 
While all chemosensitisers do have inherent low-level antimalarial activity – about three 
orders of magnitude less than CQ, in the micromolar range – the 7G8-type isolates appear to 
be more sensitive to these toxic effects than to the resistance-reversal capabilities of the 
compounds, contrasting the Dd2-type response. Following VPL treatment, the increase in the 
pH of the DV seen in CQR isolates is significantly less in the 7G8 haplotype than in Dd2 
(Lehane et al., 2008), possibly suggesting that pH change plays a significant role in the 
resistance reversal process. 
1.6.3 Other quinolines 
Resistance reversal with the other quinoline compounds has not been as widely studied as CQ 
resistance since isolates resistant to quinolines other than CQ are less commonly encountered 
in the field. However, several compounds are known to modulate resistance to other drugs in 
this family. 
Penfluridol has been shown to reverse resistance to MQ both in vitro and in vivo using the P. 
berghei mouse model (Peters and Robinson, 1991; Oduola et al., 1993). As with CQ 
resistance, no change in IC50 was seen in the MQ-sensitive strains. VPL was not able to 
change the MQ IC50.  
Penfluridol does not alter CQ resistance even though structurally it meets the criteria believed 
to be necessary to affect reversal, suggesting that MQ and CQ resistance involve entirely 
separate mechanisms. Given that Pgh1 appears to play a role in sensitivity to some quinolines 
as described above, it is possible that penfluridol interacts with it rather than PfCRT.  
Parasites containing other alleles of PfCRT show varying levels of sensitivity to quinine and 
quinidine depending on the substitution at position 76 as discussed above. All these 
phenomena, both increased and decreased sensitivity to this family of compounds, are 
susceptible to reversal in the presence of VPL, suggesting once again that CQ and quinine 












1.7 Resistance reversal in vivo and in clinical practice 
Although a level of success has been reported with some chemosensitisers in in vivo models 
such as the mouse model using Plasmodium yoellii (Peters et al., 1990; Peters and Robinson, 
1991) and the Aotus owl monkey model using P. falciparum in the species (Bitonti et al., 
1988; Kyle et al., 1993), resistance reversal has never properly progressed from the laboratory 
into clinical practice.  
1.7.1 Resistance reversal in animal models of malaria 
Prior to the 1976 development of the culturing techniques used currently to cultivate 
Plasmodium falciparum parasites in vitro, malaria was studied extensively in animal models. 
Commonly used systems included rodents and domestic birds. The rodent model is still used 
extensively as a stepping-stone between in vitro research and primate and/or human studies.  
The murine parasite model has been utilized numerous times to evaluate chemosensitisers for 
potential use as clinical resistance reversers and there has been some level of success – several 
antihistamines (Peters et al., 1989; Peters et al., 1990; Singh and Puri, 2000), calcium-channel 
blocking drugs (Kalra et al., 1993) and antidepressants (Peters and Robinson, 1991; Singh and 
Puri, 2000) have shown some promise in decreasing the survival rate of drug-resistant 
parasites in infected mice when co-administered to the animals with CQ.  
Several small studies have also been carried out in primates, with desipramine shown to 
change the course of infection of CQR Plasmodium falciparum in lemurs, using the gray-
bellied night monkey Aotus lemurinus lemurinus, commonly referred to as the owl monkey 
(Bitonti et al., 1988). Verapamil was later shown to be ineffective in the same model (Kyle et 
al., 1993) and data suggested that CQ plus verapamil caused some toxicity to the host 
animals. 
1.7.2 Resistance reversal in patients 
Several drugs have been evaluated for efficacy in reducing parasites in small samples of 
malaria patients with mixed success.  
One clinical study compared standard doses of CQ for three days to the same dose of CQ 
supplemented with desipramine and found no significant increase in parasite clearance in the 
desipramine group, which indicated that the desipramine had had no notable effect on CQ 












Conversely, another study showed that combining CQ with chlorpheniramine (an 
antihistamine) was as effective in clearing parasites in Nigerian children with malaria as using 
halofantrine in the same population (Sowunmi et al., 1998). Halofantrine was the 
recommended 1st-line agent prescribed in that particular region of Nigeria since CQ resistance 
rates in the area are estimated to be up to approximately 45%. 
A third study (Oduola et al., 1998) indicated that circulating levels of ingested promethazine, 
an antihistamine commonly prescribed to counter itching which is a common CQ side-effect, 
are sufficient to reverse CQ resistance in vitro. Experiments were carried out in which the 
plasma component of culturing medium was replaced with plasma from patients who had 
taken oral promethazine shortly beforehand; subsequent addition of standard amounts of CQ 
to the promethazine-containing growth media showed significantly increased parasite death in 
the presence of both drugs, indicating that the resistance had been effectively reversed by an 
adequate therapeutic concentration of the promethazine. 
Regardless of this, resistance reversal remains largely in the realm of the theoretical, and 
efforts to eradicate malaria remain focused on mosquito control and in the development of 
new antimalarials. 
1.7.3 Practical and safety considerations affecting resistance reversal 
There are several reasons cited for the lack of implementation of resistance reversal: 
• New and effective antimalarials have since been developed and are in use currently in 
malaria-endemic regions, with even more new compounds constantly being researched 
for introduction 
• Chemosensitisers work at comparatively high doses in vitro, frequently unachievable 
clinically 
o Doses would be toxic, or even lethal in the case of VPL, to patients 
o Known chemosensitisers have thus far tended to be highly protein-bound in 
plasma and free drug levels do not reach levels required to effect reversal 
(Warsame et al., 1992; Gbotosho et al., 2006) 
Additionally, other factors would need consideration: elimination half-life of the 
chemosensitiser would need to be examined. It has been known for decades that antibiotics 












may well suffer the same fate (Campbell, 1993). Any prolonged exposure to sub-toxic/sub-
lethal concentrations of a compound may result in increased tolerance to that compound and 
this could potentially doom any drug+chemosensitiser combination. 
Safety and unwanted side-effects would also be crucial considerations. Without extensive 
testing, which would be required with human trials, there is no guarantee that a handful of 
compounds which are non-toxic individually might not work synergistically to create an 
effect downstream which is more toxic to the patient than the parasite. This has been seen 
previously with a CQ-VPL combination in Hep-G2 cultured liver cells, where VPL 
interaction with Pgp in the cells caused CQ, usually benign at the low concentration it reaches 
in this cell type, to accumulate to levels which were toxic to the cell and could theoretically 
prove to be lethal to the patient (Watt et al., 1990). Additionally, CQ-VPL combinations have 
shown toxicity in the primate model (Kyle et al., 1993). 
The potential for widespread systemic changes, even minor transient alterations, would need 
careful evaluation to minimize the risks involved when combining chemicals in a patient or 
otherwise at-risk population. 
1.7.4 Drug availability 
Some success in reversing CQ resistance in patients has been achieved, particularly with 
antihistamines (Sowunmi et al., 1998; Gbotosho et al., 2008). Certain antihistamines such as 
promethazine would be ideal candidates for co-administration with CQ since they would be 
able to counter pruritus (itching), a common side-effect of CQ treatment (Sweetman et al., 
2007), and in fact promethazine is frequently co-prescribed with CQ for this very reason.  
Small-scale studies with this drug, however, have yielded mixed results – although the 
circulating level of promethazine in the bloodstream seems sufficiently high to reverse 
resistance (Oduola et al., 1998), the CQ-promethazine combination it does not seem as 
effective as other CQ-antihistamine combinations, such as CQ-chlorpheniramine have.  
The availability of each chemosensitiser is a crucial criterion in reversing CQ resistance. Both 
VPL and the tricyclic antidepressant desipramine, agents which are easily able to effect 
reversal in vitro, were unable to do so in human trials. The cause is believed to be the high 
level of binding (about 90%) of each drug to plasma proteins such as albumin and the α1-acid 
glycoprotein (Gbotosho et al., 2006; Sweetman et al., 2007), effectively leaving a tenth of the 












Chlorpheniramine as mentioned above, however, binds to a far lesser degree than 
promethazine, which might explain the greater success of combining it with CQ compared to 
promethazine. Studies with MDR reversing agents in cancer research have shown similar 
results (Lehnert et al., 1996).  
This suggests that standard therapeutic doses of these known chemosensitisers – i.e. as 
prescribed for their typical indications in patients – would not be nearly sufficient to achieve 
resistance reversal and would need to be increased, which in turn would bring its own suite of 
potential side-effects and toxicity. A possible solution to this problem would be to combine 
several agents simultaneously as a cocktail treatment. 
1.8 Combination chemotherapy 
In present-day practice, the use of a single agent to control a condition (monotherapy) – in 
particular certain infectious diseases such as tuberculosis (TB) and HIV/AIDS – may not be 
appropriate. Drug resistance has been increasing steadily since it was first discovered (Wise, 
2004; Soulsby, 2005). The resistance phenomenon, whereby cancer cells and parasites of a 
variety of types – from simple bacteria and viruses to protozoa and even eukaryote parasites 
like helminths – no longer respond to the agents used to control and limit their growth, has 
particularly been a problem for several of the most common and most lethal conditions such 
as TB, HIV/AIDS, cancers (Frei, III et al., 1965) and malaria.  
Monotherapy has been largely to blame for the rapid spread of resistance in infectious 
diseases. Malaria is no exception with resistance to previously first-line agents such as CQ 
and SP prevalent throughout the malaria-endemic world (Foote and Cowman, 1994), while 
instances of resistance and treatment failure to the artemisinin family are being reported in 
increasing numbers (Chrubasik and Jacobson, 2010). As a result, combination chemotherapy 
is widely recommended throughout malaria-endemic regions (World Health Organisation, 
2010a). 
1.8.1 Combination chemotherapy 
Combination regimens for appropriate conditions are developed with the same end-point in 
mind i.e. an efficient cure for the patient which reduces morbidity and mortality.  
Even though combinations can be more costly than single drugs, more efficient treatments can 












are considered (Wilkins et al., 2002). However, the rationale behind the composition of 
different combinations varies for different conditions: 
• In some cases, especially with cancers and infectious diseases such as HIV/AIDS and 
TB, several antibiotic agents which are known to be detrimental to the causative 
agent’s growth and/or multiplication are combined to create a lethal cocktail; in an 
ideal scenario, a cocktail in which synergism occurs and the compounds contained in 
the cocktail combine to create a greater toxic effect together than the sum of each one 
used individually (Frei, III et al., 1965; Adovelande et al., 1998). A typical 
combination for TB may contain as many as four different antibiotics from different 
classes (Caminero et al., 2010); and the standard management for HIV/AIDS consists 
of a regimen of three different antiretroviral agents, the so-called triple therapy (Beck 
et al., 2001).  
 
• For some of the other aforementioned conditions, however, a combination regimen is 
designed to target several different processes which the disease affects, thus providing 
curative action (and typically also symptomatic relief) on several different fronts, as is 
seen with treatment for hypertension (Elliott, 2003). 
1.8.2 Formulating combinations 
Combination treatments sometimes occur as a single formulation – anti-TB and anti-HIV 
preparations frequently contain multiple drugs packaged in a single tablet or capsule – and 
sometimes as individually-packaged drugs simply administered simultaneously.  
While the former might be preferable – in terms of ensuring that the compounds are always 
given together and in the correct ratios with as little inconvenience as possible – the latter is 
significantly easier to achieve. The reason for this is simple: development of pre-formulated 
combination treatments is expensive, and especially so if the target population resides in the 
developing world. Products are still required to follow a stringent and costly evaluation as part 
of the registration process before being allowed onto the market.  
Thus, even though each individual drug in the combination may have been registered 
previously and be available for use already, pharmaceutical firms may not benefit from 
developing a single formulation containing these compounds. The cost of developing a 












intended for use in the developing world; as a result, simple combinations of existing drugs 
administered individually are preferable. 
1.8.3 Combination chemotherapy in malaria 
Although the use of multiple drugs against malaria in patients has only recently become a 
widespread practice, current recommendations advise that this is the suggested method of 
treatment in malaria-endemic areas (World Health Organisation, 2010a). 
1.8.3.1 Combining antimalarials 
Several preparations containing different combinations of antimalarial compounds have been 
available both historically and in recent times for both prophylaxis and treatment of malaria. 
These include Co-artem©, a combination of lumefantrine and artemisinin (Kremsner and 
Krishna, 2004); Malarone©, containing atovaquone and proguanil which were shown to be 
effective as a pairing (Radloff et al., 1996); and of course the aforementioned anti-folate 
preparation Fansidar©, the sulfadoxine-pyrimethamine treatment which was used extensively 
before drug resistance rendered it largely useless in many malaria-endemic regions across the 
globe (Foote and Cowman, 1994; Rumans et al., 1979).  
Others such as LapDap©, containing the anti-folate compounds chlorproguanil and dapsone, 
and Dacart© (which was a combination of LapDap© plus artesunate), were both withdrawn 
by their manufacturer, British pharmaceutical provider Glaxo-Smith-Kline. This withdrawal 
occurred fairly late into their development as a result of side-effects which were deemed too 
severe to allow development to continue (World Health Organisation, 2008).  
The World Health Organisation currently recommends artemisinin-based combination therapy 
as first-line treatment for malaria in endemic countries (World Health Organisation, 2010a). 
1.8.3.2 Combining resistance reversers 
Although combination chemotherapy for several conditions has existed for a considerable 
period of time, this does not apply to chemosensitisers. The major reason for this is probably 
because the principles of reversing resistance and the mechanisms by which the process 
occurs is not completely understood; and as a result it has not fully moved beyond the in vitro 
laboratory environment and into clinical practice at the time of writing.  
Nevertheless, combinations of a number of different chemosensitisers have been shown to be 












shown to work in combinations included compounds from across the pharmaceutical 
spectrum such as calcium-channel blockers (Adovelande et al., 1998), antidepressants and 
antipsychotics (Taylor et al., 2000; van Schalkwyk et al., 2001), antihistamines (Singh and 
Puri, 2000) and several novel compounds designed specifically for this purpose (Yeh et al., 
2006; Wu et al., 2005).  
The use of CQ with the combined concoction in each case was more effective than the use of 
CQ with a single constituent of the combination; each compound used was able to alter the 
action of CQ significantly when used singly and thus was effective as a chemosensitiser in its 
own right. To date, no compound has been described which is able to reverse resistance as 
part of a combination treatment but which is incapable of doing so alone. 
Exactly why some combinations e.g. the calcium channel-blockers VPL and fantoforone 
(Adovelande et al., 1998) appear to be synergistic while others are simply additive has not 
been researched as yet. The mechanism of chemosensitisation by individual compounds is not 
yet fully understood; however, several chemosensitisers (including chlorpheniramine, 
desipramine, promethazine and VPL) have recently been shown to be substrates for PfCRT 
and are known to induce a leak of protons from the DV in parasite strains containing a CQR 
phenotype of the protein (Lehane and Kirk, 2010).  
One of the critical criteria for a chemosensitiser appears to be the presence of basic nitrogen 
moieties (Guan et al., 2002), which would cause the drug to accumulate in the DV via the pH 
gradient and then become protonated in the acidic environment (Daniel and Wójcikowski, 
1997). The proton leak observed is probably indicative of transport of the protonated species 
of the compound by mutant PfCRT, in the same way as the CQ-associated leak of protons is 
believed to be transport of diprotonated CQ from the DV (Martin et al., 2009).  
This observation may have shed some light on the potential mechanism of resistance reversal; 
however, it does not explain why synergism is observed in some cases. If anything, the 
occurrence of synergism suggests that simple competition with CQ for export via mutant 
PfCRT is only partly responsible for the reversal phenomenon and that several different 
interactions with PfCRT might occur. 
Regardless of mechanism, though, combinations of chemosensitisers are able to reverse CQ 












and how efficient it might prove to be has yet to be determined. This is the purpose of this 
study.  
Logically, combining two or more chemosensitisers, which act additively or synergistically, at 
low doses in an animal model would allow one to avoid the high doses required to counter the 
inadequate availability through protein-binding of each compound in the animal – and thus 
also limit toxicity and/or unwanted side-effects which would be associated with the high dose 
– while potentially still reversing CQ resistance in the parasite.  
1.9. The aims and objectives of this study 
In the almost three decades since resistance reversal was described, the phenomenon remains 
unimplemented clinically, owing to numerous logistical and pharmacokinetic considerations 
which impact its usefulness beyond the controlled laboratory environment. This research aims 
to investigate whether these obstacles can be circumvented by using a combination of 
different compounds which are CQ chemosensitisers. 
Specifically, the research project will: 
• Examine the effect of known and potential chemosensitisers on the antimalarial effect 
of CQ in several CQR isolates of the parasite 
• Examine the effect of the compounds on CQ transport in the parasite system in vitro 
• Develop an effective combination treatment, or cocktail, of chemosensitisers in vitro 
• Evaluate the cocktail in an in vivo mouse model of malaria 
• Assess the effect of the chemosensitisers on CQ transport in the mouse model 
• Examine the pharmacokinetics of the compounds and the cocktail in healthy and 












Chapter 2 – The activity of the chemosensitisers used singly 
on the human malaria parasite in vitro  
2.1 Introduction 
Many different substances, both natural and synthetic, have been shown to be toxic to 
different genera in recorded history and the human malaria parasite Plasmodium falciparum is 
no different when it comes to xenobiotics. As a result, dozens of different compounds from 
numerous drug categories and chemical families have exhibited antiplasmodial activity to the 
point where they are considered to be clinically useful as antimalarials and prescribed for 
either treatment or prophylaxis of the disease. 
2.1.1 The intrinsic antimalarial activity of the chemosensitisers 
Apart from CQ, the drugs used in this study are not traditionally regarded as antimalarials and 
as such are not prescribed or administered clinically with either disease prevention or 
treatment in mind. Although these are not used in the treatment of malaria it is necessary to 
determine whether or not the chemosensitisers have any activity in the parasite strains used in 
the study in order to accurately measure their usefulness in reversing resistance; this will also 
allow a distinction between potentiation of CQ action and simple additive toxicity. 
Compounds evaluated in the study include antihistamines, antidepressants and an 
antipsychotic (Table 2.1). Structures of compounds are shown in Figure 2.1 
Compound Abbr. Mass Clinical use Known therapeutic targets 
Amitriptyline AMT 277.34 
Antidepressant 
Noradrenaline/serotonin receptors 
Citalopram CTL 306.35 Serotonin receptors 
Desipramine DES 276.34 Noradrenaline/ serotonin receptors 
Chlorpromazine CPZ 328.83 Antipsychotic 
Dopamine and serotonin receptors, 
histamine receptors, α-adrenergic 
receptors and muscarinic acetyl-choline 
receptors 
Azatadine AZA 290.40 
Antihistamine 
Histamine H1 and H3 receptors 
Chlorpheniramine CFN 274.79 H1 and H3 receptors 
Cyproheptidine CYP 287.40 H1 and H3 receptors 
Ketotifen KET 309.43 H1 and H3 receptors 
Promethazine PRO 284.42 H1 and H3 receptors 
Table 2.1: Chemosensitisers used in the study grouped as per therapeutic indication. Data from 
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Figure 2.1: The chemical structure of the chemosensitisers used during the study. Common features, 
structural motifs and similarities are highlighted. CQ is included bottom center for reference. 
The compounds were selected for several reasons. Firstly, all of them fulfill the necessary 
criteria described in 1.6 above believed to be necessary to effect reversal in a CQR parasite 
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and Puri, 2000; Bitonti et al., 1988). All but one of them contain the same tricyclic or 
pseudotricyclic core – two benzene rings, separated by one atom to which a nitrogen-
containing aliphatic chain of varying length is attached as shown (Figure 2.1); the last 
compound, KET (Figure 2.1 f), has a single benzene ring and a 5-membered thiophene instead 
of two benzene rings. The dual benzene ring motif has proved to be a successful 
pharmacophore in previous studies (Taylor et al., 2000; Peters et al., 1990; Bitonti et al., 
1988) and is possibly responsible for some of the cross-reactivity between receptors; 
additionally, several of the compounds have been used in small-scale patient studies with 
some level of success individually (Sowunmi et al., 1998; Oduola et al., 1998). 
More importantly, they were chosen based on their known pharmacodynamic targets and 
therapeutic mechanism of action and selected in order to reduce the likelihood of unwanted 
side effects.   
Ideally, each drug in the study would only have one receptor on which it acts; however, as 
shown in Table 2.1,  some of the compounds are known to have pharmacodynamic 
interactions to a lesser or greater degree with several different targets, especially 
chlorpromazine (CPZ).  
This should not pose any additional difficulties for two reasons: 
1. The shared interactions with the other drugs used in the study affect the histamine and 
neurotransmitter receptors only and the strength of the interaction is significantly less 
than that of the antihistamines or antidepressants traditionally used for these chemical 
activities. Since CPZ is not typically prescribed nor administered for antihistamine or 
antidepressant indications (Sweetman et al., 2007), it is thought that any cumulative or 
additive toxicity or side-effects from using CPZ with an antihistamine or 
antidepressant will be small enough to be insignificant 
 
2. The aim is to administer the compounds at a sufficiently low, sub-therapeutic level 
that these additive effects will be minimized 
 
2.1.2 The effect of the chemosensitisers on CQ transport in the parasite 
Although several of the drugs used here have been studied previously in vitro, it has been 
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evaluated and not the action on CQ uptake or efflux within the parasitized erythrocyte. CQR 
isolates of P. falciparum have been shown repeatedly to accumulate less CQ than CQS 
isolates since this was first demonstrated (Fitch, 1969) and this is a definitive criterion which 
forms the basis of all the theories of CQ resistance. 
The level of CQ uptake has never been completely correlated to the level of CQ sensitivity 
amongst cultured isolates. In short, there are large differences in uptake between CQR and 
CQS cultures when viewed as independent groups of parasite; however, CQR strains 
exhibiting a higher CQ IC50 do not necessarily show significantly lower accumulation levels 
than CQR isolates with a lower IC50. This observation has been made amongst both the 
sensitive and resistant strains being cultured in the laboratory (Bray et al., 1994; Wu et al., 
2005). 
Current research implicates increased efflux instead of decreased uptake as the mechanism for 
CQ resistance in parasite strains with either Dd2 or 7G8-type PfCRT. In both types, the 
mutated protein product is proposed to transport CQ as well as protons from the DV (Lehane 
and Kirk, 2008). 
Numerous chemosensitisers have been shown to increase total CQ accumulation into the 
parasitized erythrocyte (Taylor et al., 2000; van Schalkwyk et al., 2001; Wu et al., 2005) but 
this phenomenon has not been examined using most of the compounds in this study. Although 
the increase in uptake differs between isolates and the compounds being tested, with total 
accumulation increasing from 3-10 fold over the untreated controls, the improved 
accumulation has still not been as high as that seen in CQS parasites. Whether or not this is 
related to the activity of the altered PfCRT or is an innate difference between the strains 
examined (K1 and RSA11 as the CQR isolates; D10 as the CQS) is not known.  
2.1.3 The effect of chemosensitisers on CQ activity in vitro 
More than two decades have passed since chemosensitisation was first demonstrated, and 
VPL was shown to affect the activity of CQ in a CQR isolate of malaria (Martin et al., 1987).  
Chemosensitisation had first been demonstrated some years beforehand against multi-drug 
resistant cancer cells, also using VPL (Tsuruo et al., 1981). VPL and the anticancer agents are 
substrates for the P-glycoprotein, a transporter from the ATP-binding cassette family of 
proteins, which was able to pump the anticancer drugs from the cells and prevent cell death. 
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agents to accumulate to a significantly high level (Rogan et al., 1984) to affect the cancer 
cells. The effect is transient and only lasts as long as VPL is present in the experimental 
system. 
Since these discoveries, a multitude of compounds from diverse structural and functional 
classes have shown similar action in the malaria parasite; both existing compounds (Bitonti et 
al., 1988; Peters et al., 1989; Ye and Van Dyke, 1988; Evans et al., 1998; Singh and Puri, 
2000) and novel compounds designed and synthesized expressly for this purpose (Osa et al., 
2003; Wu et al., 2005). VPL and other chemosensitisers are known to decrease the CQ IC50 in 
cultured CQR parasites when these compounds are co-administered with CQ, in a highly 
dose-dependent manner (Wu et al., 2005; Peters et al., 1989; Martin et al., 1987; Taylor et al., 
2000). Thus far, no significant change in the IC50 has been observed when the same 
compounds were tested with CQ against CQS isolates.  
In contrast to the differences noted with altered CQ uptake in CQR and CQS isolates, in 
which increased uptake in the CQR parasites is still lower than uptake in the CQS strains, 
several of the same chemosensitisers which increase CQ accumulation have been shown to 
alter the CQ IC50 in the resistant strains to a level comparable with CQS isolates (Martin et al., 
1987; van Schalkwyk et al., 2001), suggesting that potentiation of CQ activity is not 
necessarily wholly dependent on increased CQ uptake. 
The chemosensitisers were tested to determine their toxicity and inherent anti-plasmodial 
activity against several CQR and CQS strains of the human malaria parasite in vitro. This 
would ensure that drug concentrations which are sufficiently non-toxic could be chosen for 
further tests to determine whether there is an interaction between the chemosensitisers in this 
study and CQ transport and CQ activity. Once the toxicity was known, the effects of these 
compounds on CQ uptake and also the CQ IC50 were evaluated.  
2.2 Methodology 
Methods are detailed completely in Chapter 7.  
2.2.1 Parasites, culture and drug storage 
Four CQR isolates (P. falciparum K1, Dd2, RSA11 and W2) and one CQS isolate (P. 
falciparum D10) were used in the study. Briefly, parasites were maintained according to the 
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were incubated at 37°C in airtight flasks containing a low-oxygen atmosphere with some 
carbon dioxide. Drugs were stored as instructed by the manufacturer; dilutions were prepared 
freshly from concentrated frozen stock solutions. 
2.2.2. Drug suscepibility testing 
Parasite stock cultures were diluted from synchronous trophozoite cultures to a parasitaemia 
(pst) of 2% using fresh washed human erythrocytes and made up to a haematocrit (hct) of 2% 
in complete medium. The highest concentration of the drug being evaluated was prepared in 
200µl complete medium and placed into a 96-well microtitre assay plate; nine further serial 
dilutions were made by transferring 100µl to the adjacent well and adding an equivalent 
volume of complete medium, repeated until the lowest concentration at the end of the row 
was reached. An equivalent volume of parasite stock was added to each well, halving the drug 
concentration and also the haematocrit. Plates were placed in airtight chambers with a low-
oxygen atmosphere and incubated at 37°C for 48 hours.  
Toxicity was determined thereafter using the methods of Makler et al as described (Makler et 
al., 1993). 15µl from each well was transferred to the corresponding well on a duplicate 
microtitre plate containing 100µl of the Malstat reagent and 25µl of a 20:1 mixture of 
nitroblue tetrazolium and phenozine ethospulphate in water. Colour change at 620nm was 
followed on a spectrophotometer and plotted as the ratio of the colour change in each well to 
the colour change in the drug-free control. Non-linear regression analysis was performed on 
the resultant data to determine the IC50 value for each compound and for CQ. 
2.2.3 Change in CQ accumulation 
Parasite stocks at 5% pst and 2% hct were prepared from growing cultures. 500µl of the 
prepared stock was transferred to a micro-reaction vessel containing an equivalent volume of 
the test compound prepared in complete medium. The parasite/drug mixture was allowed to 
equilibrate for 15 minutes at 37°C before radiolabelled CQ was added to a final concentration 
of 4nM. The mixture was incubated at 37°C for a further 60 minutes. After that, parasites 
were pelleted and the supernatant containing the non-absorbed CQ removed by suction. 
Parasites were transferred to scintillation vials and the amount of radioactivity remaining was 
determined.  
These values were plotted against the amount of radioactivity contained in chemosensitiser-
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2.2.4 Change in the CQ IC50 
The same procedure was applied as in 2.2.2 above. However, CQ was added to each well 
instead of the test compound, which generated a CQ standard curve after the nine serial 
dilutions were prepared. 10µl of test chemosensitiser at the desired concentration was added 
to each well containing CQ; plates were incubated for 48 hours and then developed as 
described above. Two rows were left with no added chemosensitiser to act as the CQ control. 
The RMI, representing the shift in the IC50, is determined as the ratio of the IC50 obtained 
when the chemosensitiser is added (Equation 2.1; dividend, top row) to that of CQ control 






Equation 2.1: Measuring the shift in the IC50 of CQ caused by the test compounds. 
 
2.3 Results and discussion 
2.3.1 The activity of chloroquine in vitro 
 
 
Figure 2.2 The effect of CQ on different Plasmodium falciparum isolates in vitro. Data is the 
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The data presented here correlates well with previously-published data (Taylor et al., 2000; 
van Schalkwyk et al., 2001; Martin et al., 1987; Wu et al., 2005; Lehane et al., 2008) for these 
strains of Plasmodium falciparum. Additionally, the IC50 of each resistant strain was 
calculated to be significantly different to each of the other CQR isolates (p-values from 
0.0498 to 0.0005 between parasite strains). Data are summarized in Table 2.2. 
 
Isolate Type Origin CQ response 
(reported) 
CQ IC50 (nM) 
D10 Clone Papua New Guinea Sensitive*
 
16.33 ± 1.12 
Dd2 Clone Southeast Asia Resistantπ 199.60 ± 10.27 
K1 Strain Thailand Resistantδ
 257.10 ± 22.57 
RSA11 Strain South Africa Resistantµ
 
295.10 ± 9.85 
W2 Clone Indochina Resistant*
 
237.36 ± 17.97 
Table 2.2: Parasite strains utilized and their response to CQ in vitro. *Martin et al, 1987; δWu et al, 
2004; 
µ
Taylor et al, 2000; πMehlotra et al, 2000  
 
2.3.2 Intrinsic antimalarial activity of the chemosensitisers in vitro 
 
Figure 2.3: The intrinsic antimalarial activity of the chemosensitisers (colourised) and CQ (black) in 
Plasmodium falciparum D10. Data are the mean±SEM of experiments performed in duplicate on at 
least three separate occasions. Data for other strains is summarized in Table 2.3. 
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Figure 2.3 is a representative graph depicting the relative intrinsic activity of several of the 
chemosensitisers in vitro compared to CQ; the figure shows activity against the D10 clone 
which is CQ sensitive.  
The trend – anti-parasite activity of CQ far exceeding the chemosensitisers – was similar in all 
isolates of the parasite (Table 2.3). Toxic concentrations ranged between approximately 250-
fold (CTL) and 3250-fold (AZA) less than that of CQ in D10, a CQS isolate of Plasmodium. 
As expected, there was some low-level toxicity observed with each of the chemosensitisers in 
vitro. However, the concentrations required to kill the parasites is probably not sufficiently 
low to consider their activity to be useful against malaria, given that the IC50 values are in the 
micromolar range and typically used antimalarials are active at nanomolar levels. IC50 values 
obtained for each of the chemosensitisers are shown in Table 2.3 below. 
 
Compound Coded Parasite IC50 (µM) 
D10 Dd2 K1 RSA11 W2 
Chloroquine (nM)α CQ 16.33nM 199.60nM 257.10nM 295.10nm 237.36nM 
Amitriptyline AMT 8.86±1.87 7.43±0.78 8.41±1.16 12.07±4.10 9.42±3.02 
Azatadine AZA 52.94±9.11 ND* ND 37.42±7.87 27.76±6.71 
Chlorpheniramine CFN 49.22±6.15 14.92±1.61 7.88±1.58 4.80±1.11 4.39±1.12 
Chlorpromazine CPZ 6.78±1.03 5.69±0.67 6.53±1.22 7.84±2.13 8.64±1.65 
Citalopram CTL 4.01±0.79 3.98±0.31 4.66±0.89 3.66±0.50 3.14±0.58 
Cyproheptidine CYP 6.84±1.17 ND ND 7.73±0.95 8.52±1.45 
Desipramine DES 13.90±2.03 10.17±0.72 14.75±3.36 11.74±2.74 10.45±1.69 
Ketotifen KET 13.25±3.65 ND ND 3.62±0.59 3.88±1.01 
Promethazine PRO 31.62±4.52 10.52±1.44 10.89±2.05 12.08±1.01 11.39±2.62 
Table 2.3: Intrinsic antimalarial activity of compounds used in the study. Errors are recorded as the 
SEM from experiments performed on three separate occasions in duplicate. 
α
CQ reported in nM and 
not µM. *Not determined. 
 
Significant differences in IC50 values (p<0.05) between strains were seen for AZA, KET, 
PRO and CFN. In all cases where differences were recorded, drugs were less active in the 
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The reason for this is unclear, but since the chemosensitisers are quite closely related and 
additionally share some structural similarity with CQ (Figure 2.1), it is possible that there 
might be some level of cross-resistance noticeable between different isolates of the parasite; 
however, this phenomenon would be expected to follow the trend of CQ resistance and thus 
the compounds should be less active in the CQR isolates. As mentioned in the preceding 
chapter, parasites known to be CQS tend to be less susceptible to MQ and the opposite is true 
with CQR isolates; however, these compounds’ structures are not as closely related to MQ as 
they are to CQ. 
Within the CQR strains tested, there does appear to be a trend – with the exception of CFN, 
susceptibility to the chemosensitisers appears to correlate to CQ sensitivity. Inter-strain 
variability was however only significant in the case of CFN with P. falciparum Dd2 being 
least sensitive of the four CQR isolates to both CFN and CQ.  
From the dose-response data, concentrations of each compound were selected for further 
testing with a view to determining an optimal concentration for use in the chemosensitiser 
cocktail. Since these chosen concentrations were inherently non-toxic to the parasite with at 
least 90% of the parasites known to survive at that dose, the parasites’ differing sensitivity to 
the compounds was not deemed significant in terms of achieving resistance reversal and was 
not pursued further. 
2.3.3 The effect of the chemosensitisers on the uptake of chloroquine in vitro 
Chemosensitisers were initially tested across a large concentration range, approximately 1000 
fold, to examine their effect on the uptake of CQ into the parasite. Judging from the dose-
response data described above some of these concentrations were quite toxic to the parasite; 
however it was necessary to determine the effect of each of the chemosensitisers across the 
entire spectrum of its toxicity to ensure that any change in CQ transport was noted. Data is 
shown in Figure 2.3 and 2.4 and summarized in Table 2.4 below. 
As expected, no significant change in CQ uptake was observed in the CQS isolate used, P. 
falciparum D10 (Figure 2.3), with uptake levels approximating 1, the value of the untreated 
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Figure 2.3: The effect of the chemosensitisers on CQ uptake in the CQS isolate P. falciparum D10. 
Data are represented as a fraction of the untreated control. The dotted line represents the change in 
accumulation by 5µM VPL, which was 1.07±0.029 of that of the control. Data are means±SEM from 
experiments performed in duplicate on at least three separate occasions. 
 
 
Figure 2.4: The effect of chemosensitisers on CQ uptake in the CQR isolate P.falciparum W2. Data 
are represented as a fraction of the untreated control, shown itself as the black line at 1 on the y-axis. 
The red dashed line indicates the value of the increase in the 5µM VPL control, which showed an 
increase of 4.41±0.31 fold over the untreated control. Data are means±SEM from experiments 
performed in duplicate on three separate occasions. 
 
The decreases in uptake observed with most of the compounds at the higher concentrations 
are probably not attributable to a change in CQ transport during the procedure. These 
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compounds caused significant (sometimes total) hemolysis at the two higher concentrations 
over the course of the uptake period; as a result, fewer parasitized erythrocytes remained 
intact and thus less total uptake is quantified. 
In contrast, the CQR isolates all showed significant changes in CQ uptake across the entire 
range of concentrations tested for the chemosensitisers (Figure 2.4). In all cases, once the 
compounds’ concentrations were below the threshold of that causing hemolysis there was a 
clear dose effect evident with the increase in CQ uptake maximized at higher doses and 
steadily decreasing as concentration was lowered. All drugs were comparable to the 
performance of 5µM VPL at at least one concentration. 
 
 
Figure 2.5: Related compounds, clockwise from top left: AMT and DES, CPZ and PRO. Differences 
within each pair are highlighted in the image at right. 
 
Compounds more closely related to one another – PRO and CPZ, which differ only by a 
chlorine atom substituted on the tricyclic structure and one carbon difference on the side 
chain; DES and AMT which only differ by one carbon on the side chain and a substituted 
nitrogen in the ring system (Figure 3.3) – behaved in an almost identical manner. In these 
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For the two antidepressants, the increased uptake in the presence of DES was always 
significantly higher than with AMT. Whether this is related to chain length, the degree of 
substitution on the chain nitrogen (secondary vs tertiary) or the additional tertiary nitrogen in 
the 7-membered ring of DES is unclear from these data.  
The two phenothiazines, PRO and CPZ, were able to increase CQ uptake consistently more 
than any other compound/s; however, they were not significantly different to one another 
even though the trend indicates that CPZ shows greater accumulation. Both of these 
molecules, like DES, have a tertiary nitrogen on the ring system. Thus, a component of the 
chemosensitiser-mediated change in CQ uptake might be attributed to the presence of a 
tertiary nitrogen in close proximity to the side-chain of the molecule.  
The phenothiazines also increased CQ uptake to a greater level than the tricyclic 
antidepressants did. This could be as a result of the shape of the different tricyclic ring 
structures – a brace of 6-membered rings separated by a 7-membered ring in the tricyclic  
antidepressants, compared to a trio of 6-membered rings in the phenothiazines – or it could be 
the presence of the larger and slightly more electronegative sulphur atom in the phenothiazine 
ring system.  
The difference in chain length and the change in position of the chain nitrogen – tertiary 
nitrogens in both molecules – do not appear to be significant. This observation is consistent 
with previously published data, which suggested that positioning a basic nitrogen anywhere 
between two and four atoms down the chain would be sufficient to affect resistance 
(Bhattacharjee et al., 2001). 
The high level of protein binding in the bloodstream (Gbotosho et al., 2006) has largely been 
implicated in the failure of chemosensitisers to make the transition from in vitro testing 
systems to clinical practice (Warsame et al., 1992). Compounds like VPL, which already need 
a significantly high concentration of drug to exert a reversal effect, would need an even 
greater dosage administered in order to ensure that sufficient quantities remain unbound to 
achieve some level of chemosensitisation, further increasing the likelihood that patients will 
experience side-effects and/or toxicity which could lead to complications.  
In this regard, the heightened accumulation seen at the lower concentrations tested (100ng/ml; 
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2.3.4 The effect of the chemosensitisers on the IC50 of CQ in vitro 
2.3.4.1 Higher dose chemosensitisation 
 
Figure 2.6: Determining the effect of several of the tested chemosensitisers, each at a concentration 
of 100ng/ml, on the IC50 of CQ in Plasmodium falciparum D10 (CQS; top) and RSA11 (CQR; bottom). 
The red dashed line bisects each graph at the 50% survival point. Shifts in the IC50 relative to CQ 
(black dashed line) are effectively negligible in the CQS isolate (all values in Table 2.4) but are 
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Each of the compounds administered at 100ng.ml-1 simultaneously with CQ was able to alter the CQ 
IC50 in the CQR isolates to varying degrees, as shown in Table 2.4. Given that the relative masses of 
each compound are similar even when the counter-ions are taken into consideration, the 100ng/ml 
dose amounts to a range of similar molar concentrations. A typical dose-response experiment 
depicting the effect of a chemosensitiser on the CQ IC50 in both a CQS and CQR strain is shown 
below. 
None of the compounds was able to alter the CQ IC50 significantly in the CQS isolate Plasmodium 
falciparum D10, however. This shows that each compound is not simply exerting an additive toxic 
effect with CQ at a concentration of 100ng/ml; rather, the activity of CQ is being enhanced in the 




CQ IC50 (nM)  in the presence of 100ng/ml chemosensitiser 
CQ + 
100ng 
D10 (CQS) Dd2 K1 RSA11 W2 
IC50 RMI
¥
 IC50 RMI IC50 RMI IC50 RMI IC50 RMI 
CQ 
16.33±1.12 1.00 199.60±10.27 1.00 257.10±22.57 1.00 295.10±9.85 1.00 237.36±1.11 1.00 
AZA 14.21±3.08 0.87 ND* - ND - 163.11±7.21 0.56 131.05±7.44 0.53 
AMT 17.79±3.11 1.09 54.34±4.33 0.27 70.89±7.47 0.28 44.07±3.98 0.15 61.54±4.13 0.26 
CFN 17.36±1.71 1.06 65.93±2.78 0.33 70.52±7.91 0.28 67.12±5.82 0.23 78.53±3.07 0.33 
CPZ 16.79±2.52 1.03 58.91±2.53 0.29 64.19±6.48 0.26 49.18±1.98 0.16 43.57±7.11 0.18 
CTL 16.86±2.78 1.03 65.99±2.54 0.33 45.47±6.36 0.18 47.33±4.12 0.16 39.65±2.29 0.17 
CYP 15.88±3.12 0.97 ND - ND - 38.07±2.23 0.12 44.23±1.87 0.19 
DES 15.09±2.70 0.92 68.90±2.50 0.35 63.40±7.61 0.25 59.71±3.65 0.20 58.36±8.12 0.25 
KET 18.02±2.91 1.10 ND - ND  - 72.32±6.11 0.24 81.19±4.34 0.34 
PRO  5.24±1.87 0.93 78.37±3.22 0.39 69.23±10.70 0.27 71.08±5.47 0.24 68.58±3.16 0.29 
Table 2.4: Altering the IC50 of CQ with each chemosensitiser at a concentration of 100ng/ml. Reported values 
here are the mean±SEM from experiments conducted in duplicate on at least three separate occasions.
 
¥
Response modification index values are the ratio of the altered IC50 of the combination to the IC50 of CQ alone.  
 
It can also be seen clearly in Figure 2.6 that the high dose of each drug used was not toxic; this is 
shown by the level of parasite survival (approximately 100%) when the CQ concentration is 
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 exposed only to the chemosensitiser. This phenomenon is indicative of resistance reversal 
and implies a synergistic interaction between each chemosensitiser and CQ. 
Azatadine seems to have the least effect on the CQ IC50 and thus achieves the lowest level of 
reversal across the CQR strains tested (Figure 2.6). The reason for this is unclear; however, 
AZA has a fourth ring attached to the middle of the tricyclic core by a double bond (Figure 
4.2). The chain nitrogen, believed to be a critical component in resistance reversal (Gerena et 
al., 1992; van Schalkwyk and Egan, 2006), is at the distal end of this fourth ring. 
Given that the chain nitrogen is bound in a ring, and the ring is attached to the core by a 
double bond, this nitrogen is probably quite rigid in terms of its steric positioning and this 
may play a role in limiting the compound’s ability to interact with PfCRT and/or anything 
else involved in the reversal mechanism compared to a more flexible molecule. 
Of the compounds evaluated, AZA is most closely related to Cyproheptidine and Ketotifen 
(Figure 2.7) – these three all have an identical fourth ring out of the tricyclic system, but both 
CYP and KET are able to chemosensitise the parasite to a significantly greater degree than 
AZA; and CYP appears to be substantially more effective than KET in both RSA11 and W2. 
 
 
Figure 2.7: Structures of some of the related chemosensitisers. Differences are highlighted in red. 
 
The difference between activity of CYP and AZA must be accounted for by the additional 
secondary basic nitrogen in the tricyclic core of CYP – this is the only difference in the two 
molecules – further emphasizing the importance of the basic nitrogen in resistance reversal in 
Plasmodium. This additional nitrogen is also ring-bound and thus non-flexible in terms of its 
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compound suggests that the presence of additional highly electronegative/electron-
withdrawing moieties may be relevant in order to increase chemosensitisation. This is 
supported by comparing the shifted IC50 obtained with KET as discussed below, and also by 
noting the shifts observed when the chlorine-containing compounds CFN and CPZ are used, 
both of which have a Cl attached to the tricyclic core (Fig 2.1) and both of which are 
significantly better at reversing resistance than AZA. The differences between KET and CYP 
are presumably related to this extra nitrogen, present in CYP but lacking in KET, and also 
perhaps to the oxygen atom attached to the slightly different sulphur-containing tricyclic core 
found in KET. Both the oxygen and the sulphur atoms are known to be electron-withdrawing 
groups; their presence may give that region of the compound an overall negative charge 
which may alter its interaction with the components of the CQ reversal mechanism.  
Altered IC50 values determined with the various chemosensitiser-CQ combinations were 
generally not significantly different across the four CQR strains examined (Table 2.4), with a 
few exceptions; however, there were some significant differences between the corresponding 
Response Modification Index values in these isolates. Bearing in mind that the RMI is a ratio 
of the modified IC50 value obtained with the CQ+sensitiser combination to the IC50 of CQ 
alone as shown in Equation 2.1, the varied sensitivities to CQ by the diverse CQR isolates 
accounts for the observed dissimilarities in the RMI between strains.  
Following higher-dose testing in two CQR isolates, the antihistamines AZA, CYP and KET 
were discarded from evaluation at low doses. High-dose AZA is the least effective of all the 
compounds at changing the IC50 in vitro. KET has both lower maximum circulating 
concentrations and lower steady-state concentrations than any other compound (Table 2.5), 
and although its RMI values were comparable to CFN, the latter has the highest fraction of 
unbound drug in circulation. CYP, although most effective at lowering the IC50 in vitro¸ is 
rapidly metabolized (Moffat, 1986; Sweetman et al., 2007) and has effectively zero 
unchanged drug detectable in circulation for the data gathered with the parent compound in 
vitro to be considered meaningful; additionally, CYP has been shown to cause toxicity in 
animals (Kyle et al., 1993). As a result, PRO and CFN were retained for use as the 
antihistamines in the cocktail treatments.  
2.3.4.2 Lower dose chemosensitisation 
Knowing that many drugs are highly bound to plasma proteins in a live system (Gbotosho et 
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circulating molecules available to interact within the various domains of the parasitized 
erythrocyte (or any other cell type), compounds were also tested at levels which were more 
likely to be achievable and/or routinely observed in patients utilizing these agents for either 
acute or chronic indications (Table 2.5).  
The compounds utilized in the study typically achieve steady-state and/or circulating 
concentrations only in the low nanogram ranges (Sweetman et al., 2007; Moffat, 1986; Al 
Ghazawi et al., 2007; Fredricson, 1982) and are approximately 80-90% plasma protein-bound, 
so chemosensitisers were evaluated with CQ at lowered concentrations of 20ng.ml-1 and 10 




Typical acute  







Azatadine 1-4mg/day 13ng/ml Unknown Minimal 
Amitriptyline 
50-150mg; 










































up to 4mg/day 
0.6ng/ml 8ng/ml 85% 
Promethazine 
25mg;  





Up to 93% 
 
Table 2.5: Pharmacokinetic parameters observed in human patients for the chemosensitisers tested. 
*Maximum average value reported following a single dose of compound. 
µ
Steady-state value observed 
from patients following a longer-term or clinical regimen/treatment course. 
£
CYP is rapidly and 
extensively metabolized; reported concentrations are of metabolites only. Data from Sweetman et al 
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As with the dose-dependency in the increased uptake of tritiated CQ as shown above, shifts in 
the IC50 in the CQR strains are significantly less at the lower doses to those achieved with the 
corresponding drugs at 100ng/ml in the same strains (Tables 2.6 and 2.7). 
 
 
Figure 2.8: Comparing the shift in the CQ IC50 with the same chemosensitisers administered at 
100ng/ml (top) and 20ng/ml (bottom) in the CQR isolate Plasmodium falciparum RSA11. All IC50 
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This direct correlation between dose and change in sensitivity to CQ has been reported previously 
(Martin et al., 1987; Taylor et al., 2000; van Schalkwyk et al., 2001; Gerena et al., 1992; Bitonti et al., 
1988) and is typical of both CQ resistance reversal in Plasmodium as well as the reversal observed in 
the Pgp-modulated MDR cancer phenotypes (Tsuruo et al., 1981; Rogan et al., 1984) 
Table 2.6 shows the effect of the six selected compounds at a lower dose of 20ng/ml. No noteworthy 
alteration of the activity of CQ was seen in the CQS isolate D10, but there is a shift observed with 
each compound in all of the CQR parasites. 
 
As expected, there is a substantial decrease in the shift of the CQ IC50 relative to the shift seen at the 
higher concentration (100ng/ml; Table 2.4), and this appears to be correlated with the dose-effect seen 




CQ IC50 (nM)  in the presence of 20ng/ml chemosensitiser 
 
CQ + 
D10 (CQS) Dd2 K1 RSA11 W2 
IC50 RMI
¥
 IC50 RMI IC50 RMI IC50 RMI IC50 RMI 
CQ 16.33±1.12 1.00 199.60±10.27 1.00 257.10±22.57 1.00 295.10±9.85 1.00 237.36±1.11 1.00 
Amt 17.79±3.11 1.09 167.66±6.31 0.84 208.25±11.76 0.81 228.26±12.02 0.77 195.11±9.10 0.82 
Cfn 17.36±1.71 1.06 143.71±5. 82 0.72 200.10±15.25 0.78 218.83±16.74 0.74 189.41±3.93 0.80 
Cpz 16.79±2.52 1.03 157.68±7.33 0.79 217.83±11.10 0.85 268.03±11.36 0.91 176.12±8.15 0.74 
Ctl 16.86±2.78 1.03 161.68±14.45 0.81 192.83±9.45 0.75 230.46±9.89 0.78 169.24±5.19 0.71 
Des 15.09±2.70 0.92 149.10±5.61 0.75 177.40±20.89 0.69 210.50±17.16 0.71 187.28±14.26 0.79 
Pro  5.24±1.87 0.93 158.28±8.28 0.79 227.82±21.65 0.89 206.10±7.99 0.70 206.97±13.60 0.87 
Table 2.6: Altering the IC50 of CQ with each chemosensitiser at a concentration of 20ng/ml. Values are the 
mean±SEM from experiments conducted in duplicate on at least three separate occasions. *As referred in 
Figure 2.8, use of 20ng/ml AZA in RSA11 produced an IC50 of 290.33±7.23nM and an RMI of 0.98. 
 
As established at the higher dose, the compounds are all able to exert an effect at 20ng/ml to a varying 
degree with the different isolates reacting to a lesser or greater extent. CQ IC50 values decreased to 
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The reason for this might be because Dd2 is a clone, a culture grown from a single isolated parasite 
and thus theoretically with each parasite being genetically identical, whereas Rsa11 and K1 are strains 
and are likely to be a genetically mixed population of parasites from multiple infections in the patient 
prior to initial establishment as a laboratory culture. As a result, the uncloned strains might contain 
some parasites which are more CQ sensitive and simply do not respond to chemosensitisers along 
with the parasites which do respond, accounting for the smaller shift in the IC50. 
Across the isolates tested at 20ng/ml, no drug appeared to perform consistently better or worse than 




CQ IC50 (nM)  in the presence of 10ng/ml chemosensitiser 
 
CQ + 
D10 (CQS) Dd2 K1 RSA11 W2 
IC50 RMI IC50 RMI IC50 RMI IC50 RMI IC50 RMI 
CQ 16.33±1.12 1.00 199.60±10.27 1.00 257.10±22.57 1.00 295.10±9.85 1.00 237.36±1.11 1.00 
Amt 17.79±3.11 1.09 204.50±9.33 1.02 268.51±11.03 1.04 277.59±6.01 0.94 211.96±9.10 0.89 
Cfn 17.36±1.71 1.06 200.83±8.74 1.01 233.96±8.97 0.91 280.93±8.34 0.95 208.87±3.93 0.88 
Cpz 16.79±2.52 1.03 188.10±5.23 0.94 228.82±7.13 0.89 283.03±4.46 0.96 223.11±8.15 0.94 
Ctl 16.86±2.78 1.03 205.80±11.02 1.02 226.25±23.14 0.88 271.20±4.60 0.92 207.92±5.19 0.88 
Des 15.09±2.70 0.92 199.02±6.97 1.00 219.30±14.87 0.85 275.04±5.12 0.93 216.94±14.26 0.91 
Pro  5.24±1.87 0.93 194.50±13.63 0.97 238.71±6.65 0.93 266.18±7.63 0.90 206.97±13.60 0.87 
Table 2.7: Altering the IC50 of CQ with each chemosensitiser at a concentration of 10ng/ml. Values are the 
mean±SEM from experiments conducted in duplicate on at least three separate occasions.  
 
The response of each compound at 10ng/ml is even more muted (Table 2.7). However, at this low 
concentration in Dd2 the effect is almost negligible; considerably different to the response at double 
the dose. With the uncloned isolates, the response is less than at 20ng/ml but for the most part is still 
significant. Once again, K1 responded best to DES with an RMI of 0.85, the best activity of any 
compound seen in all the isolates at this concentration, and W2 responded better to PRO than any 
other with an RMI of 0.87.  
For the most part, however, compared to the changes seen at 100ng/ml the shifts in the IC50 are 
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Given that no compound was shown to be toxic at these low concentrations, which can be 
seen by the survival of more than 90% of the parasites at low concentrations of CQ in Figure 
2.8, it is assumed that the shift in the CQ IC50 is as a result of a bypass of the CQ resistance 
mechanism in the parasite and the effect seen is not simply additive toxicity.  
In conclusion, all nine chemosensitisers were shown to have little inherent antimalarial 
activity relative to current anti-plasmodial compounds in both CQR and CQS isolates of the 
human malaria parasite. All nine compounds showed a dose-dependent effect on the 
resistance-reversal phenomena – each drug was able to increase the accumulation of CQ into 
the CQR parasite system, with higher doses of each compound able to improve the uptake of 
CQ significantly more than lower doses of the same compound could; no drug performed 
consistently better between the four different CQR isolates examined. 
The increase in CQ accumulation was not seen at any concentration with any compound in the 
CQS clone. As expected, each compound was able to notably lower the CQ IC50 in all CQR 
isolates when co-administered with CQ in vitro, in a dose-dependent manner. As with the CQ 













Chapter 3 - The effect of a combination of chemosensitisers 
on the actions of chloroquine in the malaria parasite in vitro. 
3.1 Introduction 
It is becoming considerably rarer presently to find any agents used in treating illnesses, 
particularly infectious diseases requiring antibiotics, prescribed or administered singly.  
3.1 Combining treatments 
This practice is largely related to the potential for resistance to develop which might render 
the drugs useless, but there are additional benefits to using a combination of different agents 
to achieve a cure. 
In addition to preventing resistance, the combination treatment might act via several different 
mechanisms – each one the target of a specific compound – to achieve the cure more rapidly, 
which results in a far more efficient and wholly more cost-effective regimen (Goodman et al., 
2001a) and in turn eases pressure on over-burdened public health systems as well as privately 
funded medical schemes. A more efficient treatment model is also far more beneficial from 
the perspective of a national economic outlook by ensuring maximum productivity with 
minimum downtime and at minimum cost (Wilkins et al., 2002). 
Combination treatments are utilized for a number of different conditions and infectious 
diseases. Patients with tuberculosis typically take two to four different drugs during treatment 
(LoBue, 2009), either as multiple different tablets each containing one drug or as a single 
tablet containing all of them. Patients with HIV/AIDS are always on a regimen containing at 
least three different drugs which attack the virus and disease process at different targets 
(Bartlett et al., 2006). Even non-infectious conditions, such as arthritis, are frequently treated 
with a multi-target approach. 
Currently, the same is true in certain malaria-endemic regions. SP mentioned above has 
always existed inherently as a combination therapy, but it is currently used in combination 
with CQ, AQ or MQ while another combination treatment, LapDap (Dapsone-
Chlorproguanil), was  indicated for prophylaxis (World Health Organisation, 2010a).  
Artemisinin-based combinations such as Co-Artem (artemether-lumefantrine) and Artequin 
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3.2 Combining chemosensitisers 
Given the successes seen with combination chemotherapy, it is logical to postulate that 
combining chemosensitisers might increase the efficiency of the resistance reversal process. 
Given that some chemosensitisers simply are not bioavailable in patients to a level at which 
resistance reversal might prove attainable (Gbotosho et al., 2006; Warsame et al., 1992), an 
ideal next step would be to determine whether or not two or more chemosensitisers given 
simultaneously along with CQ might have an additive or synergistic effect. This might allow 
one to co-administer several compounds each at a comparatively low, safe and well-tolerated 
dose in conjunction with an antibiotic in a resistant population and still achieve a cure through 
resistance reversal. 
This concept has been explored previously in the in vitro environment, using two 
chemosensitisers in a highly CQR isolate to alter the CQ IC50 to the point where it was 
equivalent to the IC50 of the sensitive isolate tested in the same experiments (Taylor et al., 
2000; van Schalkwyk et al., 2001). Additionally, VPL has been combined with another 
calcium channel blocker, fantofarone (Adovelande et al., 1998), and it was shown that this 
pairing – each compound used at a concentration vastly lower (only 0.1-1%) than that which 
reverses resistance when used singly – is significantly more efficient than either compound 
used alone at that lower dose and that these compounds are truly synergistic.  
Why some combinations are synergistic while others are additive is currently unknown; the 
proposed mechanism of resistance reversal and the demonstration that some chemosensitisers 
are substrates for mutant PfCRT (Lehane and Kirk, 2010) is still a recent discovery, and 
combination chemosensitisation has not been widely studied. 
The compounds evaluated above were combined at lower doses and the effects of each 
combination on CQ uptake and the CQ IC50 were evaluated. 
3.2 Methodology 
Methods are described completely in Chapter 7. 
3.2.1 Change in uptake of tritiated CQ and the CQ IC50 in vitro 
Experiments were carried out as described in 2.2.2 and 2.2.3 above. The complete procedure 
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3.3 Results and Discussion 
Following the evaluation of the selected compounds at variety of concentrations to determine 
their effect on both the IC50 of CQ and the accumulation of CQ into the parasitized 
erythrocyte system, compounds were evaluated in combinations against the parasite. The 
objective was to determine whether or not a cocktail could be administered in which the 
compounds worked either synergistically or additively at low doses. Although synergism 
would be the ideal result, the compounds working additively would still be beneficial since 
this might bypass toxicity and lessen side-effects because the pharmacodynamic targets of 
each compound in the cocktail differ. 
Combinations were tested at comparatively low concentrations – 100ng/ml as a reference 
point, then more extensively at 10mg/ml and 20ng/ml. These doses were chosen since the 
compounds are known to reach these circulating concentrations in the bloodstream in patients 
being treated with these drugs therapeutically. Although the effects on both CQ accumulation 
and the CQ IC50 are significantly larger at higher doses tested in vitro, these concentrations 
are not typically seen clinically in the short term and occasionally with certain drugs used 
chronically (Table 2.5) and although non-toxic to patients the higher concentrations were 
considered impractical. 
3.3.1 The effect of the combinations on CQ uptake 
As expected, combinations of the compounds were able to increase CQ uptake into the CQR 
parasite system in vitro, as shown in the representative Figure 3.1 below of the response of the 
K1 isolate. As with the single drugs, no changes were observed in the CQS isolate D10. 
Figure 3.1 is a representative graph depicting what was seen across the four CQR isolates 
tested. Combinations were more additive than synergistic – CQ accumulation using the 
combinations was either slightly better than the increase seen using any of the three individual 
drugs which make up the combination, or at least equivalent to whichever drug increased 
accumulation the most at that dose in that isolate. The data is expanded fully in Tables 3.4-3.6 
Figure 3.2 is a representative diagram of a single combination, CTL+PRO+CPZ, at both 
20ng/ml and 10ng/ml in the four CQR isolates. No single chemosensitiser nor combination 
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The clone Dd2 shows a smaller increase in uptake relative to the chemosensitiser-free CQ 
control when compared to the uncloned strains RSA11 and K1, particularly at the lower doses 
tested (Figure 3.2). Dd2 rarely increases to double the value of the control whereas the strains 
typically show an increase which is between double and triple that of the control. The 
phenomenon occurs with both individually-used chemosensitisers as well as the triple 
combinations of antidepressant+antihistamine+antipsychotic. 
 
 
Figure 3.1: Comparing the change in CQ uptake using multiple chemosensitisers at low doses to the 
change occurring with single chemosensitisers at high and low doses in P. falciparum K1. The data is 
expanded fully in Tables 3.3-3.5 below. The red dashed line is the level of CQ uptake noted in the 
presence of 5µM VPL. Values are reported as the increase relative to the drug-free control (solid black 
line at 1) and are the mean±SEM of at least three separate experiments performed in quadruplicate. 
 
The reasons for this dissimilarity between the strains and clones is unclear. Since there are 
shifts in the CQ IC50 values in all tested CQR isolates as shown in the preceding chapter, it is 
likely that each of these cultures of Plasmodium contains the Dd2/Old World phenotype of 
PfCRT with the K76T mutation which is known to respond to chemosensitisation in vitro.  
What might be happening here is related to the make-up of the parasite culture. The uncloned 
strains are a patient isolate containing a mixture of numerous infections obtained through the 
bites of several mosquitoes, and not an infection caused by a single, genetically-identical 
population of parasites. As a result, some of the parasites growing and multiplying in the 
laboratory culture of the uncloned strains may be more CQS than other parasites in the same 
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could account for the increased uptake relative to the cloned strains, which originated from a 




Figure 3.2: Comparing changes in uptake seen each single chemosensitisers to the triple-combination 
of an antidepressant+antihistamine+antipsychotic at lower doses of 10ng/ml in four CQR isolates (l-r: 
Dd2, K1, RSA11 and W2). Data represented are the mean±SEM for experiments repeated in 
quadruplicate on three separate occasions. 
 
Very little synergism is seen in the CQR isolates when it comes to increasing CQ uptake into 
the parasite system with the combinations; additionally, compounds perform differently in the 
different isolates of P. falciparum. 
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Additionally, in K1 the combination AMT+PRO+CPZ at 10ng/ml (Figure 3.2; bottom row 
center) appears to increase CQ accumulation over the control to a level only equal to the 
lowest increase achieved by any drug used in that combination, that being CPZ. At the higher 
dose, the increase is lower than the increase seen with any single drug. Of all the tested 
combinations, this is the only instance where the mixture of compounds does not improve the 
uptake relative to the lowest increase obtained with one of the constituent compounds in the 
mixture. MPZ in K1 also produces the only significant difference between combinations 
differing only by the antihistamine present – in all other cases, there was no statistical 
significance between the same antidepressant and the antipsychotic CPZ being paired with 
either CFN or PRO. This suggests that the antagonism is related to interactions between AMT 
and PRO and the effect seen in this combination is specific to whatever is different between 
K1 and the other isolates. 
3.3.2. The effect of combinations of compounds on the IC50 of CQ in vitro 
It has been shown numerous times that single compounds can significantly and dramatically 
alter the IC50 of CQ when co-administered with CQ in a resistant isolate of P. falciparum, as 
mentioned and demonstrated above in this document as well as frequently in published 
research. It has also been shown that combining two chemosensitisers in vitro can allow one 
to use fractional amounts of each chemosensitiser to achieve the same results as a 
comparatively high dosage of one chemosensitiser would (Adovelande et al., 1998). 
As discussed in section 2.1.1 above, ideally no more than one drug from each pharmaceutical 
class utilised in the study would be administered in each combination in an attempt to produce 
a treatment which might show minimal class-related toxicity and/or adverse effects in the 
mouse model when tested there. However, certain combinations of drugs from the same class 
were tested together in the in vitro system. 
3.3.2.1 Higher-dose double combinations 
Table 3.1 shows some of the combinations which were tested in vitro against the CQR isolate 
Plasmodium falciparum RSA11 at the higher dose of 100ng/ml, relative to the drugs used 
singly. Combinations are grouped according to the single-drug abbreviations, starting with 
Azatadine. 
In all but one of the cases shown, the action of [CQ+combination] is significantly better than 
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effective than CQ alone. Shifts in the IC50 (as shown by the substantially lowered RMI) 
values were quite varied, but even the worst-performing combination (AZA+CPZ) was able 
to lower the CQ IC50 to just over 40% of the unaltered value. No single compound appears to 
be a “magic bullet” which always lowers the RMI to the greatest extent no matter which other 
compound it is combined with.  
 
COMBINATION 
CQ + 100ng/ml IC50(µM) RMI CQ + 100ng/ml IC50(µM) RMI 
AZA 0.163 0.553 CQ  0.295 1.00 
Aza/Cfn  0.075 0.254 DES 0.059 0.200 
Aza/Cpz 0.120 0.407 Des/Cfn  0.042 0.142 
Aza/Cyp 0.018 0.063 Des/Cpz 0.005 0.001 
Aza/Des 0.046 0.160 Des/Cyp 0.004 0.001 
Aza/Ket 0.057 0.193 Des/Ket 0.031 0.105 
Aza/Pro 0.043 0.146 Des/Pro 0.022 0.075 
CFN 0.067 0.227 KET 0.072 0.244 
Cfn/Cpz 0.020 0.066 Ket/Cpz 0.012 0.041 
Cfn/Ket 0.001 0.004 Ket/Ctl 0.056 0.190 
Cfn/Pro 0.008 0.026 Ket/Cyp 0.084 0.285 
Cfn/Cyp 0.023 0.080 Ket/Pro 0.039 0.132 
CPZ 0.049 0.166 PRO 0.071 0.241 
CYP 0.038 0.129 Pro/Cpz 0.049 0.166 
Cyp/Cpz 0.002 0.007 Pro/Cyp 0.053 0.179 
Table 3.1: Some of the double combinations in RSA11 at a concentration of 100ng/ml. Data colour-
coded so that groupings for combinations are apparent. The combination of KET+CYP, highlighted, is 
less effective than either drug used singly. 
 
Apart from KET/CYP, all the other combinations lowered the IC50 of CQ more than either 
individual drug did, showing the combination to be more effective than either drug. 
Conversely, KET/CYP (RMI of 0.285) was not as effective as either KET (RMI of 0.244) or 
CYP (0.129) used singly and thus the combination appears to be antagonistic.  
The reason for this is unclear. The phenomenon has been shown previously, albeit to a far 
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oxaprotiline used was shown to be entirely ineffective against P. falciparum RSA11. Each 
individual compound was able to considerably alter the IC50 and increase CQ accumulation 
over a wide range of concentrations when used singly in vitro or in combination with other 
antidepressants (Taylor et al., 2000).  
 
 
Figure 3.3: Toxicity typically observed when chemosensitisers are combined at higher doses of 
100ng/ml in Plasmodium falciparum RSA11. At low concentrations of CQ (2-4nM; left side of figure), 
100ng/ml AZA+DES (purple line) still kills 20% of the parasites and CFN+DES (yellow) kills more than 
30%. Survival with individual drugs (green, orange and blue lines) is close to 100% at low CQ. 
 
Although the dual combinations had a large effect on the CQ IC50 in vitro at the higher dose, 
the data is difficult to interpret because most of the combinations proved to be toxic at the 
higher concentration of 100ng/ml each. Figure 3.3 shows the effect commonly seen with these 
combinations at the higher dose, and is representative of many of those combinations shown 
in Table 3.1. Combinations yielded toxicities which resulted in as little as only 55-60% 
parasite survival, compared to close to 100% survival of when the compounds are used singly 
with CQ. Since the concentration of CQ at the end of the experiment is only around 2-4nM 
with an IC50 of approximately 300nM in RSA11, the low survival at these concentrations 
(around 80% with AZA+DES and only around 65% with DES+CFN) is due to additive 
toxicity from the higher doses of chemosensitiser and not as a result of potentiating the 
activity of CQ. As a result, these high-dose combinations were not pursued against the other 
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As it stands, these data might suggest that simply using two of the chemosensitisers in almost 
any combination would have a lethal effect on the parasite even in the absence of CQ, and 
that perhaps researching this as a potential new area of antimalarial chemotherapy could prove 
worthwhile given that most of these compounds have been in use for decades and their safety, 
toxicity and therapeutic windows of activity are well-established. However it must be noted 
that a circulating concentration of 100ng/ml is not typically seen in the bloodstream of 
patients using these drugs for therapeutic indications. Patients for whom some of these drugs 
are prescribed chronically may well reach steady-state concentrations within this sort of range 
in the long term – AMT and DES average over 100ng/ml albeit with a considerable range (20-
880ng/ml for DES; 50-240ng/ml for AMT; Table 2.5) and CPZ concentrations have been 
reported at over 100ng/ml (2-122ng/ml) on occasion as well – but these steady-state 
concentrations are only reached after several weeks of continuous/chronic chemotherapy with 
the psychotropic drugs like antidepressants and antipsychotics. Thus, although seemingly 
active in vitro, combinations based on psychotropic compounds are probably not entirely 
suitable as a possible antimalarial drug regimen which would need to kill the parasite far more 
rapidly than that in terms of being clinically effective. Should a pair of antihistamines, which 
are often indicated acutely, be shown to reach sufficiently high circulating concentrations for 
a sufficient duration, that combination could be explored as a potential antimalarial treatment.  
Additionally, though, it is also known that these compounds are largely bound to plasma 
proteins – up to 90% for DES – which leaves vastly lowered amounts of free drug available 
which could enter the parasite system. This in turn means that circulating concentrations 
might need to be even higher than 100ng/ml in order to leave enough free drug available to 
affect the parasite. Conversely, the circulating levels following single administration of the 
chemosensitisers tend to peak at significantly lower readings than 100ng/ml (Table 2.5), 
which might render the combination useless as an antimalarial if prescribed under these acute 
conditions. The experimental system does contain both plasma proteins and albumin, either in 
the form of human serum or the supplement Albumax, so there is a strong likelihood that a 
significant proportion of chemosensitiser is also protein-bound in vitro and still yields a 
positive result which suggests that a combination based solely on additive toxicity without 
any CQ might be a viable addition to the current pharmacopoeia of antimalarial treatments. 
3.3.2.2 Lower-dose double combinations 
At lower doses from 20ng/ml, the same sort of toxicity is not typically seen in vitro, meaning 
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possibly related to additive toxic effects caused by each chemosensitiser in the combination. 
Double combinations were evaluated at the two lower doses in two CQR isolates (Table 3.2). 
 
 RSA11 K1 
 20ng 10ng 20ng 10ng 
CQ + IC50(µM) RMI IC50(µM) RMI IC50(µM) RMI IC50(µM  RMI 
CQ  0.295 1.00 0.295 1.00 0.257 1.00 0.257 1.00 
Amt 0.228 0.773 0.276 0.935 0.208 0.809 0.269 1.044 
Amt/Cfn 0.214 0.725 0.266 0.902 0.190 0.739 0.234 0.911 
Amt/Pro 0.208 0.704 0.276 0.934 0.200 0.776 0.239 0.928 
Amt/Cpz 0.201 0.681 0.271 0.919 0.187 0.728 0.232 0.903 
Ctl 0.230 0.779 0.271 0.918 0.218 0.848 0.226 0.879 
Ctl/Cfn 0.184 0.623 0.257 0.871 0.203 0.791 0.220 0.854 
Ctl/Pro 0.192 0.652 0.264 0.895 0.207 0.809 0.809 0.912 
Ctl/Cpz 0.180 0.609 0.255 0.863 0.197 0.766 0.778 0.868 
Des 0.211 0.713 0.275 0.932 0.177 0.689 0.751 0.853 
Des/Cfn 0.201 0.681 0.256 0.868 0.152 0.593 0.848 0.837 
Des/Pro 0.187 0.634 0.247 0.837 0.166 0.647 0.689 0.878 
Des/Cpz 0.207 0.701 0.269 0.910 0.168 0.655 0.887 0.851 
Cfn 0.219 0.742 0.280 0.948 0.200 0.778 0.234 0.910 
Pro 0.206 0.698 0.266 0.901 0.228 0.887 0.239 0.929 
Cpz 0.268 0.908 0.283 0.959 0.193 0.751 0.229 0.890 
Cfn/Cpz 0.226 0.765 0.263 0.890 0.185 0.722 0.225 0.877 
Pro/Cpz 0.267 0.904 0.277 0.939 0.186 0.725 0.224 0.871 
Table 3.2: The effect of double-combinations of the selected compounds at low doses on the CQ IC50 
in P. falciparum RSA11 (left) and K1 (right). Related combinations are grouped by colour. Bold values 
are the individual/parent compounds; the combinations in green are the only low-dose (10ng) 
combinations with an RMI significantly better than that of both parent compounds. Combinations in red 
are higher-dose combinations which are less effective than one of the parent compounds used singly. 
The IC50 value is the mean value after three separate experiments conducted in duplicate; the RMI 
was determined from this mean IC50. 
As at 100ng/ml, the combination was always more effective than CQ alone; however, not all 
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green). Combinations at 20ng/ml were all more effective than the same combinations at 
10ng/ml in both isolates evaluated. 
Individual results vary between the isolates. The most effective of the single compounds at 
20ng/ml is DES in K1 and PRO in RSA11. In RSA11, use of 10ng/ml AMT shifts the IC50 by 
6.5% but the same drug at that dose has no significant impact on K1. Conversely, CPZ at 
10ng/ml has a larger effect on the RMI in K1 than it does at 20ng/ml in RSA11. The reason 
for these differences is unknown. 
As expected there is a clear dose effect, and the shifts in the IC50 using the combinations at 
20ng/ml, although significant, are noticeably lower than those observed at 100ng/ml (Table 
3.1). This phenomenon also occurs with the single drugs as shown in the preceding chapter. 
The best-performing pairing (DES+CFN in K1) showed an RMI of 0.593, lowering the IC50 
by a little over 40%, and the worst-performing pairing (PRO+CPZ in RSA11) produced an 
RMI of 0.904. The dose effect is even more pronounced with the drugs at 10ng/ml, where 
shifts in the IC50 for dual combinations are almost negligible relative to the single compounds, 
with RMI values ranging from 0.837 (both DES+CFN in K1 and DES-PRO in RSA11) to 
0.939 (PRO+CPZ in RSA11) between the strains tested. At both 20ng/ml and 10ng/ml, 
combinations which are more effective than either parent compound appear to act additively 
and not synergistically. 
3.3.2.3 Triple combinations 
 
Figure 3.4: The effect of triple-combinations of chemosensitisers on the IC50 of CQ. These 
combinations were based around the antidepressant Amitriptyline at a concentration of 10ng/ml and 



































3. The effect of a combination of chemosensitisers on the actions of chloroquine in the malaria parasite in vitro. 
64 
 
Figure 3.4 is a representative depiction showing how the activity of the combination enhances 
the action of CQ in vitro. It can be seen from the image that each combination of three 
compounds is able to alter the IC50 of CQ quite significantly (green curve). This was expected 
given that the combination is able to alter CQ uptake as shown in Figure 3.2 above. However, 
the shift in the IC50 with the triple combination is also noticeably larger than the shift with 
each compound used singly, which is not the case when it comes to altering CQ uptake. 
 
TRIPLE COMBINATION IN RSA11 
 20ng/ml 10ng/ml 
CQ + IC50(µM) RMI CQ Increase IC50(µM) RMI CQ Increase 
CQ  0.295 1.00 1.00 0.295 1.00 1.00 
Amt 0.228 0.773 3.10±0.14 0.278 0.940 1.93±0.31 
Cfn 0.219 0.742 2.78±0.20 0.281 0.952 1.70±0.19 
Cpz 0.268 0.908 2.64±0.28 0.283 0.959 1.81±0.23 
Ctl 0.230 0.779 2.10±0.13 0.271 0.919 1.87±0.17 
Des 0.211 0.713 2.85±0.44 0.275 0.932 1.61±0.18 
Pro 0.206 0.698 2.78±0.15 0.266 0.902 1.88±0.32 
Amt/Cfn/Cpz 0.171 0.579 2.63±0.22 0.231 0.784 2.78±0.16* 
Amt/Pro/Cpz 0.159 0.539 3.06±0.25 0.206 0.697 2.65±0.15 
Ctl/Cfn/Cpz 0.178 0.602 2.50±0.16 0.261 0.883 2.28±0.20 
Ctl/Pro/Cpz 0.180 0.611 2.75±0.12 0.217 0.737 2.50±0.17 
Des/Cfn/Cpz 0.194 0.658 2.38±0.10 0.231 0.784 2.52±0.13* 
Des/Pro/Cpz 0.140 0.475 2.70±0.11 0.202 0.685 2.52±0.27 
Table 3.3: Using triple-combinations of chemosensitisers at 20ng/ml and 10ng/ml in P. falciparum 
RSA11. *Denotes 10ng-driven CQ uptake increase not significantly higher than 20ng increase 
following ANOVA testing.  
 
Triple combinations at 10ng/ml and 20ng/ml were evaluated against all four CQR isolates to 
determine their effects on the IC50 of CQ. As shown above in Figure 3.4, triple combinations 
using one antidepressant, one antihistamine and the antipsychotic are able to shift the CQ IC50 
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single drugs used. The tables below compare the shift in the IC50 to the increase in CQ uptake 
with each combination in each strain. 
 
Unlike the dual combinations, each of the triple combinations is more effective than each of 
the parent drugs used singly in RSA11; this applies to both concentrations. Overall, the RMI 
values at 20ng/ml are lower for the triple combinations than the corresponding double 
combinations with the same compounds, indicating that the triple combinations are more 
effective.  
 
TRIPLE COMBINATION IN Dd2 
 20ng/ml 10ng/ml 
CQ + IC50(µM) RMI CQ Increase IC50(µM) RMI CQ Increase 
CQ  0.199 1.00 1.00 0.199 1.00 1.00 
Amt 0.168 0.84 1.48±0.19 0.205 1.02 1.66±0.14 
Cfn 0.144 0.72 1.53±0.23 0.201 1.01 1.31±0.11 
Cpz 0.162 0.81 1.52±0.34 0.206 1.02 1.69±0.17* 
Ctl 0.158 0.79 1.82±0.17 0.204 1.02 1.06±0.14 
Des 0.149 0.75 2.12±0.10 0.199 1.00 1.44±0.21 
Pro 0.158 0.79 1.64±0.22 0.200 1.00 1.27±0.23 
Amt/Cfn/Cpz 0.130 0.653 1.59±0.15 0.144 0.720 1.95±0.24* 
Amt/Pro/Cpz 0.120 0.603 1.66±0.23 0.154 0.772 1.73±0.23* 
Ctl/Cfn/Cpz 0.114 0.570 1.53±0.18 0.162 0.815 2.12±0.12 
Ctl/Pro/Cpz 0.110 0.550 1.62±0.15 0.155 0.777 1.62±0.22 
Des/Cfn/Cpz 0.135 0.677 1.87±0.20 0.181 0.907 1.86±0.31 
Des/Pro/Cpz 0.136 0.683 1.88±0.13 0.165 0.729 1.99±0.16* 
Table 3.4: Using triple-combinations of chemosensitisers at 20ng/ml and 10ng/ml in Dd2. Results in 
red denote a significantly higher uptake using the lower-dosed combination. *Denotes a higher 
increase seen at the lower concentration but result not significant following 1-way ANOVA testing.  
 
The change in the IC50, although significant, is however not as greatly improved as one might 
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combinations range from 0.61-0.69 (Table 3.2). DES-based combinations improve from 0.63-
0.70 to only 0.47-0.66; AMT improves noticeably to 0.53-0.57 from a range of 0.68-0.72. The 
data show that the effect of the combinations at 20ng/ml is more additive than synergistic. 
Shifts at 10ng/ml are more marked – the biggest shift in the double combinations showed an 
RMI of 0.83 (DES+PRO) whereas the triple combination RMI values range from as low as 
0.68-0.88. The trend is similar across all of the resistant isolates (Tables 3.3-3.5). 
 
TRIPLE COMBINATION IN K1 
 20ng/ml 10ng/ml 
CQ + IC50(µM) RMI CQ Increase IC50(µM) RMI CQ Increase 
CQ  0.257 1.00 1.00 0.257 1.00 1.00 
Amt 0.208 0.809 2.24±0.22 0.269 1.044 2.03±0.31 
Cfn 0.200 0.778 2.06±0.28 0.234 0.911 1.36±0.16 
Cpz 0.193 0.751 2.65±0.26 0.226 0.879 1.75±0.20 
Ctl 0.218 0.848 1.71±0.16 0.229 0.891 1.71±0.27 
Des 0.177 0.689 1.88±0.11 0.219 0.852 1.79±0.23 
Pro 0.228 0.887 2.39±0.14 0.239 0.929 2.07±0.19 
Amt/Cfn/Cpz 0.192 0.747 2.49±0.19 0.213 0.827 2.78±0.22* 
Amt/Pro/Cpz 0.193 0.751 1.90±0.18 0.214 0.834 2.00±0.16* 
Ctl/Cfn/Cpz 0.126 0.490 2.24±0.31 0.212 0.825 2.17±0.09 
Ctl/Pro/Cpz 0.203 0.790 3.02±0.38 0.226 0.880 1.90±0.15 
Des/Cfn/Cpz 0.111 0.432 3.27±0.20 0.184 0.715 2.25±0.39 
Des/Pro/Cpz 0.186 0.724 3.17±0.13 0.194 0.756 2.16±0.36 
Table 3.5: Using triple-combinations of chemosensitisers at 20ng/ml and 10ng/ml in K1. *Denotes a 
higher increase seen at the lower concentration but result not significant. Values in red are increases 
in CQ uptake which are statistically lower than a parent compound (CPZ) in the combination 
treatment. 
 
Perhaps the most interesting result here is the juxtaposition of the increase in CQ uptake to the 
change in the IC50 in vitro. At both concentrations, and in all the other strains tested (Tables 
3.4-3.5), the highest increase in CQ uptake did not correspond to the lowest RMI; 
additionally, the lowest increase in uptake does not always pair up with the highest RMI, 
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uptake of CQ is not as simple as it might seem. In one case, CTL+CFN+CPZ in Dd2 (shown 
in red in Table 3.4), the lower-dose 10ng/ml combination shows a significantly higher 
increase in CQ uptake than the corresponding 20ng/ml combination even though the RMI 
value in the higher-dose combination is much lower as expected. 
The reason for the non-correlation of uptake and RMI is not clear. It may be a simple case of 
antagonism or competition for PfCRT between compounds which are structurally very 
similar. The highest uptakes are not produced with CTL either singly (Chapter 2) or in 
combination, and CTL is structurally unrelated to the other five compounds; usually, the 
highest uptakes across the isolates have occurred with CPZ and PRO and these two 
compounds are found in half the triple combinations tested. Only once does a 
drug+PRO+CPZ combination produce the largest increase – using higher-dose AMT in 
RSA11.  
The difference might be related to some other components in the parasite system – Pgh1 is 
still postulated to be involved in CQR to an extent (Reed et al., 2000) and as an ABC-protein 
it fits the criteria which would make these chemosensitisers potential substrates. From the 
technical perspective, the method used to conduct the experiment quantifies levels of CQ in 
the whole parasitized erythrocyte and not only the parasite itself; the combinations producing 
the highest increases in uptake might also be increasing CQ concentration in the erythrocyte 
as well as the parasite. Similar experiments with structurally unrelated compounds might 
elucidate the reason for this discrepancy between maximized uptake and RMI. 
In conclusion, combinations of these chemosensitisers, particularly at higher doses, are almost 
always more effective at lowering the CQ IC50 than each chemosensitiser used singly. Some 
inherent toxicity is seen with combinations at the highest dose tested which might be 
worthwhile for investigation as a new class of potential antimalarials.  
The change in the IC50 is considerably less evident at lower doses (10-20ng/ml) when only 
two drugs are combined, but there is a significant improvement in efficacy following addition 
of a third compound at either of the low doses.  
The increase in CQ uptake caused by the addition of the combinations does not correlate 
perfectly with the change in the IC50, suggesting again that potentiation of CQ action is only 










3. The effect of a combination of chemosensitisers on the actions of chloroquine in the malaria parasite in vitro. 
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CQ uptake caused by combinations of chemosensiters was either equivalent to or greater than 











Chapter 4 – Ex vivo and in vivo effects of chemosensitisers 
on the murine malaria parasite 
4.1 Introduction 
The numerous different species of Plasmodium discovered already are known to infect a wide 
variety of hosts in the animal kingdom. Prior to the development of laboratory culturing 
techniques enabling in vitro growth and large-scale utilisation of and experimentation on the 
human malaria parasite Plasmodium falciparum in 1976 (Trager and Jensen, 1976), research 
into the various aspects of malaria was carried out in vivo only, using one of the existing 
animal models of the disease. These included avian malaria models in ducks and chickens 
(Osdene et al., 1967; World Health Organisation, 1971), and the murine model in mice and 
rats (Rane and Kinnamon, 1979; Peters, 1973; Peters, 1975). 
4.1.1 Historical use of animal models in malaria 
The avian and murine models were both used for many years because of the level of success 
achieved in testing large numbers of potential new antimalarials rapidly, reproducibly, 
reliably and at a relatively low cost in these in vivo systems; however more researchers today 
opt for the murine model.  
Both avian and murine models do mimic human malaria pathogenesis in terms of the 
development of cerebral malaria (Rane and Kinnamon, 1979; Macchi et al., 2010) even 
though the species involved (P.gallinaceum in birds; P. yoelii, P. berghei, P vinckei and P. 
chabaudi in rodents) are non-infectious to humans.  
Both the avian and murine models can be infected directly by blood passage using 
trophozoite-stage parasites from an infected donor (Rane and Kinnamon, 1979), as well as via 
a mosquito transmitting sporozoites during a blood meal. In short, this means that 
interventions which act at different stages of the life cycle can be evaluated.  
The murine model has been largely favoured for immunology and vaccine studies since the 
effect of P. chabaudi and P. vinckei on the rodent immune system more closely follows the 
immune response of humans than the avian model does; however, this is only true in certain 
strains of the mouse with a few specific strains of these species of the parasite (Wykes and 














response without antimalarial treatment. As a result, mice infected with P. yoelii and P. 
berghei are preferred during the evaluation of potential new antimalarials. 
4.1.2 Usefulness and limitations of the malaria animal model 
4.1.2.1 Extrapolation of data to the patient 
As with most animal models, the extrapolation of results obtained in vivo to human cases is 
imperfect (Rowan, 1997a) – in the case of malaria models, the mouse is obviously a markedly 
different species to man, and the parasites which infect the two systems are also notably 
different species, each of which is only compatible with one of the two hosts.  
Additionally, the mice used for laboratory work are not the natural host of the multitude of 
parasite species used for in vivo research (Sanni et al., 2002) – most of the parasite strains 
were isolated from the African Thicket Rat in regions of the Democratic Republic of the 
Congo in the mid-20th century. Although Plasmodium is able to infect the mouse, both by 
direct blood passage from an infected animal and through the use of mosquitoes, there has 
probably not yet been adaptation of the parasite to the mouse through evolutionary means. 
The immune response of different strains of mice to the virulence of a variety of species of 
parasite is a marked departure to the human response to malaria infection, and this has lead to 
some speculation on the suitability of the mouse model to accurately study the human disease. 
Nevertheless, strains of parasite lethal to the mouse cause a similar immune response to that 
seen with P. falciparum in man and the pathology is similar; these similarities indicate that 
the mouse model does reflect the human infection process. 
As a result of these differences between the species and that between the responses seen in the 
hosts, compounds which show promise in vitro against P. falciparum do not always work 
effectively in the animal models or using other species of Plasmodium. It also follows that 
those drugs which do show efficacy in mice are not guaranteed to work in patients (Shanks et 
al., 2009). Reasons for this may not be exclusively related to interspecies differences in the 
parasite alone – the host animal is an entire and complete biological system with phenomena 
such as bioavailability and other metabolic/pharmacokinetic factors such as plasma-protein 
binding (Warsame et al., 1992; Suzuki et al., 1985) and side effects all contributing to the test 
compounds’ efficacy and usefulness, or lack thereof. These are major considerations which do 
not typically exist in the isolated in vitro environment. In the case of VPL, the explanation for 














effect chemosensitisation in vitro is relatively high and known to be toxic in vivo and would 
be likewise in a patient (Sweetman et al., 2007). 
Additionally, even compounds which are able to produce results against parasites in the 
mouse following in vitro success are not necessarily good candidate drugs for further clinical 
development because there are no guarantees that therapeutic ranges and other 
pharmacokinetic factors for each test drug are conserved between humans and laboratory 
animals (Cohn, 2010; Wykes and Good, 2009; Menache and Menache, 1996); thus toxicity 
and bioavailability may still play a role. So although the animal model is a useful tool to 
bridge the gap between patients and the laboratory, a result in an animal is only one fairly 
small consideration before human studies can be planned.  
4.1.2.2 Metabolic and physico-chemical factors 
Animal models have to be chosen quite carefully to ensure that the data obtained are 
meaningful (Wykes and Good, 2009; Rane and Kinnamon, 1979; Peters, 1975). Inter-species 
differences between parasite species infectious to humans and animals may already play a 
role, as suggested above, but other criteria such as the route of administration of the drug are 
also critical. For example, compounds being studied in the model which are introduced to 
patients orally as tablets/suspensions and thus are absorbed through the gut in humans should 
be administered similarly via gavage in animals and not injected subcutaneously or 
intravenously into the animals – the metabolism and kinetic parameters of the compound will 
vary considerably between these routes. 
For compounds still in the development stages which show promise in vitro and are taken 
forward into an animal model for the first time, the route of administration is not always 
immediately clear. A topical preparation such as a lotion, cream or ointment is probably the 
easiest to administer but this is simply not practical for most drugs or most conditions 
requiring chemotherapy, and tablets are a more common formulation. Either way, the 
formulation needs to be stable; and if possible the route of administration should be 
acceptable and convenient to patients.  
The most important consideration, however, is that the compound is able to get to its site of 
action efficiently. For the most part, foreign compounds are taken into animal systems via 
ingestion and introduced to the system during feeding. Foreign compounds, as well as other 
critical co-factors required during the metabolic process, can also be absorbed through the 














directly to where they are intended for use. Compounds which might be destroyed by the 
acidic environment in the stomach or extensively altered through first pass metabolism in the 
liver post ingestion can also be injected to avoid these issues; injecting the test compound 
either intravenously or sub-cutaneously causes it to bypass the stomach entirely and allows 
some distribution within the tissues via the bloodstream prior to the compound entering the 
liver for processing.  
Solubility is also a critical factor for in vivo studies, since if the compound cannot be absorbed 
it will not enter the bloodstream to travel to its site of action. Solvents which may prove 
useful for insoluble compounds in the in vitro environment – such as small amounts of 
dimethyl sulfoxide or methanol – are not always well-tolerated by animals and can cause 
toxicity. In some cases, either sub-cutaneous injection or oral ingestion of a preparation of the 
compound suspended in other, better-tolerated substances such as peanut oil might allow the 
less-soluble test compounds to be properly absorbed by the animal. 
4.1.2.3 Ethical considerations 
Given the aforementioned limitations of the murine model and other animal models in general 
as discussed, a more specific simian model using chimpanzees or one of the lower primate 
malaria models, which like humans can be infected by P. falciparum, would potentially 
generate far more useful data which might be more relevant to the human context of the 
disease (Wykes and Good, 2009); however, these experiments would require a massive 
increase in spending. Additionally, it is difficult ethically to justify testing new compounds in 
these animals if that compound has not been evaluated for safety and efficacy in a lower 
vertebrate species first.  
In addition to inter-species differences and extrapolation of data from models to patients, 
critics maintain that in terms of animal health, welfare, environmental conditions and mental 
state, the animal models utilised in the laboratory environment are too different from the 
naturally-occurring animal model found in the wild for the data acquired in the laboratory 
environment to be entirely valid, and argue either that the mental health of the animals is as 
critical as their physical conditions (Duncan and Petherick, 1991), that the model environment 
should more closely reflect the natural one (Wykes and Good, 2009), or that animal-based 
research is simply not useful at all (Nyika, 2009; Rowan, 1997b; Menache and Menache, 














However, from an ethical viewpoint it is impossible to even consider human trials without 
some significant level of animal safety and efficacy data; this is a position which remarkably 
did not always exist, even as recently as the 1940s (Comfort, 2009), when inmates in an 
American prison volunteered to serve a part of their sentences as test subjects for mostly 
untested experimental drugs in the prison hospital.  
Methods, experimental design, and practices have also been criticized. Animals are typically 
utilized for a single experiment and then killed (Carbone, 2004); in some cases, for kinetic 
experiments, each group of animals is used for a single time-point only in a study and killed 
immediately after the sample is taken for that time-point (Smith et al., 1997). Depending on 
the experiment, termination of animals following use for a single experiment is frequently a 
legal requirement; researchers are usually not permitted to use an animal in more than one 
study. Scientifically, this practice is correct since use of untested compounds may cause 
unnoticed changes to the animal which might render results of future experiments in those 
same animals with different compounds useless. Additionally, for toxicity testing, animals are 
frequently examined post-mortem for cellular and systemic damage caused by the substances 
being tested. 
It is known that animals utilized every year for testing of drugs and experimental procedures 
number in the tens of millions, with estimates of as many as 100 million animals being 
reported (Cohn, 2010). The United Kingdom reported that approximately 3.7 million animals 
were used in experiments in 2010 (Blunt, 2011) and the European Union estimates about 12 
million animals used by member states in 2008 (European Union, 2010); in both cases, mice 
and rats account for more than two thirds of the animals tested on. 
Despite these criticisms and limitations, the mouse model has been used extensively and is 
still fairly widely used as a benchmark and is a useful stepping stone between the in vitro 
experimental system and the clinical occurrences of P. falciparum.  
4.1.3 Chloroquine and resistance in the murine model 
The chloroquine resistance phenomenon has been studied and debated in depth since 
resistance to the antimalarial was first reported in the early 1960s. Whether or not the same 
mechanisms of resistance and interactions between CQ and parasite components occur in 
CQR isolates of murine parasites as they do in P. falciparum has not been studied in as much 














Plasmodium differs slightly, studies have shown that the basic building block, the β-hematin 
dimer, is identical (Noland et al., 2003), and since the action of CQ on hematin and free haem 
appears to be purely chemical (Egan et al., 2000; Hoang et al., 2010; Bray et al., 1998), it can 
probably be assumed that the interactions are the same in the mouse as they have been in vitro 
with both isolated haemozoin from parasitized human erythrocytes as well as with the 
chemically identical synthetic variant, the β-hematin crystal.  
It is known that at least one species of the murine parasite, the isolate P. yoelii RC, does not 
form a DV per se because the individual vesicles transporting Hb from the mouse erythrocyte 
do not fuse together (Yan et al., 1999) and are visible under the microscope as unmerged 
units.  
However since haemozoin formation is believed to start in the vesicles before fusion with the 
nascent DV in some species of Plasmodium (Slomianny, 1990), it is probably fair to assume 
that haemozoin does form in these individual vesicles as well unless P.yoelii RC has evolved 
an entirely different mechanism to detoxify the haem which remains following digestion of 
HB. But it should be noted that RC is more highly resistant to CQ relative to other murine 
parasites from the same species, and this phenomenon in fact may well be related to its not 
forming a single DV in vivo (Mahmalgi et al., 1989). 
4.1.3.1 The CQR phenotype and CQ transport in murine parasites 
In addition to a limited amount of research into CQ action and development/mechanism of 
resistance in any animal model, the phenomena associated with CQ resistance reversal and its 
mechanisms have also not been studied in as much detail as they have with the human 
parasite in vitro.  
Although CQ resistance, and resistance to other antimalarial compounds such as MQ, has 
been noted and researched to some extent in the mouse model of malaria (Peters, 1975; Peters 
and Robinson, 1991; Singh and Puri, 2000) and some work has been done with monkeys 
(Bitonti et al., 1988), the outcomes of these experiments have been more focused on testing 
new compounds and characterizing and altering or circumventing resistance to the existing 
antimalarial compounds than focused on examining their origins, mechanisms and similarities 
to the drug resistance noted frequently in isolates of P. falciparum. Although potential 
orthologues of the proteins deemed responsible for high-level antimalarial resistance in P. 














pccg10 and pcmdr1 respectively (Carlton et al., 1998; Hunt et al., 2004), these have not been 
extensively characterized and as such not much is known definitively about their similarities 
to those found in P. falciparum, and neither their structure nor their function/s in the murine 
parasite.  
The mechanism of resistance reversal in vitro, like the mechanism of CQ resistance, remained 
elusive until fairly recently. Whether or not the aforementioned orthologues in CQR isolates 
of murine parasites behave similarly has never been determined. A single study conducted 
previously in P. chabaudi (Miki et al., 1992) has examined the effect of a few 
chemosensitisers on CQ uptake in vivo and suggested that both CQR and CQS isolates 
respond to resistance reversers with an increase in CQ uptake, something not typically seen in 
vitro as shown in preceding chapters and the literature. In that study, several chemosensitisers 
were also able to reverse resistance to both CQ and pyrimethamine in vivo and showed lower 
parasitemia in test animals treated with a combination of a chemosensitiser plus either CQ or 
PYR. This was also shown to be dose dependent. 
4.1.3.2 Bioefficacy of chemosensitisation in the murine parasite in vivo 
A significant amount of research has been carried out examining whether or not the resistance 
reversal phenomenon could occur in an animal model. A high dose of desipramine was 
proven to have a notable effect on CQ action using a CQR isolate of P. falciparum in the owl 
monkey, Aotus trivirgatus  (Bitonti et al., 1988) and so was a high-dose combination of 
chlorpromazine with CQ (Kyle et al., 1993); additionally, a variety of antihistamines and 
other antidepressants perform d similarly in mice as they did against CQR strains and clones 
of P. falciparum in in vitro experiments (Kalra et al., 1993; Peters et al., 1990; Singh and 
Puri, 2000; Evans et al., 1998). 
Other known chemosensitisers which have been effective in vitro have not proven to be 
usable in animals or patients. The Aotus chlorpromazine study (Kyle et al., 1993) showed that 
ketotifen was only moderately successful while VPL and cyproheptadine both failed to effect 
reversal and also showed signs of toxicity to the host lemurs, even though both KET and CYP 
have demonstrated some reversal activity in mice (Peters et al., 1990). The reasons for this, 
apart from inter-species differences (both parasite and host dissimilarities), might be related to 
the route of administration – oral in the monkeys and thus subject to first-pass metabolism in 
the liver, but introduced via sub-cutaneous injection in the mice. CYP was later shown to 














Puri, 2000). Suppression of parasitaemia but not complete clearance or cure was observed 
with high-dose CQ (16mg/kg) and 10mg/kg of Amitriptyline and some other agents, but not 
with 10mg/kg chlorpromazine or promethazine administered with the same dose of CQ.  
In the clinical environment, human studies using desipramine, which has worked on two 
occasions with the human parasite P. falciparum in Aotus monkeys (Bitonti et al., 1988; Kyle 
et al., 1993), were not at all successful (Warsame et al., 1992) although there was a suggestion 
that antihistamines might fare better (Sowunmi et al., 1998) as was demonstrated in a small 
study conducted in patients in Nigeria. It has been suggested that this is because these 
compounds are highly bound to plasma proteins, effectively lowering the concentration of 
available free drug to negligible levels which are too low to reverse CQ resistance in patients 
(Gbotosho et al., 2006). Conversely, moderate chemosensitisation has been noted in the 
murine model on numerous occasions, with as large a variety of compounds as are effective in 
vitro proving to have some level of efficacy in mice infected with the blood-stages of malaria 
(Singh and Puri, 2000; Peters et al., 1990).  
Chemosensitisation in monkeys was not evaluated using one of the monkey-specific parasite 
species like Plasmodium knowlesi or P. cymonolgi, but using P. falciparum, the human 
parasite which can infect several primates other than man. The CQR isolate used in these 
studies was P. falciparum Vietnam Smith/RE, isolated from a patient in 1969 (Clyde et al., 
1970) and shown to be resistant in vitro to CQ and pyrimethamine (Lambros et al., 1982) but 
not utilized much apart from being the CQR parasite chosen for use in lemurs. As a result it is 
not known whether its PfCRT is 7G8 or Dd2-type, but given the reported in vivo response to 
DES in Aotus it can probably be assumed to be Dd2-type. Whether or not a similar response 
would have been achieved with a species of parasite specific only to monkeys is debatable; to 
date, orthologues of PfCRT have not been sought in any species other than P. vivax, and have 
possibly been found in some of the murine isolates as potential open-reading frames in gene 
loci with sequence homology to PfCRT (Lakshmanan et al., 2005). Given that there has been 
a response to chemosensitisation from a variety of compounds (Peters et al., 1990; Peters and 
Robinson, 1991; Singh and Puri, 2000) both in vitro and also in vivo with a CQR isolate of P. 
yoelii, though, suggests that there probably is an orthologue present in the mouse parasite 
frequently used as a model, unless P. yoelii has evolved a different mechanism of CQ 














While resistance reversal has been tested previously with several dozen compounds in mice, 
the effect of these compounds on CQ transport was not determined. Additionally, compounds 
were only tested singly in conjunction with chloroquine, and the test compounds were 
administered at fairly high doses of up to 50mg/kg (Singh and Puri, 2000; Evans et al., 1998; 
Peters et al., 1990). With this in mind, the chemosensitisers and the six test cocktails utilized 
in this study were evaluated in the mouse model: 
1. experiments were conducted to determine whether or not the chemosensitisers act 
similarly on CQ transport in the typically-used murine isolates ex vivo to the way they 
do in vitro with the human parasite at a range of doses 
 
2. the cocktails developed for the study were tested at considerably lower doses in vivo in 
animals for bioefficacy with both CQR- and CQS-infected mice. Mice were dosed 
orally to mimic traditional CQ treatment protocols in the field where CQ is taken by 
mouth as a tablet and not typically injected into patients; lower doses than previously 
reported in the literature were evaluated in order to determine whether the cocktails 
show any additive or synergistic activity. 
4.2 Methodology 
Methods are detailed fully in Chapter 7.  
4.2.1 Parasites 
The parasites used were Plasmodium berghei N, which is CQS and also referred to in the 
literature as P. yoelii N and P. berghei Keyberg 173 (Saul et al., 1997); and P. yoelii 
nigeriensis NS (CQR). Briefly, parasites were maintained in donor animals until such time as 
the parasitemia was sufficiently high to conduct the experiments.  
4.2.2 CQ accumulation 
The principles described in 2.2.2 were utilized, with slight changes. For transport, whole 
blood containing the parasites was withdrawn from the donor animal and washed with 
complete medium to remove the plasma component, then diluted with fresh mouse 
erythrocytes to lower the parasitemia to 5%. Parasites were maintained in complete medium 














radiolabelled CQ for an hour. Parasites were pelleted and the supernatant containing 
unabsorbed CQ removed; the amount retained was determined by scintillation counting.  
4.2.3 Bioefficacy 
Peters’ 4-Day test was utilized (Peters et al., 1990). Groups of five mice were infected with 
either CQS or CQR parasites from donor mice and treated orally an hour thereafter with either 
placebo (phosphate-buffered saline; PBS), CQ or CQ+combination. CQ was administered at 
5mg/kg in all groups; chemosensitisers at 10mg/kg each. CQ and the chemosensitisers were 
dissolved and administered in PBS. 
Treatment was repeated daily till the fourth day. Parasitemia was determined microscopically 
on the fifth day. 
4.3 Results and discussion 
4.3.1 CQ transport in the murine parasite ex vivo 
Figure 4.1 shows the effect of the compounds on the accumulation of tritiated CQ in the CQS 
parasite Plasmodium berghei N.  
 
Figure 4.1: The effect of a range of concentrations of the individual test compounds against the CQS  
mouse parasite Plasmodium berghei N. The black dashed line represents the untreated control at 1. 
The increase in uptake caused by exposure to 5µM VPL, not shown in this figure, was not significantly 
different to the control at 1.02±0.08. Data are means±SEM from experiments performed in triplicate on 
three separate occasions. Values are shown in Table 4.1. 
 


































Unlike the data reported previously in the CQS isolate P. chabaudi AS (Miki et al., 1992), 
there is no notable effect on CQ uptake in the CQS isolate of P. berghei with the test 
compounds across a wide range of concentrations, nor is there a notable increase with VPL 
used at 5µM. These data are consistent with the in vitro findings in this study obtained against 
P. falciparum D10 as discussed above in Chapters 2 and 3. None of the test compounds shows 
a significant increase in the accumulation of CQ in the CQS isolate over the 1-hour period 
which is usually sufficient for similar studies against the human parasite in vitro. 
Uptake appears to have been affected at the higher concentrations used ex vivo and data 
indicate a decrease in CQ accumulation; however, this decrease is more likely to have 
occurred as a result of the significant amount of hemolysis which took place at these 
concentrations, causing a large proportion of the erythrocytes to burst. A similar phenomenon 
was noted previously at these higher concentrations with P. falciparum as shown in Chapter 3 
above. This hemolysis occurred in a highly dose-dependent manner and was less pronounced 




 [drug] ml 
Compound 
Amt Cfn Cpz Ctl Des Pro 
10µg 0.34±0.04 0.81±0.13 0.24±0.02 0.70±0.04 0.46±0.04 0.56±0.01 
1µg 0.67±0.05 0.95±0.03 0.68±0.03 0.82±0.08 0.88±0.16 0.94±0.08 
500ng 0.72±0.11 1.06±0.02 0.97±0.12 0.91±0.03 0.95±0.02 1.01±0.03 
100ng 0.97±0.08 1.03±0.02 1.07±0.07 1.05±0.08 1.01±0.08 0.93±0.08 
50ng 1.09±0.02 0.97±0.04 0.99±0.10 1.03±0.04 1.03±0.17 0.99±0.14 
10ng 1.02±0.09 0.99±0.08 1.04±0.06 1.01±0.08 1.02±0.05 1.03±0.11 
VPL 5µM 1.02±0.08 
Table 4.1: The change in CQ accumulation ex vivo in the murine CQS parasite Plasmodium berghei 
N. Values are presented relative to the control and are the mean±SEM from experiments conducted in 














Only three of the compounds showed an uptake calculated to be significantly increased over 
the control – CFN at 500ng/ml (p=0.039); CPZ at 100ng/ml (p=0.048) and AMT at 50ng/ml 
(p=0.031). However, as shown in Table 4.1, the actual level of increase is comparatively 
small relative to those seen in vitro against the CQR isolates. 
As expected, increases in CQ uptake were observed when the CQR isolate P. yoelii NS was 
exposed to the test compounds across the same range of concentrations as shown below. In 
this regard, these two isolates of the mouse parasite mimic the results seen in P. falciparum to 
an extent and suggest similarities in the mechanisms of resistance reversal in these different 
species of the parasite. 
 
 
Figure 4.2: The effect of a range of concentrations of the individual test compounds against the CQR 
mouse parasite Plasmodium yoelii NS. The black dashed line represents the untreated control at 1. 
The increase from 5µM VPL is indicated by the solid grey line and is 1.28±0.07. Data are means±SEM 
from experiments performed in triplicate on at least three separate occasions. Values are shown in 
Table 4.2. 
 
As seen in the CQS mouse isolate, several of the compounds are lytic at the highest dose; 
however, AMT, CFN and PRO do not appear to be as toxic to the NS strain as they are to the 
N strain of P. berghei. The reason for this is not clear. Additionally, the highest dose of PRO 
is both non-lytic and able to significantly increase CQ uptake into the CQR murine parasite. 
 
 


































Notable differences between CQR strains of the human and mouse parasites are evident when 
it comes to the response to VPL. A dose of 5µM VPL typically increases CQ uptake 3-5 fold 
in different CQR strains of P. falciparum (Fig 3.2; Table 3.1); in the NS strain of P. yoelii, the 
increase was considerably lower at only 1.28 times the amount of CQ accumulated by the 
untreated control. 
A similar phenomenon is seen with the test compounds – the highest recorded increase is less 
than 2-fold, demonstrated using CFN at higher concentrations (Figure 4.2 and Table 4.2). 
Increases of up to 9-fold were observed with one CQR isolate of P. falciparum using PRO in 
vitro (Figure 2.4) and the increases across the series of concentrations tested was frequently 




Amt Cfn Cpz Ctl Des Pro 
10µg 0.31±0.12 1.02±0.07 0.53±0.19 0.65±0.20 0.55±0.09 1.23±0.08 
1µg 1.04±0.13 1.79±0.05 0.84±0.11 0.87±0.22 0.86±0.07 1.73±0.07 
500ng 1.35±0.06 1.98±0.24 1.16±0.06 1.21±0.07 1.08±0.24 1.31±0.21 
100ng 1.53±0.20 1.27±0.13 1.64±0.04 1.31±0.12 1.19±0.04 1.48±0.14 
50ng 1.44±0.07 1.28±0.15 1.59±0.06 1.37±0.04 1.36±0.05 1.35±0.06 
10ng 1.11±0.20 1.08±0.20 1.15±0.15 1.05±0.07 1.10±0.09 1.09±0.09 
VPL 5µM 1.28±0.31 
Table 4.2: The change in CQ accumulation ex vivo in the murine CQR parasite Plasmodium yoelii NS. 
Values are presented as the increase relative to the control and are the mean±SEM from experiments 
conducted in triplicate on three separate occasions. Values in bold indicate greater uptake than the 
level achieved with 5µM VPL, which was 1.28±0.31. 
 
The reason for this lowered increase is unclear; apart from differences between the two 
dissimilar species of parasite (human vs murine) and inherent differences in each host, this 
might be related to the presence of white cells and other immune components remaining with 
the freshly-isolated parasites after washing as described in the Methods. Since the test 














and albumin protein found in human plasma (Gbotosho et al., 2006; Boulter et al., 1993; 
Suzuki et al., 1985), which accounts for the extremely low circulating concentrations of free 
drug in the bloodstream, even small amounts of plasma remaining in the parasite preparation 
could noticeably alter the concentration of drug the parasites are exposed to. As a result, the 
lower overall increases might be occurring because the concentration which is actually 
achieved in the reaction vessel in the ex vivo experiment is lower than that which is calculated 
and prepared prior to the addition of the parasites and any remaining plasma. 
Unlike in the human parasite in vitro, increase in CQ uptake is maximized in the murine 
parasites at lower concentrations and the clear dose-effect seen previously is not quite as 
pronounced ex vivo. With the exception of DES, there is no significant difference between 
increases seen for each compound at 100ng/ml and 50ng/ml; for AMT and PRO this 
phenomenon occurs at 500ng/ml as well. 
Also unlike the effects seen in P. falciparum, the lower doses of each drug are able to increase 
CQ uptake to a level at least equal to that achieved with 5µM VPL, and in some cases still 
higher than that. The reason for this is not immediately clear; inter-species differences 
between the human and mouse parasites and erythrocytes might be the most significant 
factors involved. 
Although some evidence for them does exist, the murine equivalents for the proteins 
responsible for high-level CQ resistance in vitro – PfCRT and Pgh1 – have never been 
isolated or characterized extensively in other species of Plasmodium. The isolate used here is 
described as being moderately CQ resistant and its emulation of the response to the 
chemosensitisers and VPL seen in vitro suggest that the resistance mechanism of the murine 
parasite might be closely related to that of the Old-world phenotype of CQ resistant strains 
and clones of P. falciparum.  
In conclusion, to a lesser extent the mouse parasite ex vivo seems to mimic the response of the 
human parasite in vitro when exposed to tritiated CQ over a range of concentrations of each 
compound. In the CQR strain of the murine parasite which was examined, accumulation of 
CQ is increased in the presence of low doses of the chemosensitisers. 
4.2.2 Bioefficacy in the mouse model 
None of the triple-combination cocktail+CQ treatments, comprising each of a single 














lower the parasitaemia in the test animals further than when CQ at 5mg/kg was used alone in 
the animals infected with the CQS isolate of the parasite Plasmodium berghei N (figure 4.3; 
Table 4.3), but five of the six combinations were fairly effective against the CQR isolate P. 
yoelii NS (Figure 4.4; Table 4.3) over the course of the 4-day treatment period. A dose of 
5mg/kg of CQ administered daily for four consecutive days with P. berghei N is known to 
suppress the parasitaemia significantly without causing complete clearance (Peters, 1975) as 
was seen in the experiment; the same dose in the moderately-CQR isolate P. yoelii NS is 
noticeably less effective (data in Table 4.3). All combinations in both strains, as well as the 
use CQ alone, were better than the placebo.  
 
 
Figure 4.3: The in vivo effect of combinations of three chemosensitisers co-administered at 10mg/kg 
each with CQ at 5mg/kg on the survival of the CQS isolate Plasmodium yoelii N in groups of 5 mice 
after four days of treatment post-infection. Data is the mean±SEM and is in Table 4.3. 
 
The lack of increased activity with the cocktail treatments against the CQS isolate in vivo 
mimics the response of the CQS isolate in vitro (Chapter 2) and is consistent with numerous, 
but not all, previously published reports regarding chemosensitisation in CQS parasites in the 
mouse model. Two studies have shown improved CQ activity against CQS isolates using P. 
chabaudi (Miki et al., 1992; Evans et al., 1998), one of which used Citalopram, but this has 
not been seen with strains of P. yoelii or P. berghei. There are several possible reasons for this 
dissimilarity – firstly, the parasite species concerned are different and may respond to the 
compounds differently. Secondly, the routes of administration were dissimilar – in the 




































intra-peritoneal space compared to the oral dosing used here, which leads to significantly 
different metabolism in the animal.  
In addition to no potentiation of CQ action, the lack of further killing effect on the CQS 
isolate implies that a daily dose for four consecutive days of the triple-combinations 
themselves is not toxic to the parasites; or if the concentrations are in fact toxic then the 
toxicity does not persist for a sufficiently lengthy duration to disrupt parasite growth and/or 
multiplication.  
Since the murine parasite has a 24-hour life cycle during the blood stages as opposed to the 
48-hour life cycle of P. falciparum, the daily-dosed combinations do not appear to have 
affected the murine parasite over four complete cycles. Compounds absorbed in the gut are 
subject to first-pass metabolism and are exposed to liver enzymes before circulating in the 
bloodstream (Campbell, 1993); the injected routes tend to enter the bloodstream and circulate 
unaltered for a while prior to reaching the liver for metabolism. This means the injected drugs 
in the preceding studies might concentrate to a higher, possibly toxic level in the parasitised 
erythrocytes before being processed by the liver, unlike the drugs in this study which were 
introduced by gavage and which clearly do not kill the parasite. 
 Given that the murine model is an entire living system means that numerous factors will 
contribute to the circulating levels of each compound – the times taken to reach a maximum 
concentration might differ as might the amount of free drug available which is unbound to 
plasma proteins or not sequestered in other organs and compartments; compounds may be 
quite quickly converted into inactive metabolites by liver and other enzymes – all of which 
could interfere with the compounds’ ability to work synergistically and cause damage or death 
to the parasite. However, the combination itself seems to have little effect on parasite 
survival; and the regimen of the combination co-administered with a standard dose of CQ was 
not significantly better or worse than CQ used alone.  
The picture is quite different in the CQR isolate P. yoelii NS. As expected, the comparatively 
low dose of CQ had a slight but significant effect on the parasites (Figure 4.4; black and pale 
blue bars), unlike the noticeable and significant suppression of parasite growth seen in the 
CQS strain. 
Results with the combinations are also quite pronounced compared to the data from the CQS 














were co-administered at 10mg/kg each with CQ, with striking suppression of parasitaemia 
seen when these compounds were combined. The addition of AMT+CFN+CPZ (yellow bar) 
to CQ (black bar) failed to further enhance CQ action, however. Although AMT+CFN+CPZ 
was not significantly better than CQ, it was shown to have notably lower parasitaemia than 
the placebo group (pale blue bar; p=0.0021). 
 
Figure 4.4: The in vivo effect of combinations of three chemosensitisers co-administered at 10mg/kg 
each with CQ at 5mg/kg on the survival of the CQR isolate Plasmodium yoelii NS in mice. Data is 
contained in Table 4.3 and represents the mean percentage±SEM of infected erythrocytes in groups of 
5 mice remaining after 4 days of treatment. 
 
As with the CQS isolate in vivo, the cocktails do not seem to be inherently toxic to the 
parasite over the course of the four days of treatment. The reasons for the differences between 
the potentiating activity of the cocktails is not clear. As in the preceding in vitro section (3.3.1 
above), there is no magic bullet in vivo either and the cocktail treatments produce a fairly 
mixed bag of results. 
Both cocktails using CTL as the antidepressant are able to significantly lower the parasite 
level when combined with CQ. Using CFN in conjunction with the two other drugs in the Ctl 
cocktails appeared more effective than using PRO. The opposite was seen when the 
antidepressant was switched to either DES or AMT, though, with PRO showing a seemingly 
noteworthy increase in efficacy over CFN with either of the other antidepressants. Examining 
the intra-cocktail difference using analysis of variance (Anova) showed no significant 




































using DES and either antihistamine. The difference between the AMT cocktails was deemed 
highly significant (p<0.01). Anova between the varied antidepressants revealed the only other 
notable difference to be between CTL+CFN+CPZ and the seemingly unaltered AMT-CFN-
CPZ (orange vs yellow bars in Fig 4.4), with the other cocktails being determined to have p-
values greater than 0.05 when compared to each other. Given that the experiment was 
conducted with only five mice tested in each group, a larger number of mice used in each arm 
of the study could provide a result which is statistically more certain to determine whether or 
not the cocktails with similar activity are in fact different. 
Previous use of CTL has shown that it is moderately effective in its own right at 10mg/kg in a 
CQR isolate of P. chabaudi when injected sub-cutaneously (Evans et al., 1998). The results 
obtained here indicate that an oral dose shows similar improvements, even if the other drugs 





CQ (5mg/kg) +  
Combo (10mg/kg) 
P. yoelii N (CQS) P. yoelii NS (CQR) 
% pRBC
α
 p (vs CQ)
φ
 Significant % pRBC p (vs CQ) Significant 
CQ (5mg/kg) 1.79±0.41 - - 6.690±0.68 - - 
Ctl+Cfn+Cpz 2.16±0.29 0.4792 No 1.48±0.34 0.0001 *** 
Ctl+Pro+Cpz 1.99±0.36 0.7343 No 3.84±0.83 0.0292 * 
Des+Cfn+Cpz 1.74±0.40 0.9304 No 4.28±1.40 0.0425 * 
Des+Pro+Cpz 2.15±0.29 0.4921 No 3.12±1.30 0.0235 * 
Amt+Cfn+Cpz 1.76±0.49 0.9646 No 5.60±0.93 0.6443 No 
Amt+Pro+Cpz 2.00±0.52 0.7582 No 2.24±0.43 0.0005 *** 
Placebo 7.42±0.75 0.0002 *** 8.88±1.59 0.0422 * 
Table 4.3: Comparing the effect of the cocktails to the use of CQ only in vivo using CQS and CQR 
isolates. Values denoted in bold type indicate a significant difference to CQ. 
δ
CQ was administered at 
5mg/kg; the cocktails contained 10mg/kg of each compound plus 5mg/kg CQ all dissolved in 200µl 
PBS. Placebo group animals were dosed with 200µl PBS only. 
α





p-value obtained from unpaired t-test. *Result deemed significant; ***result deemed 
very highly significant.  
 
Although DES has been used successfully in a primate model, its improvement of CQ action 














study some low-level activity was present and the activity increased as the dose of DES 
increased from 3mg/kg to 10mg/kg, but no further increase in effect was seen at doses from 
10-60mg/kg. Both DES-containing cocktails administered orally show some improvement in 
the activity of CQ here.  
The reason for the lack of improvement in CQ activity when AMT+CFN+CPZ is co-
administered is not clear. Since other cocktails containing CFN are able to potentiate the 
activity of CQ, it is unlikely that CFN is not reaching the target. Given that substituting CFN 
with PRO in the other AMT-based cocktail generates a striking reduction in parasitemia, it is 
also unlikely that AMT is not getting to the target; AMT used singly in previous studies 
showed moderate activity at 10mg/kg with CQ (Singh and Puri, 2000); it is worth noting, 
however, that CQ was used at 16mg/kg, more than three times the dose used here.  
Possible explanations would include the likelihood that AMT and CFN might antagonize one 
another’s action on the target in the mouse system, something which was not seen in vitro. 
This could result from inter-species differences between P. yoelii and P. falciparum and the 
mechanism/s of resistance in each species. Another possible, and perhaps more likely, 
explanation is related to the numerous other factors such as metabolism and drug 
compartmentalization which come into play inside an entire living system such as the mouse 
model – the presence of AMT might alter the absorption of CFN from the gut, or increase its 
breakdown in the liver, preventing it from adversely affecting the parasite. If there is no 
antagonism between compounds in the parasite in vivo, and perhaps none should be expected 
since the combination did produce a result in the CQR isolates in vitro, these data suggest that 
the circulating concentrations of each of the three compounds is not sufficiently high enough 
for sufficiently long enough to affect CQ action in the mouse model individually as well as in 
combination. 
There are limitations to the study. Mice were not followed up for 28 days or until death; since 
there was no complete cure noted (i.e. pst > 0%) it was assumed that pst would increase once 
CQ treatment ceased. Drugs were not evaluated singly against CQ in the mouse model with 
the 4-Day test, which makes the data difficult to interpret completely. Use of a lower dose of 
CQ, which is known to only moderately suppress parasite growth relative to the higher doses 
utilized in previously-published studies, does not allow for direct comparison of those studies 
to these data. The reason for the failure of AMT+CFN+CPZ to alter resistance in the CQR 














may be a result of the compounds interfering with each other’s pharmacokinetics. These 
issues could be more thoroughly examined by conducting a larger study in which each 
compound is evaluated singly with both higher and lower doses of CQ. A second arm of the 
study would involve administration of the combinations with both doses of CQ, in order to 
completely determine the effects of the single drugs on CQ action and determine to what 
extent the combination further improves CQ efficacy in vivo relative to the individual drugs. 
In conclusion, it does seem that mechanisms of CQ resistance and its reversal share some 
similarities between the species responsible for malaria in the different hosts, since the 
response is mimicked between the parasites responsible. In both P. falciparum tested in vitro, 
and isolated P. yoelii and P. berghei evaluated ex vivo, chemosensitisers are able to alter total 
CQ accumulated within the parasitized erythrocyte in a dose-dependent manner. Use of the 
cocktail treatment with CQ in the mouse model in vivo shows that the CQS isolate is 
unresponsive while the CQR isolate shows that the combinations can potentiate CQ action; 
these are hallmarks of resistance reversal in vitro. Although the orthologues of PfCRT and 
Pgh1 postulated to exist in the mouse parasite Plasmodium yoelii have never been 
characterized, these data suggest that the orthologues behave in a similar but possibly 
attenuated manner in the species. These data show that in vivo use of the chemosensitisers 
administered orally in combination at 10mg/kg with only small amounts of CQ can still cause 












Chapter 5 – In vivo evaluation of pharmacokinetic aspects 
of chemosensitiser use in the murine model 
5.1 Introduction 
All compounds introduced into a living system are subject to metabolism – the breakdown of 
those compounds by chemical and/or enzymatic processes for either use or detoxification by 
that living system.  
5.1.1 Metabolism of exogenous compounds 
Although ultimately all metabolism occurs at the cellular level, in more complex 
(multicellular) organisms such as plants and animals, metabolism largely takes place in 
specific cells housed in specific organs such as the liver (Campbell, 1993; Campbell, 1991b) 
while the by-products, in the form of both utilizable/required nutrients and also waste, are 
transported through the host’s body to other sites via the bloodstream. During the metabolic 
process, compounds are broken down into a variety of by-products and metabolites which are 
diverted into numerous other pathways to provide any number of substrates and nutrients 
required by the entire living system to carry out vital functions such as cell maintenance and 
division at the cellular level up to more complex processes performed such as temperature 
regulation and generation of energy for muscle contraction and nervous functions, to name a 
few. 
5.1.2 Drug absorption and bioavailability 
Drug delivery plays an important role in the use of therapeutics, since the drug is entirely 
useless if it does not reach its intended target. Complications involved in drug delivery 
include the aforementioned issues with metabolism, but also drug absorption – the movement 
of the drug into the bloodstream. If the drug is not absorbed into the bloodstream its 
usefulness is nullified; as a result, absorption is one of the most critical factors under 
consideration during the drug development process. The drug bioavailability, the ratio of 
unchanged/non-metabolised drug absorbed into the bloodstream versus the amount 
administered, is an important pharmacokinetic parameter. In the case of inhaled drugs and 
compounds administered intravenously, absorption is 100 percent, and thus so is 
bioavailability; this is rare for drugs administered orally, however. 
Factors which affect absorption, and thus also bioavailability, are numerous. Some of these 
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stomach affect the rate of drug absorption; the nature of these contents may also pose 
challenges, since certain fruit juices such as grapefruit are known to interfere with liver 
enzymes like the cytochrome P450 CYP3A4 and thus decrease metabolic rates and drug 
breakdown which can effectively cause an overdose.  
Other factors such as the physical and chemical characteristics of the compound, like 
solubility and hydrophilicity, can also limit absorption. Another factor which can be 
controlled to an extent is the drug formulation as mentioned above. Some of the factors 
affecting absorption and bioavailability cannot be controlled, however – the age, gender, race 
and/or geographical location, overall health and gastro-intestinal health of a patient may all 
alter the absorption of a drug from the predicted/normal value seen in other populations. 
5.1.3 Quantification of drug concentrations 
It is comparatively easy to predict the concentration of a drug in an isolated in vitro 
environment since most of the factors involved in changing that concentration (i.e. 
metabolism by the other components of that living system in vivo) are not present to carry out 
their usual functions. Chapters 2-4 of this document detailed experimental work carried out in 
vitro and ex vivo using cultured parasites maintained in fresh human or harvested from live 
mice to which fixed concentrations of the various drugs were added; in all cases, the external 
concentration of each drug which the parasitized erythrocyte came into contact with was 
known with some certainty. The same is not true in the in vivo environment where the 
concentration of compounds is constantly changing as metabolism occurs and the compound 
is distributed through the tissues before being eliminated. 
Quantification methods are numerous. Frequently utilized procedures involve enzyme-based 
kits which produce a colour change in relation to the amount of drug present, conceptually 
similar to the pLDH method used to determine parasite survival in vitro. The compound of 
interest might also be quantified by means of a spectrophotometer operating in the visible, 
infra-red or ultra-violet light wavelengths, or by exploiting the compounds’ fluorescent or 
other innate physicochemical properties. Other more complex procedures require the sample 
to first be extensively processed before being subjected to separation methods via a 
chromatograph which would isolate the chemical of interest before one of the aforementioned 
techniques can be applied.  
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One extremely sensitive quantification method is the combination of high-performance liquid 
chromatography (HPLC), used to separate the compound of interest from the biological 
matrix, and mass spectrometry (MS), which uses a mass-detector to count how much of a 
certain compound is present. Although the process is often labour-intensive when it comes to 
extracting the drug from the sample, the combination of the two makes for an efficient and 
highly sensitive mechanism for determining drug levels extracted from many different sources 
such as blood, hair and urine. The added sensitivity of the MS component allows detection of 
extremely low levels of compound (high picogram range) from comparatively small volumes 
of sample such as 1-2µl. This makes the system ideal for determining kinetics in small 
animals – numerous small-volume samples can be harvested without any adverse effect on the 
animals’ health from loss of blood.  
This is quite different from older protocols, quite often in which a group of 3-5 animals would 
represent a single time-point and be killed in order to get sufficient volumes of blood to 
quantify the sample taken at that time point. This method is subject to extraneous factors – 
although the data was averaged, each time point effectively originates from a different 
population. Use of small volumes in the LCMS system, however, means that an entire kinetic 
curve taken over 12-24 hours can be constructed using multiple samples from the a single 
group of 3-5 animals. 
Given that the in vitro resistance reversal parameters had been quite firmly established as 
detailed in the preceding sections of this document prior to investigating their behavior in the 
murine model both ex and in vivo, the determination of their bioavailability and quantification 
of circulating levels in the animal bloodstream was carried out.  
5.2 Methodology 
Methods are detailed completely in Chapter 7. Briefly, each compound was worked up using 
an LCMS system in order to develop a method which could quantify all six drugs 
simultaneously.  
Once this was in place, five healthy and five malaria-infected mice were dosed with all six 
compounds simultaneously at the cocktail concentration tested in the preceding section, 
10mg/kg. Blood samples of approximately 10µl were taken from the tail of each animal at 
predetermined time points to construct a curve to develop a profile of each compound over 24 
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drugs from the blood, then run on an HPLC-MS/MS system to determine how much of each 
drug was circulating at each time-point on the curve. 
5.3 Results and discussion 
5.3.1 LCMS method development 
Since the compounds utilized in the study are all weakly basic and thus known to accumulate 
in an acidic environment where they would be protonated (Daniel and Wójcikowski, 1997), 
the method was developed with the MS using electrospray ionization (ESI) and running in 
positive-ion mode, which adds a proton to the compound and increases the fragment masses 
by 1 atomic mass unit. These conditions have been shown to be successful previously (de 
Castro et al., 2007; Shinozuka et al., 2006) with some of these compounds as well as others of 
a similar nature.  
 
 
Figure 5.1: The mass-spectrum of amitriptyline (parent ion [M+H
+
]=278.3amu) obtained using the 
specified conditions. 
 
The MS component was performed on an API 3200 tandem mass-spectrometer sourced from 
AB Sciex. It was run in the positive mode using Turbo Spray on the ion source at 400°C and 
  +Q1: 1.524 min from Sample 1 (TuneSampleID) of MT20080520114706.wiff (Turbo Spray) Max. 5.4e6 cps.
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with 5500 volts generating the electric field. Each of the six compounds was counted for 
150ms. The MS system was controlled by the proprietary software package Analyst v1.5.1 
which was also used to generate calibration curves from the integrated data, and to fit the 
unknowns in each sample to determine the concentrations of each drug at each sampled time. 
Compounds were dissolved in water and then diluted to a concentration of 1µg/ml in the 
mobile phase which was a mixture containing a 1:1 ratio of formic acid (0.1%v/v) and 
acetonitrile; similar conditions have proved favourable in work carried out with related 
compounds elsewhere (McClean et al., 2000; Aymard et al., 1997). 
Full spectra were obtained for each compound individually, and 4-5 fragmentation product 
ions for each compound were chosen which gave the best transitions to allow the MS to detect 
each compound unambiguously via its daughter ions which in turn would allow simultaneous 
quantification of all six chemosensitisers before one was selected. Transitions traced by the 
system are listed in Table 5.1 below. Given that with the exception of Citalopram the parent 
compounds are quite closely structurally related in both the tricyclic core and the attached 
side chain, as discussed in Chapter 2, it was critical to ensure that different fragment ions 
were selected which were not common to two or more compounds and which might interfere 
with the accuracy of the count. Following MS optimization, an HPLC method was developed. 
 






Amitriptyline 278.229 233.100 
Chlorpheniramine 275.172 230.100 
Chlorpromazine 319.173 58.200 
Citalopram 325.261 109.100 
Desipramine 267.238 77.100 
Promethazine 285.180 86.100 
 
Table 5.1: Chosen transitions following parent molecule fragmentation in the collision cell of the Mass 
Spectrometer traced by the system to quantify each chemosensitiser. 
 
Figures 5.2a and b below are representative diagrams of the different column conditions and 
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Figure 5.2a: HPLC trace of all six compounds run simultaneously with a variety of different columns 
and conditions. Trace using a C-18 column (top row) with a 1:1 ratio of formic acid (0.1% v/v) and 
acetonitrile at 25°C (top) and 35°C (bottom). In order: Amt, Cfn, Cpz, Ctl, Des, Pro                              ).  
 
XIC of +MRM (6 pairs): 278.2/233.1 amu from Sample 3 (Sample003) of DataSET1.wiff (Turbo Spray) Max. 9.1e4 cps.







































XIC of +MRM (6 pairs): 278.2/233.1 amu from Sample 1 (all_Drugs002) of DataSET12.wiff (Turbo Spray) Max. 9.1e4 cps.
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Figure 5.2b: HPLC trace of all six compounds run simultaneously with a variety of different columns 
and conditions. Trace using a Hilic column at 35°C with 9:1 ratio of mobile phase (top) and with a 
Luna-PFP column using a 1:1 ratio at 35°C (bottom). In order: Amt, Cfn, Cpz, Ctl, Des, Pro 
 
XIC of +MRM (6 pairs): 278.2/233.1 amu from Sample 1 (all_drugs016) of DataSET1.wiff (Turbo Spray) Max. 4.5e4 cps.







































XIC of +MRM (6 pairs): 278.2/233.1 amu from Sample 1 (all six) of 1008.wiff (Turbo Spray) Max. 9.7e4 cps.
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Chromatography was carried out on an Agilent 1200 HPLC stack comprising of a binary 
pump, a heated column compartment and a temperature-controlled autosampler. Separation 
was achieved using the Luna PFP (pentafluorophenyl) silica column, the C18 octadecyl-silane 
column and the HILIC column, all provided by Phenomenex, as the stationary phase. 
Samples were run at a flow rate of 300µl/minute using a 1:1 ratio of acetonitrile and 0.1% 
(v/v) formic acid in water as the mobile phase. The column was held at 35°C. All parameters 
were controlled remotely using the proprietary Analyst v1.5.1 software by Applied 
Biosystems (AB Sciex). 
Work carried out on some of these and other related compounds provided a framework for the 
chromatography (Aymard et al., 1997). Several silica columns were evaluated for their ability 
to separate these compounds from a biological matrix consisting of frozen plasma in a manner 
which was both efficient and timeous; tests were conducted using a variety of temperatures 
and under different flow rates with altered mobile phase ratios. 
Although fairly good separation was achieved with a C-18 column (Figure 5.2a), at least one 
of the compounds was eluting on the solvent front and peaks were not particularly sharp; nor 
were peak intensities sufficiently high at any of the temperature conditions tested. Increasing 
the temperature (Figure 5.2a vs 5.2b) decreased peak intensity further; this effect was even 
more profound at 45°C (data not shown). 
Use of a Hilic column failed to give adequate peak separation across a range of mobile phases 
from 1:4 formic acid (0.1%v/v) and acetonitrile (data not shown) through 1:1 (not shown) and 
up to 9:1 (Figure 5.2b) of the same two solutions. All six compounds eluted on the solvent 
front at higher acetonitrile levels and showed very low peak intensity and poor separation at 
higher levels of formic acid. 
Although the data is not shown, similarly poor levels of separation and peak intensity were 
observed with a Phenyl column as well as a C-6 column before adequate results were obtained 
using the Luna-PFP column (Figure 5.2,b, bottom) and seen to be optimized at 35°C with a 
1:1 ratio of the two solvents as mobile phase. 
5.3.2 Quantification of levels in mice 
All drugs were then spiked into frozen whole mouse blood and diluted to generate 
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developed which would allow for quantification for samples taken directly from the tails of 
the mice.  
 
 
Figure 5.3: A typical calibration curve obtained using the LCMS/MS system with the Luna-PFP 
column at the specified conditions. The curve is the detected trace for AMT at a range of 
concentrations. Regressions for each drug ranged from 0.98-0.9989. 
 
Spiked whole-blood aliquots were collected in 50µl of carbonate buffer at high pH to drive 
the weak bases into their protonated and thus unionized form; in turn, each aliquot was 
resuspended in 250µl ethyl acetate and vortexed vigorously to denature and precipitate the 
proteins, which would release any bound fraction of the unionized chemosensitisers into the 
organic layer. Proteins were pelleted via centrifugation at 13000rpm for 120 seconds.  
200µl of the supernatant from each sample was transferred to a clean vial and dried by gentle 
heating for 30 minutes at 30°C under vacuum. Dried samples were resuspended in 100µl of 
 28052008_curves.rdb (275.2 / 230.1): "Quadratic" Regression ("1 / x" weighting): y = -0.428 x^2 + 2.83e+003 x + 4.92e+003 (r = 0.9988)
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mobile phase and run on the PFP column for separation prior to being quantified on the mass-
spectrometer. A sample calibration curve is shown in Figure 5.3. 
Once this was completed and results deemed satisfactory, 5 uninfected and 5 malaria-infected 
mice were each dosed with 10mg/kg of all 6 chemosensitisers and the amount of each drug 
circulating was determined at a series of time-points over 24 hours. Data is presented in 
Figures 5.4 and 5.5 below. 
Samples at each time point were collected from live mice via a small excision on the tail; 10µl 
of whole blood was transferred to a reaction vessel containing 50µl of carbonate buffer at 
pH11, vortexed vigorously for 30 seconds, and then frozen until such time as they were 
analysed. When analysed, samples were allowed to reach room temperature before 
undergoing liquid-liquid extraction and drying as described above. All samples were extracted 
simultaneously and run on the LCMS with a set of known controls as a single batch. 
 
Time post  
dose (hrs) 
Concentration ng/ml 
Amt Cfn Cpz Ctl Des Pro 
0 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 81.03 202.00 630.80 89.88 132.00 72.50 
1 69.01 185.67 446.00 73.47 128.67 73.20 
2 61.33 139.93 350.50 67.50 104.10 60.55 
3 59.38 136.00 334.93 61.45 95.88 58.00 
4 58.00 123.67 274.33 54.00 98.25 56.03 
6 51.35 102.40 273.25 47.65 78.10 30.88 
8 40.63 25.00 103.47 25.05 38.08 15.11 
12 23.10 19.10 59.10 9.99 13.93 10.58 
24 4.68 2.67 17.00 5.25 4.25 6.50 
Table 5.2: Calculated concentrations of each chemosensitiser in healthy mice over 24 hours following 
a 10mg/kg dose of all six compounds simultaneously. Data reported as the mean±SEM of readings 
from 5 animals; maximum concentrations in bold. 
 
Figure 5.4 shows the calculated concentrations in the circulating blood of uninfected mice. 
Drugs are grouped according to the determined ranges present to accurately show the scale 
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Figure 5.4: Circulating concentrations of each chemosensitiser in healthy mice following oral dosing of 
each drug simultaneously at 10mg/kg. Data presented as the mean concentration±SEM from five 
animals; the same five animals were used throughout the 24-hour evaluation. 
It is clear that very little of the unaltered drug remains circulating in the animals’ bloodstream 
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been dosed again if treatment was being administered as in the 4-day test described in Chapter 
4 above. Peak concentrations are seen within the first 60 minutes for all six compounds. 
Maximum concentrations attained from a 10mg/kg dose varies considerably between the 
related compounds, with the antipsychotic CPZ reaching over 600ng/ml at its peak (Table 5.2) 
and the antihistamine PRO reaching only 73.2ng/ml at its maximum. CTL and AMT achieved 
similarly low maxima during the course of the experiment. 
As has been mentioned, and demonstrated previously, the resistance-reversing compounds 
utilized in this study are largely bound to plasma proteins such as albumin and the α1-acyl 
glycoprotein (Warsame et al., 1992; Gbotosho et al., 2006), in some cases up to 99%, which 
would leave very little of each drug available to affect the parasite. The circulating 
concentrations above are calculated from a whole blood aliquot and as such it is not clear to 




Figure 5.5: The kinetics of the chemosensitisers in mice infected with the parasite. Data is the 
mean±SEM of samples collected from five different animals; the same five animals were used for the 
full evaluation period. 
 
Given that some level of resistance reversal was achieved when the compounds were co-
administered with CQ in vivo, it follows that enough of each drug was present to potentiate 
the action of CQ. Like CQ, all compounds are weakly basic and thus should be driven by the 
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pH gradient into the parasite; thus, even relatively small amounts of each compound entering 
the parasitised erythrocyte should accumulate within the parasite by simple Michaelis-Menten 
kinetics. Although the drug levels decrease quite rapidly initially i.e. they drop between 25 
and 40% between 60 and 120 minutes post-dose, the elimination slows quite considerably 
over the next four hours. For all drugs barring PRO and CPZ, there is still more than half the 
maximum circulating after 6 hours, and the bioefficacy data in the preceding chapter shows 
that in five of the six combinations, the remaining circulating amounts of drug are sufficient 




Time post  
dose (hrs) 
Concentration ng/ml 
Amt Cfn Cpz Ctl Des Pro 
0 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 224.00 53.30 891.00 685.60 323.20 281.20 
1 157.72 64.07 820.00 523.00 258.60 250.40 
2 129.58 7.90 759.40 431.80 153.09 131.30 
3 78.45 0 563.83 304.92 122.43 60.03 
4 33.56 0 503.33 288.60 116.33 48.98 
6 12.58 0 416.17 226.80 60.70 22.97 
8 10.98 0 378.67 201.80 86.47 11.32 
12 3.712 0 277.00 134.00 21.58 9.14 
 
Table 5.3: Calculated concentrations of each chemosensitiser in infected mice over 24 hours following 
a 10mg/kg dose of all six compounds simultaneously. Data reported as the mean±SEM of readings 
from 5 animals; maximum concentrations reached are shown in bold. 
 
Beyond 8 hours, though, the concentration of CFN drops to approximately an eighth of its 
maximum. This may in part account for the lack of effect shown when AMT+CFN+CPZ were 
combined with CQ. Given that AMT does not reach as high a level in the bloodstream as DES 
or CTL, and that the level of CFN drops more rapidly than other drugs, the combination of 
these two drugs may not reach sufficiently high levels in vivo to potentiate the action of CQ, 
even though CFN has the smallest plasma-bound fraction of all the compounds tested (Table 
2.5).  
A similar phenomenon exists when examining the kinetics in infected animals (Figure 5.5 and 
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than in the healthy mice. CTL in particular reaches close to six times the concentration it does 
in healthy animals; DES, PRO and AMT all reach at least double the concentrations seen in 
healthy animals. The increase in concentration with CTL seen in the infected mice might 
explain why the CTL-containing combinations were both effective – CTL and CPZ both reach 
higher concentrations in infected animals than in healthy ones. As a result, even though PRO 
and CFN do not circulate at raised concentrations beyond 6 hours after dosing, there is 
sufficient CTL and CPZ present to continue to potentiate CQ action in the parasite as a 
double-combination. In contrast, with both AMT and CFN not lingering at high 
concentrations, the combination AMT+CFN+CPZ becomes effectively useless as was seen 
with this combination failing to improve CQ action in vivo. 
The method has several limitations. A full validation of the method, as is typical for clinical 
research, was not carried out. Although the standard curves, one of which is depicted in 
Figure 5.3, were produced a second time from stored frozen stocks which had been thawed 
previously, samples were not subjected to several rigorous freeze-thaw cycles and so the 
stability was not determined – this might have ramifications should repeat analysis of the 
blood be required. Given that this was a fairly small preliminary study, no deuterium-labeled 
internal standard was used as an additional quality-control mechanism. Nevertheless, the 
standard curves have regression values of 0.982 to 0.9989 and thus the method seems 
sufficiently sensitive and accurate to allow quantification of the compounds from the small 
volumes of whole blood taken from each animal. Whether or not the data can be extrapolated 
is debatable – circulating drug concentration maxima in the animals from 10mg/kg doses of 
each chemosensitiser are notably different to those seen in humans; CPZ, for example, 
reaches in excess of 600ng/ml in mice but the highest range reported in patients is only 
122ng/ml (Table 2.5) and that is an averaged value from several different studies. Repeating 
this experiment in a primate model may yield data which could be better compared to 
patients. 
In conclusion, the kinetic data obtained from both healthy and malaria-infected animals using 
the LCMS system support the observations made when animals were treated with 
combinations of chemosensitisers simultaneously with CQ in vivo. The method is simple and 
accurate. The small volumes of blood required allows numerous samples to be taken from 
single animals, meaning that fewer animals are used for the experiment. There is also more 
certainty in the accuracy of the data since each time-point is measured in the same population 











Chapter 6 –– Summary and Conclusions 
 
Even in the 21st century, malaria remains a massive burden to human health and prosperity, 
causing upward of 200 million infections annually. Current estimates put the death toll at 
around a million people per year; about 90% of these occur in sub-Saharan Africa, in children 
under the age of 5. Treatments and interventions to interfere with the spread of the disease are 
numerous and include prophylaxis and chemotherapy for patients as well as physical methods 
aimed at the parasite vector, the mosquito, such as insecticide programmes, wide-spread use 
of bed-nets, removal of standing water and ensuring water flow, and even the introduction of 
larvae-eating fish species to control mosquito breeding.  
Patient treatment is undermined by drug resistance on a global scale, however, and the former 
mainstay drugs used as first-line treatment such as chloroquine and sulphadoxine-
pyrimethamine are effectively useless against the parasite. Although resistance to CQ can be 
circumvented in vitro¸ the practice has yet to develop to a point where it can be commonly 
practiced clinically because the chemosensitisers which are able to reverse CQ resistance 
work at concentrations which are either not achievable – proteins in plasma can bind in excess 
of 90% of the circulating drug, leaving very little available to interact with the parasite – or 
toxic to the patient.  
Numerous compounds from across the chemical class and the medicinal/therapeutic spectrum 
have been shown to transiently alter the parasite response to CQ in vitro; far fewer have been 
successful in animal models of malaria and, although promising results have been reported in 
a small preliminary study, none have worked effectively in patients 
This thesis explores the potential of utilizing combinations of chemosensitising compounds 
simultaneously. The principle behind this proposal is that several drugs used in small 
concentrations which are both achievable and non-toxic to the host could work additively or 
synergistically to reverse resistance, in essence using several compounds to safely do what 
one compound does in vitro but cannot do safely or easily in patients. Drugs from different 
pharmaceutical classes were chosen in order to minimize the potential for additive toxicity to 
the host; the objectives were to evaluate their effectiveness singly and then in combination in 
vitro in order to produce a cocktail treatment consisting of several drugs at low doses which 
could then be tested in an animal model. The circulating level of each drug in the animal 










6. Summary and Conclusions 
104 
Nine drugs – three antidepressants; five antihistamines and one antipsychotic – which had 
shown some moderate reversing activity in vitro against cultured parasites or in vivo at high 
doses in animals were tested against five laboratory strains of Plasmodium falciparum known 
to have differing sensitivity to CQ (one sensitive, four moderately or highly CQ resistant; IC50 
values of 16nM for CQS and 200-300nM for the CQR isolates). All of the drugs were 
determined to have no intrinsic/utilizable antimalarial activity in that they only killed the 
parasite at concentrations 2-3 orders of magnitude higher than existing antimalarial drugs are 
able to. Some minor differences in the parasites’ sensitivity to three of the compounds was 
reported, but the results for each drug were generally not significantly different between 
strains; IC50 values ranged from 3µM to 53µM for the nine drugs. 
The compounds’ effect on CQ uptake was also examined across a wide range of 
concentrations. Each of the compounds was able to increase the accumulation of tritiated CQ 
in CQR isolates but not CQS isolates, which is typical of most CQ chemosensitisers; the 
change in uptake was highly dose-dependent. Inter-strain differences were noted between the 
CQR isolates; no compound was able to consistently maximize uptake in all four isolates. 
Although each compound is able to heighten the accumulation of CQ in vitro, the level of 
increase over the control varied considerably with observed maxima between 9.5-fold in the 
best-performing compounds and only 3-fold in others.  
Maxima decreased considerably towards the lower doses (100ng and lower) which were the 
ranges intended for the combination treatment. Since these compounds are known to be 
plasma-bound to a lesser or greater degree and their circulating concentration ranges tend to 
be fairly low (averages between 0.6 and 170ng/ml between the 9 compounds), it was illogical 
to expose the parasites to a range significantly greater than that. 
The effect on the CQ IC50 was examined. A fixed amount of each compound (100ng/ml) was 
added to CQ and the shift in the IC50 was noted. Each compound was able to noticeably lower 
the IC50 of CQ at 100ng/ml in the CQR parasites; varied results were observed between the 
four strains evaluated. No significant effect was observed with the CQS isolate. As with the 
uptake data in the CQR parasites, no single compound routinely outperformed the other eight; 
however, one compound, azatadine, did perform consistently worse and was not evaluated at 
lower doses. Another compound which has the lowest circulating concentration in patients 
and which only moderately lowered the CQ IC50 and did not improve CQ uptake at low doses, 
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moderately and was able to alter the CQ IC50 by a large margin but is rapidly and extensively 
metabolized in vivo and it was considered impractical to pursue studies with the parent 
compound since so little of it remains unchanged in the bloodstream. The remaining six 
compounds (three antidepressants, two antihistamines and the antipsychotic) were tested for 
their effect on the CQ IC50 at 20 and 10ng/ml. As with the CQ uptake, a clear dose-effect is 
evident and shift in the IC50 are substantially lower at 20ng/ml and lower yet at 10ng/ml. The 
least CQR of the four CQR isolates did not respond to several of the compounds at 10ng/ml at 
all. 
Compounds were then paired and the parasites exposed to these combinations at 100ng/ml 
each to see the effect of the grouping on the CQ IC50. As expected, the combinations were 
more effective at altering the CQ IC50 in CQR isolates than each drug was individually; this 
was true in all cases except one (KET/CYP) where the combination, although effective in its 
own right, was not as effective as either parent compound used singly. The other 
combinations’ activity was more additive than synergistic. Significant toxicity was seen in 
both CQR and CQS isolates, however, with some pairings able to kill 30-40% of the parasites 
in the absence of CQ, so triple combinations at these doses were not tested. While this makes 
these combinations unsuitable for the study of the reversal phenomenon, it does raise the 
possibility of combining non-antimalarials f r use as a potential new “class” of drugs against 
the parasite. The obvious advantage is that these drugs are not new and are all registered and 
on the market, meaning that significant amounts of necessary data such as safety and toxicity 
and contra-indications are already known.  
Drugs were also paired at 20ng/ml and 10ng/ml and tested in two isolates. 20ng/ml pairings 
were substantially less active than 100ng/ml pairings, and several of the pairings at 20ng/ml 
were less active than at one of the parent compounds used singly. 10ng/ml pairs were even 
less effective than 20ng/ml pairs; in most cases the activity of the combinations was not 
significantly different to the parent compounds used individually. 
Triple combinations were tested at 20ng/ml and 10ng/ml, with the effects on both CQ uptake 
and also the IC50 examined. Combinations all featured a single antidepressant with a single 
anthistamine and the lone antipsychotic. At 20ng/ml, shifts in the IC50 from the combinations 
were more substantial than the shift produced by each parent compound, but the combined 
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from double combinations at 20ng/ml. Most of the shifts at 10ng/ml with triple combinations 
were significantly better than those produced by pairings at 10ng/ml. 
IC50 data and uptake data do not correlate entirely, however. The combinations producing the 
largest shifts did not necessarily cause the largest increase in CQ uptake; likewise on the 
opposite side of the scale. In some cases combinations produced similar increases in uptake at 
both 10 and 20ng/ml while the shift in the IC50 was substantially higher with the 20ng/ml 
mixture. These data suggest that CQ uptake and the process of potentiation of CQ action by 
chemosensitisers may be somewhat independent of one another, although thus far the two 
phenomena have always occurred together. 
Single drugs were tested at a range of doses on murine malaria parasites ex vivo to determine 
whether or not the CQR mouse parasite and the CQR human parasite respond similarly to 
resistance reversal in terms of CQ uptake. Although the increases are muted in mice, there is a 
clear dose-effect as was seen with the human parasite; maximum uptake into the murine CQR 
parasite was increased just under 2 fold as opposed to the over 9 fold increase seen in P. 
falciparum. As with the human parasite, however, no effect was seen on the murine CQS 
isolate.  
Mice were then infected with either CQR or CQS parasites and the triple combination 
evaluated for bioefficacy in vivo over 4 days against low-dose CQ and also a placebo. No 
significant improvement in CQ action was seen with the CQS isolate, but a noticeable 
reduction in parasite level was seen in mice infected with the CQR parasite with five of the 
six triple-combinations. Compounds were used at doses which were substantially lower than 
those tested previously (10mg/kg as opposed to the published values of up to 50mg/kg) with a 
low dose of CQ in order to determine whether the compounds show additive or synergistic 
activity in the animals. 
Both uninfected and infected mice (5/group) were also dosed with the cocktail treatment in 
the absence of CQ in order to determine the level of each drug in the bloodstream. An 
extraction method was developed for use in a high-performance liquid chromatography 
system linked to as mass spectrometer; the use of this extremely sensitive tandem apparatus 
allows very small samples to be taken from the animals (10µl of blood, taken from the tip of 
the tail) over the course of 12 hours with no danger to the animals’ health from the loss of 
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sensitive methods relied on the dosing of multiple groups of animals simultaneously and the 
use of an entire group for use as a single data point. The method proved to be precise and 
robust and the kinetic data obtained from the system supported the observations seen during 
the bioefficacy experiment – that the compounds circulate at a sufficiently high concentration 
which the uptake data indicates should increase CQ levels within the parasite and cause 
resistance reversal. 
In conclusion, these data suggest that combinations of these chemosensitisers work additively 
and not synergistically, and that there is a clear dose effect on the IC50 of CQ with both double 
and triple combinations at low doses. Although increasing CQ uptake appears to play a role in 
resistance reversal, the level of this increase is not perfectly matched to the changes observed 
in the IC50. The data also indicate that combinations of known chemosensitisers used at low 
doses are able to significantly improve CQ activity in the animal model, and as such suggest 











Chapter 7 – Materials and Methods 
 
7.1 Parasites 
7.1.1 The human parasite Plasmodium falciparum 
The CQ sensitive isolate D10 was a gift from Alan Cowman at the Walter and Eliza Hall 
Institute in Melbourne, Australia; it was originally cloned from FQC-27 which was isolated in 
Papua New Guinea (Ekong et al., 1993). 
The CQR isolate RSA11 was obtained from Janet Freese at the South African Medical 
Research Council laboratory in Durban, South Africa, taken from a patient i  Kwazulu-Natal 
(Freese et al., 1990). 
The CQR isolates K1 and W2 were obtained from the Malaria Research and Reference 
Reagent Resource Center (MR4) at BEI Resources, National Institute of Allergology and 
Infectious Diseases at the National Institutes of Health in Manassas, Virginia, United States of 
America. Both originated in South-east Asia – K1 isolated from a patient in Thailand (Joy et 
al., 2003), and W2 in Indonesia (Martin et al., 1987). 
The CQR isolate P. falciparum Dd2 was a gift from David Walliker at the University of 
Edinburgh in Edinburgh, Scotland. Dd2 was cloned from W2-Mef, the parent strain of which 
was isolated in Indochina (Guinet et al., 1996).  
7.1.2 The mouse parasite Plasmodium yoelii 
Professor Walliker also generously donated Plasmodium yoelii N (CQS) and P. yoelii NS 
(CQR). Mouse parasites were isolated from thicket rats in the Democratic Republic of the 
Congo (Ferrer-Rodriguez et al., 2004).  
7.2 Parasite culture 
Parasites were grown in vitro as described previously (Taylor et al., 2000; Egan et al., 2002) 
based on existing methods (Trager and Jensen, 1976). 
Parasites were maintained at 37°C in RPMI 1640 growth medium (Biowhittaker and Sigma) 
supplemented with 22mM glucose, 25mM HEPES buffer (4-(2-hydroxyethyl)-1-
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prevent growth from bacterial contamination. The human serum component in the original 
method was replaced with 0.5% (w/v) Albumax II (Gibco). The medium was passed through 
a sterile 0.22µM filtration system into sterile containers and refrigerated. Prior to use, medium 
was warmed to 37°C and made complete via the addition of a 5% sodium bicarbonate 
solution to correct the pH; 4ml bicarbonate was added per 100ml of incomplete medium. 
Culture medium was replaced daily using aseptic techniques. Parasites were pelleted via 
centrifugation for 3 minutes at 600g and the supernatant was removed via suction. 
Parasitaemia (pst) was determined microscopically using methanol-fixed Giemsa-stained 
slides viewed under oil. Parasites were cultured at a haematocrit (hct) < 4% and at 5-10% pst. 
Parasitaemia was maintained by dilution of centrifuged trophozoites with isolated washed 
human erythrocytes as required. Cultures were maintained in sealed flasks under gas pressure 
of 3% O2 and 4% CO2 in nitrogen. 
Culture synchronicity was maintained by the addition of 10 volumes of warmed 5% sorbitol 
(w/v) to pelleted parasites during the ring stage. Parasites were suspended in sorbitol for 10 
minutes at 37°C then pelleted and the sorbitol was removed along with any parasite lysate 
before parasites were placed back into culture medium. 
Erythrocytes were supplied by Western Province Blood Transfusion Service’ (WPBTS) 
laboratory at Groote Schuur Hospital in Cape Town. 30ml erythrocyte concentrate was 
transferred to a sterile centrifuge tube and washed via the addition of 20ml complete medium. 
The mixture was spun at 1200g for 5 minutes and the supernatant and remnants of the buffy-
coat/white blood cell layer removed by suction. Washed erythrocytes were kept refrigerated 
for approximately 3 weeks after being harvested by WBPTS. 
7.3 Lactate dehydrogenase assay for parasite survival 
The parasite lactate dehydrogenase (pLDH) assay (Makler et al., 1993) was used to determine 
antimalarial activity of the test compounds as well as to evaluate their effectiveness at altering 
the CQ IC50.  
The assay is colorimetric and parasite viability is determined by a secondary marker, which is 
the activity of the lactate dehydrogenase enzyme (LDH). LDH catalyses the conversion of 
lactate to pyruvate in the process of glycolysis using NAD+ as a co-factor which results in 
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adenine dinucleotide), which is a substrate of pLDH. Although human LDH can utilize 
APAD+, it does so at a significantly lower rate and thus the APADH present is mostly 
produced via pLDH and thus functions as a measure of parasite survival. The amount of 
APADH produced is quantified by the addition of a mixture of Nitro-blue Tetrazolium and 
phenozine ethospulphate (NBT/PES); in the presence of APADH, the yellow NBT is reduced 
to a blue formazan salt product which can be quantified by a spectrophotometer. The process 




Figure 7.1: The chemistry of the pLDH assay 
 
Parasites in the trophozoite stage were diluted to a hct and pst of 2%. Drugs were diluted to 
double the desired starting concentration required and transferred to a 96-well microtitre plate. 
Two-fold serial dilutions were performed until there were 10 concentrations of each drug in 
the plate. An equivalent volume of the parasite stock was added to each well, halving the 
concentration of each dilution of the drug to the correct amount and simultaneously diluting 
the hct to 1%. Erythrocyte and drug-free parasite controls were added to each plate in addition 
to the test concentration range.  
For resistance reversal, plates containing CQ only were set up as described with a 
concentration range starting from 1000ng/ml. After the addition of parasites, 10µl of a stock 
of the chemosensitiser/s was added to each well, creating a mirror of the control CQ 
concentration range containing a fixed dose of the chemosensitiser/s. Plates were placed in a 
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Figure 7.2: Reversing resistance using the parasite lactate dehydrogenase assay. Darker purple wells 
indicate living parasites; lighter pink/orange wells show where parasites have not survived the drug. 
The drug-free parasite control (pRBC) representing 100% survival is the purple column 2. The last 3 
rows show the standard CQ response from a CQR isolate with the CQ IC50 at position 1 (column 5). 
The highest dose of CQ is on the left of the plate in Column 3; lowest is in Column 12 at far right. Each 
column is a two-fold dilution in CQ. The middle two rows show the slight effect of Drug B on CQ, with 
the altered IC50 at position 2 (column 7). The significantly altered IC50 produced using Drug A is shown 
at position 3 in Column 11, indicating that Drug A is able to reverse CQ resistance to a large extent.  
After 48 hours, plates were removed and the parasites resuspended carefully in each well. A 
duplicate plate was set up; each well contained 100µl of Malstat reagent containing the 
APAD+ and 25µl of a solution containing 20:1 (m/m) ratio of nitroblue tetrazolium and 
phenozine ethosulphate. 15µl of resuspended parasites were transferred to the corresponding 
well on the duplicate plate and the colour change monitored by a spectrophotometer reading 
visible light at 620nm wavelength. The experimental blank was the non-parasitised 
erythrocytes, and the positive control representing 100% survival was the average absorbance 
of the wells containing the drug-free parasites. Survival in all other wells was determined as 
the ratio of their absorbance to the 100% control.  A sample plate is shown in Figure 7.2 
below. 
 
pRBC control Highest [CQ] 
RBC control 
Lowest [CQ] 
CQ + Drug A 
CQ + Drug B 
CQ only 
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Ratios were plotted against log concentration values using the Graphpad Prism v4.0 scientific 
analysis software package. Non-linear regression analysis was carried out and a curve fitted to 
the data which allowed the IC50 to be calculated. 
 
7.4 The murine model 
Parasites were grown in male albino (Balb/C) mice. Frozen isolates of P. yoelii and P. berghei 
were stored in liquid nitrogen until required.  
To infect host animals, vials were retrieved and allowed to thaw at room temperature. An 
equivalent volume of phosphate-buffered saline (PBS) was added to the thawed parasites and 
host mice were inoculated intraperitoneally (i.p.) with 500µl of this mixture. Pst was 
monitored microscopically from the third day post-inoculation until such time as it was 
deemed high enough (>20%) to inoculate the test groups. 
Host mice were anaesthetized with a 3:2 (v/v) mixture of ketamine and xylizine; the mixture 
made up to 20% (v/v) in PBS and each donor mouse was injected with 150µl i.p. Once 
anaesthetized, mice were exsanguinated by cardiac puncture; removed whole blood was 
collected in heparinised containers to prevent clotting and donor mice were killed in a sealed 
chamber via inhalation of halothane. Erythrocyte density in the whole blood was determined 
microscopically and from this value and the pst value it was possible to determine how much 
infected blood should be used to infect each test animal with 1x107 pRBC. This volume of 
donor blood was made up in PBS such that 200µl of the mixture contained the correct amount 
of pRBC and test mice were infected with 200µl of this stock via i.p. injection.  
The 4-Day Test as described by Peters was used for the bioefficacy experiments. Animals 
were dosed orally 120 minutes post-infection on Day 0. Subsequent doses were administered 
every 24 hours for the next 3 days (D+1 to D+3). Mice were monitored and scored twice daily 
for discomfort or distress in accordance with regulations set out by the Research Ethics 
Committee at the University of Cape Town. 
Parasitemia was determined microscopically on D+4; slides were made using a drop of blood 
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7.5 Radiolabelled CQ accumulation in vitro and ex vivo 
Tritiated chloroquine (3H-CQ) was obtained from Amersham (23Ci/mmol) and Moravek 
(7Ci/mmol) and diluted in Millipore water to a concentration of 100nM. Mouse parasites were 
obtained via cardiac puncture as described above. Parasitemia was determined 
microscopically in either mice or the growing cultures; parasites were diluted to a pst of 5% 
with fresh human or mouse erythrocytes and made up to a stock hct of 2% in culture medium 
for the experiment. Drugs were made up to double the required concentration in 500µl culture 
medium in a 1.5ml reaction vessel and then 500µl of parasite stock was added, halving the hct 
and the drug concentration. Parasite/drug mixtures were incubated at 37°C for 15 minutes to 
allow equilibration of the drugs, then 40µl of the 3H-CQ stock was added to give a total CQ 
concentration of 4nM and the parasites vortexed to ensure even distribution of CQ. Samples 
were held at 37°C for an additional 60 minutes with resuspension via vortex after 30 minutes 
to allow CQ transport to take place. Uninfected erythrocytes with no chemosensitiser were 
exposed to 4nM simultaneously to act as the experimental blank. 
After 60 minutes, 100µl of dibutyl phthalate was added, creating an organic layer; samples 
were then pelleted in a microfuge at 13000rpm for 30 seconds. Erythrocytes passed through 
the organic layer, effectively trapping any accumulated CQ; the supernatant containing 
medium and unabsorbed CQ was retained above the organic layer and was removed by 
suction.  
The bottom of the reaction vessel was cut off and transferred to a tube designed for use in a 
scintillation counter. 100µl of tissue solubiliser (Solvable©; Perkin-Elmer) was added to each 
sample and samples were vortexed vigorously for 60 seconds to completely solubilise the 
pellet and release the 3H-CQ, then 2ml scintillation fluid (Packard Ultima Gold) was added to 
each tube.  
The tubes were shaken overnight to ensure the radioactivity was evenly dispersed throughout 
the solution. Radioactivity accumulated was quantified in a liquid scintillation counter 
(Packard-Canberra TriCarb 2100).  The counts seen in uninfected erythrocytes were 
subtracted from all other readings to account for the amount of CQ taken up by the 
erythrocyte. Since larger trophozoites take up greater amounts of labeled CQ than smaller 
ones, this was countered by determining the increase in uptake as the ratio of 
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7.6 Statistical analyses 
Unpaired t-tests and ANOVA tests were carried out using the statistical functions of 
Graphpad’s Prism v4.0 software package.  
Data was first tested for normality prior to any further analysis. 
7.7 High Performance Liquid Chromatography (HPLC) 
Chromatography was carried out on an Agilent 1200 HPLC stack comprising of a binary 
pump, a heated column compartment and a temperature-controlled autosampler linked to a 
mass spectrometer.  
Separation was achieved using the Luna PFP (pentafluorophenyl) silica column, the C18 
octadecyl-silane column and the HILIC column, all provided by Phenomenex, as the 
stationary phase. 
Samples were run at a flow rate of 300µl/minute using a 1:1 ratio of acetonitrile and 0.1% 
(v/v) formic acid in water as the mobile phase. The column was held at 35°C. All parameters 
were controlled remotely using the proprietary Analyst v1.5.1 software by Applied 
Biosystems Inc. (AB Sciex). 
7.8 Mouse sample extraction and analysis 
Samples were collected from live mice via a small excision on the tail; 10µl of whole blood 
was transferred to a reaction vessel containing 50µl of carbonate buffer at pH11, vortexed 
vigorously for 30 seconds, and then frozen.  
Liquid-liquid extraction was performed simultaneously on all samples. Vials were thawed and 
vortexed for 30 seconds. 250µl of ethyl acetate was added to each sample and the mixture was 
immediately vortexed vigorously for 30 seconds to allow drugs to move into the organic 
layer. Precipitants were pelleted by centrifugation at 13000rpm for 30 seconds and 200µl of 
the supernatant was carefully transferred to a glass insert for use in an HPLC sample vial. The 
organic layer was evaporated by spinning the inserts for 25 minutes at 30°C under vacuum.  
Samples were then reconstituted in 100µl of the mobile phase and transferred to the 
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7.9 Mass Spectrometry 
The mass spectrometry (MS) component was performed on an API 3200 tandem mass-
spectrometer sourced from AB Sciex. It was run in the positive mode using Turbo Spray on 
the ion source at 400°C, and with 5500 volts generating the electric field. Each of the six 
compounds was counted for 150ms. 
The MS system was controlled by the proprietary software package Analyst v1.5.1 which was 
also used to generate calibration curves from the integrated data, and to fit the unknowns in 
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